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Abstract 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by the rapid 
and progressive degeneration of upper and lower motor neurons in the spinal cord, brain stem 
and motor cortex. Approximately 90% of ALS cases are sporadic (sALS) in nature, and the 
remaining 10% are termed familial (fALS), being associated with mutations in a broad set of 
genes including SOD1, TDP-43, OPTN, C9orf72, ALS2, FUS, and UBQLN2. The first of 
these genes linked to ALS was the gene encoding the ubiquitous free radical scavenging 
enzyme superoxide dismutase-1 (SOD1), which currently has over 180, mostly missense, 
ALS-associated mutations identified. Curiously, SOD1-associated fALS patients show 
remarkably broad mean survival times (< 1 year to ~17 years death post-diagnosis) which are 
mutation dependent, indicating that mutation may govern disease severity. In its native fold, 
SOD1 is a 32 kDa homodimer where each 153 amino acid subunit contains an intramolecular 
disulfide, as well as zinc and copper cofactors; the latter of which catalyses the conversion of 
oxygen radicals to either molecular oxygen or hydrogen peroxide, and all of which confer 
significant thermal and kinetic stability. Early research, using knockout animal models, 
determined that a loss of enzymatic activity is not the cause of SOD1-associated fALS 
pathology, suggesting that mutation is inducing a gain of cytotoxic function. A hallmark of 
SOD1-associated ALS is the deposition of SOD1 into large insoluble aggregates in motor 
neurons. This is thought to be a consequence of mutation induced structural destabilisation 
(dimer dissociation, metal binding disruption, and disulfide reduction) and/or oxidative 
damage leading to the misfolding of SOD1 into a neurotoxic species. Recent work has 
emphasised the ability of SOD1 to transmit misfolding molecularly, intercellularly, and from 
organism-to-organism in a prion-like manner, providing some rationale for the 
spatiotemporal spread of pathology observed in ALS. In this study we investigate the effects 
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of fALS-associated mutations and their consequences on protein structure and aggregation 
using recombinant protein and cultured cell models. Using native mass spectrometry (MS) to 
direct the dissociation and unfolding of purified SOD1 variant dimers in vacuo, we 
determined that the SOD1
G37R
 variant had significantly altered charactersitics comparative to 
the other variants examined, where it presented a more asymmetric partitioning of charge yet 
did not dissociate more readily. Following from this we observed that our SOD1 variants 
were modified at Cys111 by glutathione, which the data present here suggested alters the 
dimer dissociation constant (KD) of SOD1. MS analysis determined the extent of 
glutathionylation, as well as the dimer KD’s of several SOD1 variants in their unmodified 
(uSOD1) and glutathionylated (gsSOD1) forms, finding that glutathionylation increased the 
dimer KD’s differentially, where specific wild-type-like mutants were significantly 
augmented (uSOD1
G93A
 = 12 ± 1 nM, gsSOD1
G93A
 = 160 ± 32 nM) compared to SOD1
WT
 
(uSOD1
WT
 = 9 ± 1 nM, gsSOD1
WT
 = 34 ± 5 nM). These data suggest that glutathionylation, 
and potentially other modifications, of Cys111 in SOD1 may contribute to its misfolding and 
subsequent aggregation, and highlights the necessity of identifying post-translational 
modifications prior to biophysical analysis. 
Owing to the ability of native MS to resolve differentially modified protein species, provide 
information on oligomeric distribution, as well as information on protein conformation, we 
utilised MS to interrogate the structural consequences of metal loss and disulfide reduction on 
fALS-associated SOD1 variants. We determined that, after DTT/EDTA-treatment, the most 
abundant SOD1 species was reduced apo-SOD1 for all variants, and that the conformational 
state of this species was dependent on mutation. All variants showed evidence of unfolded, 
intermediate, and compact conformations (as determined by Gaussian distributions of mass-
to-charge ratios), with SOD1
G37R
, SOD1
G93A
 and SOD1
V148G
 having the greatest abundance 
of intermediate and unfolded SOD1. SOD1
G37R
 was a curious outlier as it did not aggregate to 
vi 
 
the same extent (measured by thioflavin T) as SOD1
G93A
 and SOD1
V148G
 in aggregation 
assays. Furthermore, seeding the aggregation of DTT/EDTA-treated SOD1
G37R
 with 
preformed SOD1
G93A
 fibrils elicited minimal response, indicating that the arginine 
substitution at position-37 blocks the templating of SOD1 onto preformed fibrils. Position-37 
is encompassed by a sequence segment (
30
KVWGSIKGL
38
) identified as having a high 
aggregation propensity and being involved in the intermolecular transmission of misfolding. 
Within this sequence segment is Trp32 which has previously been identified as a contributor 
to SOD1 misfolding and aggregation. We investigated the effect of Trp32 on aggregation by 
generating SOD1 variants with a W32S mutation. Our analysis established that the W32S 
substitution decreased the stability of the reduced apo-form of each SOD1 variant, but 
remarkably decreased their aggregation propensity both in isolated protein assays and in cell 
culture. We found that SOD1
G93A-W32S
 had a decreased ability to template onto preformed 
SOD1
G93A
 aggregates, suggesting that Trp32 is an aggregation modulating residue. 
This study clearly demonstrates the utility of native mass spectrometry in the study of 
disordered and modified proteins in the ability to assess both conformational and 
modification state simultaneously. The data reported here illustrate the complexity involved 
in unravelling the cause of SOD1-associated fALS, but provides evidence that strongly 
indicates the role of a sequence segment encompassing Trp32 in aggregation and 
propagation. It is hoped that by understanding the interplay between mutation effect on SOD1 
stability and subsequent aggregation formation may help identify the particular aggregate 
species responsible for toxicity and provide targets for therapeutic intervention. 
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1.1 Overview 
 
Proteins that misfold or unfold are sometimes able to bypass or overwhelm the cellular 
protein quality control mechanisms, often leading to aggregation in the form of insoluble 
protein deposits (Dobson, 2003). Normal cellular function can be disrupted by aggregates 
interacting inappropriately with cellular components such as membranes, receptors and other 
proteins (Chiti and Dobson, 2006). Protein aggregation has been associated with multiple 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and 
amyotrophic lateral sclerosis (ALS). Most ALS cases are sporadic, but 10% are associated 
with inheritance of a mutation in a number of possible genes, with much research focusing on 
superoxide dismutase-1 (SOD1), due to its early discovery and the fact that mutants of this 
protein are associated with 20% of familial ALS (fALS) cases (Benatar et al., 2006). 
Sufferers of SOD1-linked fALS often have protein inclusions comprised primarily of SOD1 
in their affected neurons (Boillée et al., 2006). How mutation results in aggregation of SOD1 
is not well understood; over 180 possible mutations in SOD1 are linked to fALS and as a 
result a variety of physical properties are implicated as contributing to the aggregation 
mechanism. It is clear that aggregation of SOD1 is dependent primarily on dissociation of the 
dimer, the release of bound metals, and the reduction of the disulfide bond (Chattopadhyay 
and Valentine, 2009), implicating that an immature form of SOD1 may be responsible for 
aggregation. Although there is good evidence to suggest metal binding and disulfide 
reduction are involved in the aggregation of SOD1, not all mutations directly disrupt these 
properties, leaving the precise intermolecular and intramolecular interactions taking place 
during this process unclear.  
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1.2 Protein Folding and Quality Control 
 
Protein folding is key to the correct functioning of most cellular processes, and if proper 
folding of newly synthesised proteins is disturbed, the consequences can be fatal (Dobson, 
2003). When a polypeptide is newly synthesised it is acted upon by physical forces and 
cellular machinery to reach its native conformation (Anfinsen, 1973, Hartl et al., 2011). 
Paradoxically, proceeding from a polypeptide strand to a complex three dimensional structure 
by cycling through all possible conformations would take years, but when observed 
experimentally, folding processes take milliseconds to occur (Levinthal, 1968). The energy 
landscape (Fig. 1.1) theory of protein folding addresses this issue by suggesting that the 
folding is determined by a funnel-like progression from highest free energy to lowest free 
energy in the protein structure (Onuchic and Wolynes, 2004). This infers that the number of 
possible conformations a protein can occupy becomes smaller as free energy decreases, 
effectively directing folding towards a single end state commonly known as the ‘native 
conformation’. The native conformation of most proteins is thermodynamically favourable 
and is thought to be the form responsible for carrying out processes within a cell (Karplus and 
Sali, 1995). Even though the energy landscape theory suggests a funnel-like progression 
towards native conformation, the process of folding can see polypeptide chains transition 
through many partially-folded and unfolded states that facilitate subsequent folding steps, 
before assuming its lowest energy state (Karplus and Sali, 1995, Dobson, 2003, Ecroyd and 
Carver, 2008). These above processes are, for the most part, dictated by amino acid sequence.  
Small proteins (60-110 amino acid residues) have been the focus of many studies 
investigating the molecular steps in protein folding (Fersht and Daggett, 2002, McLaughlin 
and Weeds, 1995, Radford and Dobson, 1999). It has been proposed that small proteins fold 
into their native conformation in a single step, bypassing the need for intermediate folding 
states (Jackson, 1998). Evidence from nuclear magnetic resonance, fluorescence and circular 
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dichroism spectroscopy experiments have been used to conclude that smaller proteins 
transition from unfolded polypeptides to their native conformation by nucleation of 
hydrophobic residues followed by a hydrophobic collapse (Fersht, 2000, Kim and Baldwin, 
1982, Vendruscolo et al., 2001).  
 
Figure 1.1: The energy landscape of protein folding. The pathways that lead to a protein’s native 
conformation (blue). The free energy decreases as order increases when polypeptides fold. The 
intermediates (green) limit the ways a large polypeptide can fold, thus narrowing the funnel. Unfolded 
polypeptides (red) can either reach the native conformation or become misfolded (orange) (Schultz 
2000). 
 
In contrast, the three main physical states for larger proteins have been described as the initial 
unfolded state, followed by an ensemble of intermediate states, and lastly the native 
conformation (Radford and Dobson, 1999). This sequential theory of the protein folding 
pathway begins with the formation of secondary structures, such as α-helices and β-sheets, 
which is then followed by the formation of the tertiary structure (Pace et al., 1996). Another 
theory suggests that the intermediate states induce the formation of a molten globule that is 
similar to the native state (Vendruscolo et al., 2001). The concentration of the native 
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interactions in the molten globule forces the peptide into its native conformation (Makarov 
and Plaxco, 2003). Both theories state that the final step in the folding of large proteins 
includes the exclusion of water from the hydrophobic core (Cheung et al., 2002). Once a 
protein is in its native conformation it is stabilised by interactions between amino acid side 
chains that include hydrogen bonding, hydrophobic, electrostatic and covalent interactions 
(Murphy and Kendrick, 2007). These types of bonds can also occur between side-chains not 
normally found in the native fold or between individual polypeptides during the folding 
process, leading to inappropriate interactions. The maintenance of the entire proteome in its 
collective native conformation, and at a concentration and location that promotes correct 
function, is termed protein homeostasis or proteostasis. 
Protein quality control processes that maintain proetostasis have evolved in cells due to the 
importance of proper protein folding (Yerbury et al., 2005). Proteins can misfold or unfold 
from the native conformation as a consequence of changes in the intracellular environment 
that can include oxidation/reduction potential, pH, and resource availability. It is also 
necessary for some proteins to remain partially folded for transport in the cellular 
environment, potentially leading to unwanted interactions. The inhibition of inappropriate 
interactions is facilitated by molecular chaperones; which are proteins that mediate correct 
folding, and stabilise unfolded proteins during cellular stress or membrane translocation, and 
can even refold, hold, or unfold and disaggregate proteins for delivery to degradation systems 
(Arrigo et al., 2007, Gregersen et al., 2006, Muchowski, 2002, Neuwald et al., 1999). Many 
chaperones are heat-shock proteins, meaning their expression is up-regulated when a cell is 
undergoing heat or other stresses. If chaperones are unable to fold a protein to its native 
conformation, then it is necessary for the protein to be degraded to prevent the formation of 
cytotoxic aggregates (Goldberg, 2003, Muchowski and Wacker, 2005).  
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Misfolded proteins are degraded via two main pathways within eukaryotic cells, that 
essentially break down the stubbornly misfolded protein material for recycling (Goldberg, 
2003). Primarily, the cell uses the ubiquitin-proteasome system to degrade soluble proteins; 
misfolded proteins are covalently modified with the small marker protein ubiquitin (typically 
multiple times to form a poly-ubiquitin chain) and transported to the proteasome for 
degradation (Wilkinson, 2005). A proteasome is a large protein complex that forms a barrel-
like structure in to which an unfolded protein is delivered (after removal of ubiquitin) and 
internal active protease sites mediate the degradation of the protein (Wilkinson, 2005). The 
second major pathway for degradation in the cell is the autophagy-lysosomal pathway in 
which membranous vacuoles, called autophagosomes, encase cell organelles or large protein 
aggregates, merge with lysosomes to facilitate degradation of the cargo via acidic hydrolases 
(Yorimitsu and Klionsky, 2005). If either of these two processes are operating at reduced 
capacity, or overwhelmed by an influx of misfolding, then protein aggregation can occur.  
 
1.3 Native Mass Spectrometry 
 
Protein folding is a multifaceted process, requiring the utilisation of a diverse set of 
techniques to elucidate specific information about different levels of structure within a 
protein. Assessment of protein structure on primary, secondary, tertiary, and quaternary 
levels is essential for understanding protein function and dysfunction within biology. A 
technique which can allow for the rapid assessment of protein structure, ranging from 
primary to quaternary structure is mass spectrometry (MS). A mass spectrometer, by its very 
definition, is a device that measures mass as a function of intensity, giving an output 
spectrum where the specific mass of a molecule has the most intense signal. In order to 
analyse samples via MS they must first be buffer exchanged into a volatile buffer to facilitate 
their conversion into a gas-phase ion (Figure 1.2 A). Native MS, as the name implies, is the 
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MS based study of biological molecules in a ‘native-like’ state. The term ‘native-like’ is used 
to describe native studies of biological molecules using MS because the molecules are 
required to transition from the solution-phase into the gas-phase, which alters the 
physicochemical forces that govern protein structure such as hydrophobicity and electrostatic 
interactions (Bich et al., 2010b). This phase transition has been extensively optimised 
throughout the history of the technique, resulting in the ability to maintain important native 
features of biological molecules in vacuo. Native mass spectrometry has been especially 
useful in the investigation of the non-covalent interactions within biological assemblies, 
binding stoichiometries, and protein complex architectures (Benesch et al., 2007). 
In the case of native MS of biological macromolecules, ‘soft ionisation’ is essential to 
transfer the molecule into the gas-phase whilst maintaining native structure (e.g. non-covalent 
interactions between binding partners). The most commonly used form of soft ionisation 
technique in native MS studies is electrospray ionisation (ESI), in which an electrical 
potential (typically positive charge) is applied to an inert gold-coated glass capillary 
containing aqueous sample for analysis, resulting in the expulsion of small charged droplets 
containing analyte from the capillary into an electric field of opposite charge. As these 
droplets traverse from the capillary into the instrument, they undergo both evaporation and 
fission until very little, or none, of the solvent is left surrounding an analyte, resulting in a 
multiply charged gas-phase ion  (Kebarle and Verkerk, 2009). Droplet evaporation and 
fission are important to the production and accurate measurement of gas-phase ions, and in 
some cases, facilitation of evaporation and fission requires harsh conditions which are 
unsuitable for the analysis of intact complexes. The production of multiply charged ions from 
ESI is a consequence of the ionisation of solvent exposed basic (positive ion mode) or acidic 
residues (negative ion mode), resulting in the generation of mass spectra containing multiple 
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peaks, which can be a useful measure of relative protein fold in response to changes in 
solution-phase conditions (Mann et al., 1989).   
Nano-electrospray ionization (nano-ESI) has many advantages over typical ESI, including the 
use of smaller sample volumes (microlitres instead of millilitres), production of smaller 
droplets (nanometres instead of micrometres), and higher tolerance to salts (which can 
suppress signal in typical ESI), all of which contribute to an enhanced analysis of native 
protein dynamics. The smaller droplet size produced in nano-ESI is particularly useful for 
native MS as there is a reduced chance that multiple analyte species are present in one droplet 
and therefore the likelihood of non-specific interactions are decreased. In conjunction with 
this, the smaller droplet size requires less energy to desolvate, which results in a lower 
internal energy of measured ions and decreases the chance of unwanted gas-phase 
dissociation and fragmentation (Juraschek et al., 1999). These features, in conjunction with 
the aforementioned production of a multiply charged ion, as well as complementary 
technologies combined result in an extremely powerful tool for the examination of protein 
structure. 
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Figure 1.2: A Typical protein native mass spectrometry workflow. (A) Samples must be partially 
or fully purified for native MS and exchanged into a volatile buffer. Ammonium acetate (10 µM – 
1 M, over a wide pH range) is the most commonly used buffer system for native MS. (B) Samples are 
ionised to convert them into gas-phase ions using ESI where a capillary is charged with electric 
potential (positive for most proteins) increasing attraction of the sample to an oppositely charged 
field. This creates a fine nebulising spray from the capillary where proteins inhabit the droplets. 
Droplets undergo desolvation and fission until there is minimal or no aqueous buffer remaining on the 
protein. (C) Typical protein MS measures denatured proteins that are usually unfolded monomers 
carrying high levels of charge due to exposure of basic residues during ionisation. Native protein MS 
can result in the measurement of protein multimers in a ‘native-like’ conformation, carrying low 
charge due to basic residues being buried during ionisation. 
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1.4 Ion Mobility-Mass Spectrometry 
 
The combination of ion mobility separation to MS (IM-MS) has vastly increased level of 
structural data that can be obtained from, MS based experiments. In simple terms, the size 
and shape of an ion can be measured through the addition of a drift cell to a mass 
spectrometer. Drift cells are chambers that produce a weak electric field that promotes the 
passage of an ion against an inert countering gas-flow (typically argon). Both the electric 
field and gas flow can be modified to augment the passage of ions through a drift cell, giving 
the user a high degree of control and separation  in IM experiments (Kanu et al., 2008). IM 
studies have been conducted using various technologies, the first of which is a simple linear 
drift-tube that works as described above (McDaniel et al., 1962). Later IM-MS based studies 
have made use of a travelling wave system (TWIMS), which is a more compact IM cell that 
utilises alternating electric potentials to generate waves that gas-phase ions ‘surf’ against the 
countering gas flow (Shvartsburg and Smith, 2008).  
 
Ions subjected to IM-MS separate based not only on mass-to-charge ratio (m/z) but also based 
on their shape, or more specifically their rotationally averaged cross-sectional area termed a 
‘collisional cross-section’ (CCS) (Wyttenbach et al., 1996). CCSs are energy and temperature 
dependent measures of the gas-phase conformational state of ions and have been strongly 
correlated to the areas derived from X-ray crystal structures when conditions are considered 
native (Jurneczko and Barran, 2011). Data obtained using traditional drift tubes can be 
assessed using the Mason-Schamp equation to directly determine CCSs of ions (McDaniel et 
al., 1962), whereas TWIMS systems must make use of calibrants with known CCSs to 
interpolate the CCS of unknown ions (Ruotolo et al., 2008b).  
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IM-MS has been particularly useful for the study of large macromolecular assemblies, as 
there is now abundant evidence indicating that the binding interactions of large biological 
molecular assemblies can be maintained in vacuo if the right conditions are met (Benesch et 
al., 2007). By using IM-MS to measure the size of protein complexes and their corresponding 
sub-complexes, researchers have been able to effectively produce and refine structural 
models of macromolecular complexes that are difficult to study by standard techniques such 
as X-ray crystallography. An example of this is in the study of molecular chaperones such as 
the small-heat-shock proteins, which form large polydisperse oligomeric assemblies that 
confound traditional structural analysis, but can be effectively resolved with MS and the 
underlying structures can be examined with IM-MS providing constraint for in-silico 
modelling (Baldwin et al., 2011). 
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Figure 1.3: Ion mobility-mass spectrometry of protein assemblies. (A) Schematic showing the 
general principle of ion mobility (IM) of ions. In this case a travelling-wave system is shown, where 
gas-phase ions are carried by the travelling-wave potential against a countering inert gas-flow. Ions 
separate based on their shape and size. (B) A typical ion chromatogram showing the measured arrival 
time distributions of the ions being sampled, where larger ions take longer to traverse the cell and 
therefore arrive later. Inset is a panel showing the MS –based deconvolution of a peak of mixed 
species that share a similar arrival time but different m/z values. This can also be reversed, where 
similar m/z values can be resolved using IM to determine different arrival times.    
 
1.5 Collision-Induced Dissociation and Unfolding 
 
Although native MS must be carefully performed to maintain native interactions, unfolding 
and dissociating ions in the gas-phase can reveal much about their structure and oligomeric 
composition. MS gives the user not only excellent separation of moderately heterogeneous 
samples, but also unique capabilities that allow for further separation and analysis of specific 
ions within mixtures. Integral to the investigation of protein complexes is an understanding of 
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their underlying composition as not all complexes are composed of homogenous subunits. A 
common feature in all mass spectrometers is a collision-cell; a chamber in which ions can be 
forced to undergo increasing collisions with an inert gas leading to the dissociation, 
unfolding, and fragmentation of protein complexes dependent upon the amount of energy 
input into the cell. Although this energy directed dissociation of heterogeneous protein 
complexes is not generally correlated with solution-phase events, one can determine the 
components of a heterogeneous complex with high accuracy and reliability via this method 
(Sharon, 2010). In the gas-phase, collision-induced dissociation (CID) of multiply charged 
protein complexes proceeds through pathways defined as symmetric and asymmetric 
dissociation which is dependent upon the partitioning of charge after dissociation has 
occurred. Symmetric dissociation results in fragment ions where charge is equal to the 
proportion of mass represented by the ion (a dimer example = dimer
n+
 = 2 × monomer
(2/n)+
), 
whereas asymmetric dissociation results when a fragment ion of a complex carries a 
disproportionate amount of charge after it has been dissociated (dimer
n+
 = monomer
>(2/n)+
 + 
monomer
<(2/n)+
). Asymmetric dissociation is the most typical form of dissociation that occurs 
during CID-based studies (Felitsyn et al., 2001, Jurchen and Williams, 2003b, Versluis et al., 
2001), and is thought to be the consequence of the unfolding of a subunit within a complex, 
which increases the accessible chargeable surface area, resulting in the migration of charge to 
maintain a uniform charge density (Benesch et al., 2007, Benesch et al., 2006, Wanasundara 
and Thachuk, 2007a). The asymmetric dissociation of complexes can be avoided by either 
manipulation of ion charge (Bornschein and Ruotolo, 2015), or by utilising other activation 
methods, such as surface-induced-dissociation (SID) where complexes are dissociated by 
colliding with an inert, or functionalised, surface which results in a predominantly symmetric 
dissociation pathway (Beardsley et al., 2009). 
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In combination with tandem mass spectrometry (multiple mass spectrometers operating in 
sequence), single ion populations can be selected and subject to collisions with increasing 
energy, resulting in both collision induced unfolding (CIU) and CID. The advent of IM-MS 
has allowed for more in depth studies into CIU and CID, where researchers have been able to 
monitor both unfolding and dissociation, linking them within a kinetic framework that 
defines the gas-phase dynamics of protein complexes. Recently, CIU was used to investigate 
the gas-phase unfolding of monomers composed of 1 to 4 ubiquitin domains, as well as 
cytochrome C, glutathione S-transferase, green-fluorescent-protein, and γD-crystallin. It was 
determined that the gas-phase unfolding of these proteins was highly correlated to the number 
of specific domains within their structure if the charge state chosen for examination was 
below the average charge state produced by ESI (Zhong et al., 2014). Furthermore, it has also 
been determined that CIU can be effectively used in measuring protein stability in the 
presence of ligands and small molecules (Allison et al., 2015, Rabuck et al., 2013) which is 
an important metric when developing organic molecules for the stabilisation of proteins 
involved in misfolding-related diseases.  
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Figure 1.4: A typical IM-MS/MS workflow for CID and CIU. (A) Samples are ionised and 
detected by the first MS (MS1) which is used to isolate an ion-population by its m/z value. The 
selected ion population traverses the collision-cell where increasing collisions with an inert gas can 
dissociate and unfold proteins. The dissociated and/or unfolded proteins then traverse the IM-cell 
where they are separated based on their CCS, after which they are detected by a second mass 
spectrometer (MS2). (B) A basic mass spectra acquired from an IM-MS/MS experiment where the 
selected ion (green) decreases in intensity relative to the product ions generated from CID (red and 
blue) as collisional energy is increased. (C) The CIU fingerprint heat-map of an isolated ion shows 
that as collisional energy is raised, the ion shows increased drift times, which correlate to increased 
surface area. i.e. the ion is unfolding.   
 
1.6 Misfolded and Unfolded Proteins 
 
An increasing number of neurodegenerative diseases, such as Alzheimer’s disease, 
Huntingtin, Parkinson’s disease, and amyotrophic lateral sclerosis, are associated with the 
misfolding, unfolding, and subsequent aggregation of disease specific proteins. The 
intracellular environment is tightly regulated to decrease the chance of protein misfolding or 
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unfolding (Dobson, 1999). However, cells can still be subjected to stresses such as 
temperature, pH change, and increased levels of oxidants, that can alter the normal 
physiological conditions within the cell. When the physiological conditions in the 
intracellular environment change, the stabilizing forces of hydrophobic interactions and 
hydrogen bonds can be disrupted, leading to unfolding or misfolding (Carver et al., 2003, 
Ecroyd and Carver, 2008). Protein unfolding describes the loss of native conformation in an 
already folded protein, whereas protein misfolding describes the process of a newly 
synthesized protein folding inappropriately into a non-native conformation. Protein 
misfolding can result from mistakes during translation, unwanted interaction with metal ions, 
and commonly, mutations within the amino acid sequence (Bross et al., 1999, Fink, 1998).  
Since the native conformation and its resulting free energy is determined primarily by the 
primary structure of a protein, genetic mutations that result in changes to the amino acid 
sequence have a marked effect on the correct folding of the protein (Chiti et al., 2002, 
Gregersen et al., 2006). When specific residues are mutated, they can have substantial effects 
on the entire protein, such as decreasing net charge and increasing the number of exposed 
hydrophobic residues (Chiti and Dobson, 2006). Two possible outcomes can be described by 
the energy landscape model of protein folding, one representing correct folding regardless of 
mutation, and the other representing mutations that have produced interactions that lead to a 
structure with a lower free energy state than that of the native conformation (Clark, 2004, 
Gregersen et al., 2006). If these unfolded or misfolded proteins persist in a cell and evade or 
overwhelm the protein quality control mechanisms, there is a high chance of protein 
aggregates forming (Carver et al., 2003, Dobson, 1999, Muchowski and Wacker, 2005). 
The list of proteins involved in misfolding and disease is extensive (Chiti and Dobson, 2006) 
and interestingly there does not seem to be a common structural theme of these 
amyloidogenic proteins, as they can inhabit primarily α-helical, β-sheet, and intrinsically 
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disordered native-folds. Typically, natively folded proteins mask their hydrophobic residues 
in their interior to minimise unwanted interactions, however, misfolded proteins may expose 
these residues which invariably increases their aggregation propensity and propensity for 
potentially cytotoxic interactions in cells (Goldschmidt et al., 2010). It has been suggested 
that misfolded proteins may inhabit conformations that expose hydrophobic patches or 
inhabit dynamic molten-globule states that maintain a semblance of secondary structure but 
no defined tertiary structure, allowing them to easily take part in intermolecular interactions 
(Jahn and Radford, 2008). Recent work, using the amyloidogenic β2-microglobulin protein 
that is involved in dialysis-related amyloidosis, has shown that a stable, but transiently 
populated, state is almost exclusively responsible for aggregation in an in vitro system, and 
that murine β2-microglobulin cannot undergo transition into this state (Karamanos et al., 
2016). Collectively, the evidence appears to point in a direction where misfolded states are 
able to not only increase their propensity for intermolecular interactions, but also interact 
through specific transient structures that lead to pathogenic aggregation. 
1.4 Protein Aggregation 
 
Protein aggregation occurs due to the inappropriate interaction of exposed hydrophobic 
residues on separate misfolded proteins and can lead to two structurally based outcomes; 
(i) disordered and (ii) ordered aggregation (Carver et al., 2003). Disordered aggregation leads 
to the formation of amorphous aggregates that, if not cleared by intercellular quality control 
mechanisms, precipitate irreversibly when they reach a certain size (Ecroyd and Carver, 
2008). Ordered aggregation leads to the formation of amyloid fibrils, which are filamentous 
structures that are rich in β-sheet (Dobson, 1999). Characterisation of the structure and 
formation of amyloid fibrils has been the focus of intense research as they are a key 
pathological feature of many neurodegenerative diseases (Chiti and Dobson, 2006). Amyloid 
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fibrils are generic in structure, even though they are usually composed of different proteins 
that are often not related. The fibril is generally an unbranched structure 7-12 nm in diameter 
and hundreds of nanometres in length (Chiti et al., 1999, Serpell, 2000, Sunde et al., 1997). 
The structure is a combination of 2-6 protofilament strands which are twisted around one 
another in a helical arrangement (Dobson, 2004, Serpell, 2000).  Protofilaments are 
predominantly composed of β-sheets forming β-strands that are perpendicular to the axis of 
the fibril, giving a twisted appearance (Serpell, 2000, Sunde et al., 1997). These fibrils are 
highly stable and resistant to cellular degradation processes due to the large amount of 
hydrogen bonding between the β-strands, and low solvent accessibility to the fibril core 
(Dobson, 2004, Ecroyd and Carver, 2008, Sunde et al., 1997).   
Results from studies using thioflavin T (which binds to the β-strand motifs in fibrils) have led 
to the assertion that amyloid aggregation obeys Boltzmann-sigmoidal kinetics where there is 
a lag-phase, exponential growth phase, and plateau (Fig. 1.5 A). The molecular events 
occurring during these phases are a topic of great interest, as understanding them is essential 
to resolving the specific cytotoxic species that are responsible for disease. The lag-phase is 
suggested as encompassing the unfolding of proteins, and their subsequent polymerisation 
into aggregate nuclei, which is termed ‘primary nucleation.’ Fragmentation of these nuclei is 
suggested to increases the number of interface points for monomer scaffolding, essentially 
feeding back into the process until enough fibrillar species are present for a detectable 
increase in aggregate abundance, i.e., the beginning of the elongation phase (Fig. 1.5 B) 
(Knowles et al., 2014). Fibril formation ensues rapidly during the elongation phase (Chiti and 
Dobson, 2006), where the same processes determining the lag-phase are measurable due to 
the exponential increase in their occurrence (Knowles et al., 2014). For most amyloid 
diseases, as fibrils composed of specific proteins grow in length they are likely to fragment 
which increases the number of available ‘ends’ for monomers to template, a process which is 
19 
 
defined as ‘fragmentation-controlled’ (Xue et al., 2008, Buell et al., 2014), although this is 
not the case for the classical amyloid-β protein which seems to nucleate and elongate in vitro 
under quiescent conditions in comparison to other amyloid proteins (Tiiman et al., 2013). 
An apparent consequence of amyloid formation, within cells, seems to be the tangling of 
fibrils, forming plaques or protein deposits (Dobson, 2004, Ecroyd and Carver, 2008, Serpell, 
2000). It is as of yet definitively determined whether the primary toxic species in in amyloid 
diseases are small soluble oligomers or fibrils. Oligomers have been highlighted for their 
soluble nature which allows them to diffuse freely within cells to increase the potential for 
cytotoxic interactions (Kayed et al., 2003, Lesne et al., 2006, Shankar et al., 2008), whereas 
fibrils have been suggested as causing toxicity through disruption of cellular membranes 
(Gharibyan et al., 2007, Pieri et al., 2006, Meyer-Luehmann et al., 2008), where their 
cytotoxicity is greatly enhanced via fragmentation (Xue et al., 2009). 
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Figure 1.5: The kinetics and processes of fibrillar aggregation. (A) The typical Boltzmann-
sigmoidal kinetics observed for fibrillary aggregation in the presence of thioflavin T, where τlag is the 
lag-phase duration, elongation is the exponential growth phase, plateau is the saturation of 
thioflavin T binding. (B) A basic schematic of fibrillar aggregation where unfolded monomers 
associate into aggregate nuclei via primary nucleation. Additional monomers polymerise onto the 
nuclei to either form mature fibrils or fragment into more nuclei, feeding back into the process.  
 
 
1.5 Disease is Associated with Protein Aggregation 
 
The formation of protein rich plaques and deposits is a characteristic of neurodegenerative 
disease, but whether the aggregates themselves are the cause of pathology is still debated. It 
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is suggested that the early structures of the aggregation cascade, such as prefibrillar 
oligomers, are the most cytotoxic, and as such, are responsible for the onset of the disease 
(Bucciantini et al., 2002, Dobson, 2004, Stefani and Dobson, 2003). Recent work has 
identified small Amyloid-β and α-synuclein oligomers as potential diagnostic biomarkers 
correlated with Alzheimer’s disease and Parkinsonism respectively (Hansson et al., 2014, 
Hölttä et al., 2013). A primary hypothesis is that the toxicity observed in protein misfolding 
diseases is the result of newly formed aggregates interacting inappropriately with cellular 
machinery (Stefani and Dobson, 2003); however, the precise mechanism of toxicity is 
unknown. Potential mechanisms by which these aggregates could be toxic include, inhibition 
of the correct functioning of cellular machinery via inappropriate reactions, or physical 
disruption of the cellular environment (Stefani and Dobson, 2003).  
There is a lack of correlation between the amount of deposited protein and the severity of 
disease in the case of most neurodegenerative disorders. Whilst there is evidence suggesting 
that the amount of pathological TAR DNA binding protein-43 (TDP-43) aggregates in 
amyotrophic lateral sclerosis patients is correlated with disease severity, it is difficult to 
determine if these larger visible aggregate structures are the causative agent. It is thought that 
the lack of correlation for most neurodegenerative diseases may be explained by the toxicity 
of the prefibrillar aggregates (Stefani and Dobson, 2003). This is supported by the 
consequences of the structural differences between oligomer and mature fibril, such as the 
dramatically lower stability of oligomers and their smaller size allowing for higher mobility 
in cells and tissue. It has also been suggested that the formation of amyloid fibrils and protein 
deposits acts to remove the toxic prefibrillar aggregates from the cellular environment 
(Lansbury, 1999, Soto and Estrada, 2008).  The toxic oligomer hypothesis has implications in 
all protein deposition associated neurodegenerative disease, signifying the importance of 
understanding the specific aggregation related interactions within certain diseases. The failure 
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of protein quality control is implicated as a major factor in neurodegenerative disease 
(Yerbury et al., 2016), however, specific diseases are usually associated with specific 
aggregating proteins. Alzheimer’s disease is associated with deposition of Amyloid-β, and 
primarily manifests as a substantial loss of neurons throughout the cerebral cortex, consistent 
with the observed memory deficiency of sufferers (Petersen, 2012). In contrast, Parkinson’s 
disease is associated with α-synuclein aggregation, and loss of neurons in the substantia 
nigra, responsible for movement control and initiation, consistent with the loss of motor 
control (Beitz, 2014). Indeed, the differences in pathology and aetiology between 
neurodegenerative diseases suggest different molecular causes are responsible for each 
disease, and that a breakdown of protein quality control, whilst perhaps important, is not a 
root cause. Amyotrophic lateral sclerosis is a prime example of the difficulty in determining 
the molecular culprit of disease as it is associated with mutations in a wide range of genes, 
and most cases are sporadic in nature. 
1.6 Amyotrophic Lateral Sclerosis 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease initially presents as 
muscle weakness that progresses to severe muscle paralysis in the patient. The paralysis 
typically occurs first in the distal limbs and spreads rapidly throughout the body for 1-5 years, 
after which respiratory failure leads to death (Pasinelli and Brown, 2006). The disease affects 
the large neurons in the spinal cord, cortex and brain stem responsible for motor control, 
leading to a common reference to the disease as ‘motor neuron disease’. The degeneration of 
both upper and lower motor neurons is a key characteristic of the disease, leading to atrophy 
of skeletal muscle as a result of denervation (Mitchell and Borasio, 2007). This degeneration 
is observed to begin at a focal point in the central nervous system, after which it spreads 
throughout the 3D anatomy of the nervous system, consistent with the progressive nature of 
23 
 
the disease (Ravits and La Spada, 2009). ALS is the most prevalent motor neuron disease, has 
an average age of onset of around 50-60 years, and risk of development increases with age 
(Andersen and Al-Chalabi, 2011b). Lifetime risk (~1:300 to 1:400) is the most appropriate 
measure of ALS frequency within the population, as most sufferers die soon after diagnosis, 
leading to a seemingly low prevalence (Andersen and Al-Chalabi, 2011b). 
The majority of ALS cases are sporadic (sALS) with no discernible cause of pathology; 
however, inclusions composed of ubiquitinated and phosphorylated TDP-43 (TAR DNA 
binding protein) have been associated with most disease cases (Mackenzie, 2007). 
Approximately 10% of ALS cases are familial (fALS), as they are linked to autosomal 
dominant mutations in several genes (including SOD1, TDP-43, FUS, C9orf72 and OPTN). 
Within the fALS group, 20% of cases can be linked to mutations in the gene encoding the 
SOD1 protein (Bruijn et al., 2004, Valentine et al., 2005). It is believed that due to the 
similarity of the disease profiles between sALS and fALS, study of the more well understood 
fALS cases will yield insight into sporadic ALS as well (Pasinelli and Brown, 2006). 
However, the relevance of SOD1-associated fALS to sALS has recently been questioned (Liu 
etal. 2009; Kerman etal. 2010). 
1.7 SOD1 Structure and Function 
 
Previously known as erythrocuprein, SOD1 is an antioxidant protein that resides within the 
cytosol. SOD1 catalyses the dismutation of superoxide free radicals and is one of the body’s 
prime defences against reactive oxygen species (McCord and Fridovich, 1969, Pasinelli and 
Brown, 2006). The SOD1 protein is a homodimer composed of two polypeptides folded as 
eight-stranded Greek key β-barrels. Each monomer is 153 amino acid residues in length and 
in its native conformation contains both a zinc and copper atom (Fig. 1.6) (Cleveland and 
Rothstein, 2001). The metal-binding region is encased by two large loops which are 
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important for the protein’s function. The loops are called the electrostatic and zinc loops and 
both contribute to the viability of the metal binding region, but also to stability (Hough et al., 
2004). Each SOD1 monomer also has an intra-subunit disulfide bond (Cys57 – Cys146) that 
is important in the stability of the dimer and the monomeric subunits (Arnesano et al., 2004, 
Furukawa et al., 2004). 
 
Figure 1.6: Crystal structure of SOD1 in its native conformation.  SOD1 exists as a homodimer of 
two 16 kDa subunits that adopt a Greek key β-barrel conformation. The copper atom (blue sphere) is 
primarily coordinated by the electrostatic loop (blue), and the zinc atom (orange sphere) is 
coordinated by the zinc-loop (orange). An intramolecular disulfide between Cys57 and Cys146 links 
loop-IV with β-strand-VIII (PDB accession: 1HL5 – (Strange et al., 2003)). 
 
The SOD1 dimer was initially found to be 32 kDa in size and to contain 0.34% copper by 
weight (Markowitz et al., 1959). The copper is essential for the activity of SOD1 in its 
superoxide scavenging role, as its removal was revealed to abolish activity in early studies 
(McCord and Fridovich, 1969). The copper atom is able to react with the superoxide radicals 
and produce molecular oxygen or hydrogen peroxide via two reactions dependent upon Cu 
oxidation state: 
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1. O2
-
 + Cu
II
ZnSOD  → O2 + Cu
I
ZnSOD  
2. O2
-
 + 2H
+
 + Cu
I
ZnSOD → H2O2 + Cu
II
ZnSOD 
The hydrogen peroxide is subsequently converted to H2O by glutathione peroxidase 
(Cleveland and Rothstein, 2001). Studies have highlighted the importance of a helper protein 
called the human copper chaperone for SOD1 (hCCS), which recognizes newly synthesised 
SOD1 and activates it by installing the copper ion and catalysing the oxidation of the 
disulfide bond in the SOD1 monomers (Brown et al., 2004, Culotta et al., 1997, Furukawa et 
al., 2004). 
The superoxide scavenged by SOD1 is primarily a by-product of the molecular processes 
taking place in the mitochondrion, such as oxidative phosphorylation (Pasinelli and Brown, 
2006).  Reactive oxygen species produced by oxidative phosphorylation can cause 
irreversible damage to cell membranes, proteins and DNA (Stadtman et al., 1992), signifying 
the importance of SOD1 in cellular homoeostasis. It was suggested that mutations in SOD1 
were responsible for the onset of fALS due to an impaired or complete loss of enzymatic 
activity, leading to an increase in reactive oxygen species (Olanow, 1993). However, 
research carried out on purified SOD1 in vitro and also on transgenic mice, where knocking 
out SOD1 did not cause ALS symptoms, has indicated that a loss of enzymatic function is 
not the cause of fALS (Bowling et al., 1993, Reaume et al., 1996, Rosen et al., 1993) but 
rather suggests it is caused by a toxic gain of function (Reaume et al., 1996). 
Furthermore, an in vitro study determined the relative enzymatic activity of various SOD1 
mutants and analysed this against the mutant variants clinical pathology (age of onset, rate of 
progression). No correlation was found between the enzymatic activity of the mutants and 
fALS pathology, further suggesting that gained toxic properties are the main factor behind its 
association with ALS (Cleveland et al., 1995). Perhaps the most substantial evidence is that 
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mutant variants with full enzymatic activity still cause fALS (Borchelt et al., 1994). The 
hypothesis linking loss of SOD1 activity to ALS was dealt a further blow when researchers 
attempted to increase dismutase activity by increasing the expression of SOD1
WT
 in mutant 
SOD1 expressing mice. The increase in dismutase activity was found to have no effect upon 
the progression of fALS (Bruijn et al., 1998) and one study found that an increase in human 
SOD1
WT
 expression accelerated the disease in mice (Jaarsma et al., 2008). In addition to this, 
overexpression of SOD1 with mutated Cu-coordinating residues resulted in an aggressive 
ALS phenotype in mice (Wang et al., 2003). Given that a loss of function in SOD1 activity is 
not associated with ALS, research has focused upon the mutant variants and their possible 
gain in toxic properties as a result of structural instability and aggregation. 
1.8 SOD1 Stability 
 
SOD1
WT
 has been described as an incredibly stable protein in its fully metallated (two copper 
and two zinc atoms), disulfide oxidised, and dimeric form (Valentine et al., 2005).  Both 
human and bovine SOD1
WT
 proteins have exceedingly high thermodynamic stability, and are 
resistant to proteolytic digestion with trypsin and aminopeptidase (Rodriguez et al., 2002, 
Senoo et al., 1988). The remarkable stability of SOD1 is further demonstrated by its ability to 
maintain its native conformation in concentrations of guanidine HCl as high as 3.2 M, as 
measured by circular dichroism and tryptophan fluorescence spectroscopy (Mei et al., 1992, 
Rumfeldt et al., 2006). Lindberg and colleagues argue that using measurements of stability of 
the disulphide bonded holo-state are not valid owing to the unfolding process of this SOD1 
form not being complete, and also show that the greatest effect of mutation on stability is 
observed for the reduced apo-state. (Lindberg et al., 2002). Apart from the disulfide bond, 
SOD1 is stabilised by a number of hydrogen bonds throughout the macromolecule. 
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This exceptional stability is highly dependent upon the binding of the metal ions to the 
protein, as the wild-type SOD1 apo-protein has a melting temperature of 52 ºC (Valentine et 
al., 2005). Additional destabilisation is caused by the reduction of the intramolecular 
disulfide, decreasing the melting temperature further to ~43 ºC and also effectively halving 
the kinetic stability, as measured by guanidine HCL unfolding (Lindberg et al., 2002). The 
relative importance of each metal ligand, with respect to stability is debatable, however, it is 
clear from unfolding studies that both contribute significantly to stability (Kayatekin et al., 
2008, Lynch and Colón, 2006). The dependence of SOD1 stability on the coordination of the 
metal ions indicates that mutations affecting the metal binding affinity of the protein would 
have substantial effects upon stability. With a large number of mutations in SOD1 being 
associated with fALS it is important to assess whether they affect the metal ion affinity of the 
protein or not. 
1.9 Mutations in SOD1 
 
Over 183 different mutations in SOD1 have been identified and associated with fALS 
(http://alsod.iop.kcl.ac.uk (Abel et al., 2013b) (see Fig. 1.7). Most of these mutations have 
been identified as missense mutations, although deletions and truncations have also been 
found. The mutations are not concentrated to specific regions of SOD1, but rather are spread 
throughout the amino acid sequence, and all are able to alter the structure to varying degrees 
(Cleveland and Rothstein, 2001) (Fig. 1.7). The mutations have been found to have diverse 
effects upon the physical properties of the SOD1 protein, making it difficult to identify a 
singular cause of toxicity. Effects can include a decrease or increase in thermostability 
(Rodriguez et al., 2005, Shaw and Valentine, 2007), a lowering of affinity for copper and zinc 
ions (Valentine et al., 2005), or inhibition of the intramolecular disulfide bond between 
Cys57 and Cys146 (Hayward et al., 2002). SOD1 mutant variants that lose affinity for copper 
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or zinc, or lose the intramolecular disulfide bond between Cys57 and Cys146, have been 
found to have a lower conformational stability than SOD1
WT
, making them more prone to 
aggregation (Arnesano et al., 2004, Valentine et al., 2005).  The fALS mutant variants of 
SOD1 have been separated into two classes based on biophysical studies of SOD1 activity, 
metal content, and spectroscopic characteristics (Hayward et al., 2002, Tiwari and Hayward, 
2003, Valentine and Hart, 2003). These classes are designated metal-binding region (MBR) 
and wild-type-like (WTL) fALS mutant SOD1 proteins.  
 
 
Figure 1.7: SOD1 monomer with ALS-associated point mutations. (A) Frequency of point 
mutations across the SOD1 amino acid sequence. (B) Point mutations (red spheres) associated with 
ALS are noted throughout the structure of SOD1 (PDB accession: 1HL5 – (Strange et al., 2003)). 
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1.10 Metal Binding Region and Wild-Type Like SOD1 Mutants 
 
The MBR class of SOD1 mutants are defined by mutations localized to the metal-binding 
sites of the protein including the surrounding electrostatic and zinc loops. MBR mutations 
have diverse effects upon the protein structure and activity. This is due to the direct 
disruption of the metal coordinating amino acids that bind either zinc or copper, alteration of 
the overall metal-binding affinity, or a substantial destabilization of the structure around the 
metal-binding region (Valentine et al., 2005). 
SOD1
H46R
 has been studied in vitro where it was found that the native zinc binding site of the 
protein is able to bind copper or zinc, but the native copper site no longer binds metal ions 
(Liu et al., 2000). Studies involving transgenic rodents have been carried out with rats 
expressing H46R (Nagai et al., 2001) and mice expressing a H46R/H48Q double mutation 
(Wang et al., 2002). In both studies the rodents developed ALS-like symptoms, but the 
disease progression was not as aggressive for SOD1
H46R
 as it was for the SOD1 double 
mutant. Indeed, in humans the SOD1
H46R 
mutation results in ALS that has an average disease 
progression of 17 years after diagnosis, much longer than other mutants, even those that are 
WTL (Wang et al., 2008). This may be related to the curious observation that the H46R 
substitution increases the stability of the disulfide reduced apo-state compared to SOD1
WT
, 
indicating that destabilisation of this state may be linked to SOD1 pathogenesis (Rodriguez et 
al., 2005). In contrast to the MBR mutants, WTL mutants are associated with correct metal 
coordination and near SOD1
WT
 activities, but can still contribute to disease. 
The WTL mutant SOD1 variants have been researched in depth owing to the fact that even 
though they still retain activity and stability similar to SOD1
WT
, they are implicated in fALS 
cases. The thermostability of various WTL SOD1 mutants was assessed by comparing the 
melting temperatures of mutant SOD1 to that of the wild-type (SOD1
WT
), with a report of a 
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1-6°C drop in melting temperature across the mutants (Rodriguez et al., 2002). In addition, 
the enzymatic activity of various WTL SOD1 mutants was compared to SOD1
WT
 where the 
results showed little distinction between the two (Lindberg et al., 2002). For example, a 
biologically metallated SOD1
A4V
 mutant isolated from both yeast (Goto et al., 2000) and 
insect cells (Hayward et al., 2002) was shown to be appropriately metallated in addition to 
having full enzymatic activity on a per copper basis. This combination of a relatively high 
stability and little to no loss of enzymatic activity amongst the WTL SOD1 mutants makes a 
cause of toxicity difficult to identify, at least in regards to natively folded SOD1 variants and 
suggests, in conjunction with analysis of post-mortem tissue, that an off-folding pathway 
leading to aggregation may play a role. 
The high stability of SOD1 would infer that its aggregation propensity would be low, 
however, SOD1 is associated with aggregates in motor neurons in ALS post-mortem tissue 
(Forsberg et al., 2010). Several reasons have been suggested for the aggregation of SOD1, 
including mutation or oxidative damage increasing the exposure of hydrophobic surfaces 
(Munch and Bertolotti, 2010), and a destabilization of the dimer interface which increases the 
propensity of dimer dissociation (Khare et al., 2006). Structural changes to SOD1 observed in 
WTL mutants are not as substantial as the changes observed in MBR mutants, which should 
suggest a lower propensity of WTL mutants to aggregate. This is not the case, however, as 
both theoretical (Wang et al., 2008) and empirical studies (Prucendio et al., 2009) have 
determined that aggregation propensity does not correlate to whether the mutant is MBR or 
WTL. 
1.11 SOD1 Aggregation 
 
Electron microscopy imaging of protein inclusions harvested from ALS patients revealed that 
they are distinct from amyloid, having an amorphous or granular structure (Kato et al., 2000) 
31 
 
that does not stain with Congo red, and stains relatively weakly with Thioflavin S (Kerman et 
al., 2010). However, recent research has suggested that although in vivo SOD1 deposits 
appear to be amorphous by staining, at a molecular level there is a repetitive structure, as 
determined by sequence level analysis using conformation specific antibodies in SOD1 
transgenic mice (Bergh et al., 2015, Lang et al., 2015), and addition of SOD1
G93A
 mouse 
spinal cord homogenate to an in vitro aggregation assay showing a seeding effect (Chia et al., 
2010). If these structural elements exist in motor neurons from human SOD1-associated 
fALS patients remains to be determined.  
Although mutations in SOD1 are known to increase the aggregation propensity of the protein, 
spontaneous aggregation of a fully metallated disulfide bonded ALS associated SOD1 variant 
is yet to be observed. Initially, research into SOD1 aggregation utilised high temperatures, 
extreme pH conditions, and organic solvents to induce aggregate assembly (Banci et al., 
2008, DiDonato et al., 2003, Stathopulos et al., 2003), conditions with little relevance to the 
intracellular environment. Due to this, most modern SOD1 in vitro aggregation protocols rely 
upon destabilising SOD1 via reduction of the disulfide and chelation of the metals, which are 
events more likely to occur in the reducing chelating intracellular environment, as well as 
agitation to increase the number of molecular contact events and therefore speed up the 
process (Abdolvahabi et al., 2016, Chan et al., 2013, Chattopadhyay et al., 2008, Furukawa et 
al., 2008, Roberts et al., 2013).  Together this suggests that the immature form of SOD1, 
without the stabilising post-translational modifications, may be a major vulnerable species 
prone to aggregation and a primary template for SOD1 seeded aggregation. In the context of 
typical amyloid aggregation kinetics (discussed in section 1.7), generally speaking SOD1 
aggregation appears to follow amyloid like kinetics, although recent work has shown that the 
formation of structured or unstructured aggregates is an entirely stochastic process dependent 
upon the initial formation of primary aggregate nuclei (Abdolvahabi et al., 2016). 
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1.12 Oxidatively induced damage and modification of SOD1 
 
That SOD1 aggregates are found in both sALS and non-SOD1 associated fALS cases 
(Forsberg et al., 2010), indicates that mutation is not necessary for SOD1 aggregation to 
proceed. Furthermore, the use of novel antibodies raised against epitopes of misfolded 
(protein that has folded into a non-native conformation) SOD1 has shown that misfolded 
SOD1 can be found in sALS patients and fALS patients, and that overexpression of fALS 
associated proteins such as TDP-43 and FUS in human neurons can induce SOD1 misfolding 
(Bosco et al., 2010, Pokrishevsky et al., 2012b). Interestingly, the processes of misfolding 
and aggregation appear to be specific to brain and spinal cord motor neurons (Rakhit et al., 
2007), even though SOD1 is ubiquitously expressed at high concentrations (Pardo et al., 
1995). One of the most studied factors that may be responsible for this  is oxidative damage , 
which is thought to be associated with  many neurodegenerative diseases, including ALS 
(Jellinger, 2010). Oxidative stress is thought to play a role in many diseases, as a primary 
cause, and also a contributing factor (Kennaway et al., 2005). Reactive oxygen species have 
the capability to damage or modify proteins irreversibly, leading to changes in structure 
and/or function (Sobott et al., 2002, Banci et al., 2014). A single point mutation is capable of 
severely destabilising the structure of SOD1, and therefore oxidative damage may have the 
potential to produce similar changes in structure. SOD1 is a prime target for oxidative 
damage and modification due to its role of scavenging superoxide and catalysing the reaction 
to transform it to hydrogen peroxide. Studies have shown that SOD1 can be oxidatively 
damaged through reactions with hydrogen peroxide (McAlary et al., 2013b), hypochlorite 
(Pokrishevsky et al., 2012b), peroxynitrite (McAlary et al., 2013a), bicarbonate (Coelho et 
al., 2014), or fatty acid derived hydroperoxides (Appolinário et al., 2015) all of which can 
potentially occur in vivo. SOD1 purified from human erythrocytes has been shown to be 
oxidatively modified at the solvent exposed residue Cys111 to sulfonyl cysteine (C-SO2H) 
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and sulfinyl cysteine (C-SO3H) (Fujiwara et al., 2007), modifications possible from reactions 
with either superoxide anion or hydrogen peroxide (Forsberg et al., 2010), and identified on 
SOD1 extracted from human post-mortem neural tissue (Auclair et al., 2014). Indeed, 
SOD1
WT
 at physiological concentration has been reported to misfold and aggregate in vitro 
when oxidatively damaged potentially exposing hydrophobic regions responsible for toxicity 
(Rakhit et al., 2004). Furthermore, oxidative damage may explain the selective neurotoxicity 
of SOD1 in motor neurons as these cells are long lived, and where endogenous SOD1 may 
persist for up to hundreds of days due to the slow transport from cell body to axon (Rakhit et 
al., 2002). SOD1 having a long half-life in highly metabolically active motor neurons (Shaw 
and Eggett, 2000) would strongly suggest that oxidative damage may be a factor in SOD1 
associated ALS, as the protein would be more likely to accrue oxidative damage throughout 
its long lifetime, leading to misfolding. 
There is also evidence to suggest the protection of SOD1 from oxidative damage, by the 
covalent binding of low molecular weight antioxidants, can contribute to SOD1 misfolding. 
SOD1 purified from human erythrocytes has been found to be glutathionylated at Cys111 
(Wilcox et al., 2009). Cys111 is close to the dimer interface of SOD1, and it has been shown 
that non-covalent binding of either glutathione or cysteine to this residue can reduce the 
stability of the SOD1 dimer leading to an increased population of monomers (Auclair et al., 
2013a, McAlary et al., 2013a, Redler et al., 2011). Glutathione is a tripeptide that protects 
proteins from permanent oxidative damage by reversibly binding to free cysteine residues 
(Townsend, 2007). It exists within cells primarily in its reduced form (GSH) at 
concentrations of 1-10 millimolar (dependent upon tissue type) and is the major low 
molecular weight antioxidant within the cellular environment (Schafer and Buettner, 2001). 
Covalent binding of cysteine to Cys111 has been observed to occur on human SOD1 in 
neural tissue extracted from both ALS patients and transgenic mice (Auclair et al., 2013b). 
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There is, as of yet, no evidence that SOD1 becomes glutathionylated in neural tissue, but 
recent in vitro work performed on purified glutathionylated SOD1 showed that this 
modification increased the reactivity of a disease associated epitope specific antibody (C4F6) 
to SOD1 (Redler et al., 2014), suggesting that this modification, or other modifications 
localised to Cys111 potentially contribute to SOD1 misfolding.    
1.13 Prion-like properties of SOD1 
 
Whilst it is possible that an increase in oxidative damage over time, or the presence of a 
mutation or modification, may cause SOD1 to misfold into a toxic species, one might expect 
these to consistently effect SOD1 throughout life, yet onset of ALS is typically 50-60 years of 
age (Andersen and Al-Chalabi, 2011a). This infers either a sudden appearance of a 
neurotoxic species or a decline in the ability of cells to process a consistently forming 
neurotoxic species. The evidence for deposited protein observed in ALS patients, implicates a 
decrease in the cellular proteostasis capacity of motor neurons; i.e. mutant SOD1 is 
constantly expressed but the proteostasis machinery of the cell is acting to facilitate proper 
folding, as well as degrade and clear misfolded and aggregated species of SOD1. However, a 
decrease in proteostasis capacity does not sufficiently explain ordered spatiotemporal 
progression of ALS pathology observed in patients. Recent work has suggested that 
misfolded SOD1 may act similarly to prion protein (Ayers et al., 2014a, Bergh et al., 2015, 
Grad and Cashman, 2014, Munch et al., 2011), Prion protein (PrP) is known to inhabit two 
conformations; a benign physiological conformation (PrP
c
), and a disease-associated 
conformation (PrP
sc
) that readily aggregates (Málaga-Trillo and Sempou, 2009). The PrP
sc
 
form can recruit benign PrP and convert it to the disease-associated conformation (Riesner, 
2003). Expression of the truncation mutant SOD1
G127X
 and aggressive SOD1
G85R
 mutant in 
human neural cells has been shown to induce the misfolding of endogenous human SOD1
WT
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(Grad et al., 2011). Furthermore, this misfolded SOD1 can propagate intercellularly, similar 
to PrP associated disease (Grad and Cashman, 2014), providing a potential explanation for 
the ordered degeneration of motor neurons in SOD1 associated fALS.  
A discrepancy still persists in relation to the curious differences in patient survival, where 
particular fALS associated SOD1 mutants have a rapid disease progression and others don’t 
(Wang et al., 2008). This has prompted a hypothesis by which different SOD1 mutations can 
influence misfolding and/or aggregation, to result in variable structures that have different 
propagation kinetics, and are correlated with differential survival times (Bergh et al., 2015, 
Bidhendi et al., 2016). Indeed, the standard models of SOD1 associated fALS are mice 
overexpressing SOD1
G93A
, SOD1
G37R
, or SOD1
G85R
, and it has been shown that injection of 
spinal cord homogenate from SOD1
G93A
 mice into the sciatic nerve of ALS inducible 
SOD1
G85R
-YFP (yellow fluorescent protein) mice, produces an ALS pathology and 
phenotype (Ayers et al., 2014a). However, injection of homogenate from SOD1
G37R
 mice 
does not induce an ALS pathology or phenotype, even though SOD1
G37R
 transgenic mice 
develop the disease (Ayers et al., 2014a). Altogether, this supports the idea that separate 
strains of misfolded or aggregated SOD1 can propagate intercellularly, and that different 
misfolded or aggregate forms may dictate survival time (and potentially onset), making 
identifying a therapeutic specific to SOD1-associated ALS a challenge.   
1.14 Tryptophan-32 is implicated in SOD1-associated ALS 
 
A striking observation in murine-based models of SOD1 misfolding and aggregation is that 
endogenous murine SOD1 (mSOD1) does not co-aggregate with human SOD1 (hSOD1), or 
react with misfolded SOD1 specific antibodies (Bergh et al., 2015, Grad et al., 2011). The 
sequence identity of hSOD1 and mSOD1 is relatively high (83.3%), however, a region 
corresponding to loop II and β-barrel III has a comparatively greater concentration of non-
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conserved residues than the rest of the protein, and within this region is tryptophan-32 of 
hSOD1 (Serine-32 in mSOD1) (Grad et al., 2011). Tryptophan is regarded as the amino acid 
with the highest propensity to aggregate (Pawar et al., 2005), and indeed mutation of this 
residue to a serine in SOD1 has been shown to reduce the binding affinity of misfolding 
specific antibodies after passaging misfolded forms successively, thus blocking 
intermolecular transmission (Grad et al., 2011). Trp32 is also identified as a site of oxidative 
modification in hSOD1 extracted from human and mouse blood samples (Taylor et al., 2007), 
further implying that oxidative damage may play a role in SOD1 associated ALS 
pathogenesis. Mutation of this residue to a phenylalanine on a SOD1
G93A
 backbone was 
shown to decrease the aggregation potential of SOD1 in cultured cells (Taylor et al., 2007). 
The combination of Trp32 and oxidative damage strongly suggests that this residue may be 
the common toxicity modulating feature across all SOD1 associated ALS cases, however 
further study is necessary to determine if this is the case. 
1.15 Aims and Objectives 
 
Over 180 mutations in SOD1 are associated with fALS and the combined research into this is 
extensive, yet the cause of toxicity and its determining factors are still unknown. It is clear 
that protein aggregation is a hallmark of ALS and there is potential for SOD1 misfolding or 
aggregation to be a common feature of all ALS cases, marking the cause of these processes as 
a therapeutic target. Research into SOD1 stability has focused on metalation state and 
disulfide status, owing to them imparting an exceptional stability to the native conformation. 
However, there are still gaps in knowledge pertaining to the effect of mutation on these 
features and subsequent aggregation in the context of mutation specific patient survival, and 
the common identified aggregation modulating feature W32. Therefore, the subsequent work 
detailed within this thesis investigates:  
37 
 
 The gas-phase directed dissociation and unfolding of fALS associated SOD1 variants 
 The effect of glutathionylation on the dimer dissociation of fALS associated SOD1 
variants 
 The structural consequences of disulfide reduction and metal chelation, as well as 
their relationship with aggregation of fALS associated SOD1 variants 
 The effect of a W32S substitution on the aggregation of fALS associated SOD1 
variants 
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2. General Materials and Methods 
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2.1 General Materials 
Details of general buffer compositions are listed in Appendix A 
2.2 Bacterial culture methods 
2.2.1 Basic Escherichia coli culture 
Escherichia coli (E. coli) containing plasmid DNA for DNA purification (E. coli DH5α) or 
protein expression (E. coli Bl21(DE3)) were grown on Luria-Bertani (LB)-agar plates 
containing either 100 µg/mL ampicillin, or 50 µg/mL kanamycin, overnight at 37 °C. Liquid 
E. coli cultures were grown using a single colony from LB-agar plates in LB media 
containing either 100 µg/mL ampicillin or 50 µg/mL kanamycin, overnight with shaking at 
180 rpm at 37 °C. 
2.3 Plasmid DNA purification 
2.3.1 Plasmid extraction and purification for bacterial expression 
Plasmid DNA for bacterial expression was extracted and purified using the GeneJET Plasmid 
Miniprep Kit (ThermoFisher Scientific, USA). Bacterial cultures were grown, as stated in 
2.2.1, in 10 mL of LB media. Cells were pelleted via centrifugation (6 200 × g, 10 min) and 
resuspended in 250 µL of the resuspension solution (with added RNase A) and transferred to 
a microfuge tube. After cells were resuspended, 250 µL of lysis solution was added and the 
cells mixed by inverting the tube four times. Cell lysis was typically achieved in 4 min, after 
which 350 µL of neutralization solution was added and mixed by inverting the tube 4 times. 
Immediately after mixing, the cell debris and chromosomal DNA was pelleted via 
centrifugation (16 000 × g, 10 min) and supernatants were transferred to the supplied 
GeneJET spin columns and centrifuged (8 000 × g, 1 min). Spin columns with bound plasmid 
DNA were washed twice with 500 µL of wash solution via centrifugation (8 000 x g, 1 min). 
Elution of the plasmid DNA was achieved by adding 50 µL of elution buffer to the spin 
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column and incubating at room temperature for 2 min before centrifugation 
(8 000 × g, 1 min) into a sterile microfuge tube. 
2.3.2 Plasmid extraction and purification for mammalian expression 
Plasmid DNA for mammalian expression was extracted a purified using the CompactPrep® 
Maxi Plasmid Kit (Qiagen, Germany) using the manufacturer’s instructions and buffers (all 
buffers for this section were supplied by the manufacturer). Briefly, bacterial cultures were 
grown, as stated in 2.2.1, in 100 mL of LB media. Cells were pelleted via centrifugation 
(6 200 x g, 10 min) and resuspended in 5 mL of buffer P1. After cells were resuspended, 
5 mL of buffer P2 was added and cells were mixed thoroughly by inverting the tube 6 times, 
following which cells were incubated for 3 min at room temperature. After incubation, 5 mL 
of buffer S3 was added to the cell lysate, which was mixed immediately by inverting the tube 
6 times, and centrifuged (20 000 × g, 30 min at 4 °C). Following centrifugation, the 
supernatant was transferred to clean tubes and centrifuged again (20 000 × g, 15 min at 4 °C). 
Following this, 5 mL of buffer BB was added to the supernatant and mixed via inverting 
tubes 6 times. Supernatants were transferred to the supplied CompactPrep columns with 
attached tube extenders and supernatant was passed through the columns via gravity flow. 
Following this, 700 µL of buffer PE was added to the columns and they were centrifuged 
(8 000 × g, 1 min), the flow through was discarded, and the columns centrifuged again 
(8 000 × g, 1 min). Plasmid DNA was eluted by addition of 200 µL of buffer EB to the 
columns, which were incubated for 1 min, followed by centrifugation (8 000 × g, 1 min) into 
sterile microfuge tubes. 
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Table 2.1: Plasmid constructs used throughout this project. Plasmid constructs are separated into 
‘bacterial expression’ and ‘mammalian’ expression vectors, and further separated by the final amino 
acid residue substitutions made to SOD1, and fluorescent tag. Sources of plasmids are listed with 
corresponding references. Those noted as “commercial” were designed in-house and generated using 
commercial services with sequencing to confirm correct mutation. Bacterial expression proteins were 
also analysed by mass spectrometry to confirm correct mutation. 
Bacterial expression vector 
pACA forward yCCS hSOD1 
Contains genes for the expression of both yeast CCS and human SOD1 
under a lac operon. The antibiotic resistance is Amp
r
. 
Variants used in study Source Reference 
SOD1-Wild type 
Oliveberg group (Stockholm, 
Sweden) 
(Lindberg et al., 2002) 
SOD1-A4V In-house - 
SOD1-G37R In-house - 
SOD1-H46R In-house - 
SOD1-G85R In-house - 
SOD1-D90A In-house - 
SOD1-G93A 
Oliveberg group (Stockholm, 
Sweden) 
(Lindberg et al., 2002) 
SOD1-E100G In-house - 
SOD1-I112T In-house - 
SOD1-A140G In-house - 
SOD1-V148G In-house  
SOD1-W32S In-house - 
SOD1-G93A-W32S In-house - 
SOD1-V148G-W32S In-house - 
Mammalian expression vector 
pEGFP-N1 
Contains multiple cloning site prior to the EGFP gene which has been 
modified for mammalian expression. The antibiotic resistance is Km
r
.  
Variants used in study Source Reference 
EGFP(vector) Clontech, USA (Turner et al., 2005) 
SOD1-Wild type-GFP 
Turner group (Melbourne, 
Australia) 
(Turner et al., 2005) 
SOD1-Wild type-tdTomato In-house - 
SOD1-A4V-GFP In-house - 
SOD1-A4V-tdTomato In-house - 
SOD1-G37R-GFP In-house - 
SOD1-H46R-GFP 
Hatters group (Melbourne, 
Australia) 
Unpublished 
SOD1-G85R-GFP 
Hatters group (Melbourne, 
Australia) 
Unpublished 
SOD1-G85R-tdTomato In-house - 
SOD1-D90A-GFP In-house - 
SOD1-G93A-GFP 
Turner group (Melbourne, 
Australia) 
(Turner et al., 2005) 
SOD1-G93A-tdTomato In-house - 
SOD1-V148G-GFP In-house - 
SOD1-V148G-tdTomato In-house - 
SOD1-W32S-GFP In-house - 
SOD1-A4V-W32S-GFP In-house - 
SOD1-G85R-W32S-GFP In-house - 
SOD1-G93A-W32S-GFP In-house - 
SOD1-V148G-W32S-GFP In-house - 
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2.4 Generation and transformation of expression stocks 
2.4.1 Preparation of electro-competent E.coli 
Single colonies of E. coli grown on an LB-agar plate with no antibiotics were used to 
inoculate 10 mL of LB media and grown overnight as described in 2.2.1. The overnight 
cultures were used to inoculate 1 L of LB media which was grown at 37 °C with shaking at 
180 rpm until an optical density (OD600) 1.0 was reached. The cells were pelleted via 
centrifugation (6 200 × g, 10 min) kept at 4 °C for the rest of the protocol. The cell pellet was 
resuspended in 80 mL of ice cold sterile dH2O and pelleted again via centrifuge 
(6 200 × g, 10 min), this was repeated twice. Cell pellets were then resuspended in 80 mL of 
ice cold 10% glycerol and pelleted again as before. Following the final wash, the cells were 
resuspended in 2 mL of ice cold 10% glycerol (v/v) and snap frozen in liquid nitrogen for 
storage at -80 °C. 
2.4.2 Preparation of chemically-competent E.coli 
Single colonies of E. coli grown on an LB-agar plate with no antibiotics were used to 
inoculate 10 mL of LB media and grown overnight as described in 2.2.1. The overnight 
cultures were used to inoculate 1 L of LB media which was grown at 37 °C with shaking at 
180 rpm until an optical density (OD600) 0.35 was reached, after which the cells were 
immediately incubated in an ice water bath. From this point all materials and buffers were 
chilled on ice. Cells were harvested by centrifugation (6 200 × g, 10 min at 4 °C), following 
which they were resuspended and washed in 400 mL of sterile ice cold 100 mM MgCl2. The 
washed cells were pelleted via centrifugation (3 000 × g, 10 min at 4 °C), followed by 
resuspension and washing in 200 mL of sterile ice cold 100 mM CaCl2. The recently washed 
cells were incubated for 20 min on ice, after which they were harvested via centrifugation 
(3 000 × g, 10 min at 4 °C) and the pellet resuspended in 50 mL sterile ice cold 85 mM CaCl2 
15% glycerol (v/v). Resuspended cells were harvest via centrifugation 
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(1 000 × g, 15 min at 4 °C), resuspended in 2 mL of sterile ice cold 85 mM CaCl2 
15% glycerol (v/v), aliquoted, and snap frozen in liquid nitrogen for storage at -80 °C. 
2.4.3 Transformation of electro-competent E. coli 
Electro-competent E.coli were transformed using a Bio-Rad Gene Pulser electroporator (Bio-
Rad, USA) according to the manufacturer’s instructions. Transformation mixtures consisted 
of 50 ng of plasmid DNA in 50 µL of competent cells (DH5α or BL21(DE3) cells) in an ice 
cold electroporation cuvette. The electroporator was set to 2.5 kV, 25 µ FD, and 200 Ω. After 
electroporation, cells were transferred to 500 µL of LB media and incubated for 1 h at 37 °C 
with shaking at 180 rpm. Aliquots of 100 µL and 300 µL were spread onto LB-agar plates 
containing the appropriate antibiotics and incubated overnight at 37 °C. 
2.4.4 Transformation of chemically-competent E. coli 
Chemically-competent E.coli stocks were defrosted on ice and 50 ng of plasmid DNA was 
added and gently mixed, following which cells were incubated on ice for 30 min. Cells were 
then subject heat-shock (42 °C) for 45 sec and immediately placed onto ice for 5 min. After 
the ice incubation, cells were diluted to 500 µL with LB media and incubated for 1 h at 37 °C 
with shaking at 180 rpm. Aliquots of 100 µL and 300 µL were spread onto LB-agar plates 
containing the appropriate antibiotics and incubated overnight at 37 °C. 
2.4.5 Generation of glycerol stocks of transformed cells 
Single colony of transformed E.coli was picked from plates and grown overnight in 10 mL of 
LB media containing the appropriate antibiotic resistance as stated in 2.2.1. Overnight 
cultures were used to inoculate (1/100 dilution v/v) 10 mL of LB media containing 
appropriate antibiotics and the OD600 monitored until 0.5. Once at OD600 0.5, 750 µL of 
bacterial suspension was mixed with 750 µL of sterile 40% glycerol (v/v) 2% casamino 
acids (w/v) in a cryovial. Cryovials were snap frozen in liquid nitrogen and stored at -80 °C. 
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2.5 SOD1 bacterial expression and purification 
2.5.1 SOD1 bacterial expression 
The basis for the protocols describing SOD1 expression and purification have been 
previously published (Lindberg et al., 2002). For the purpose of generating destabilised 
mutants, modifications were made to the protocol. Initial 20 mL LB media starter cultures 
containing appropriate antibiotics were inoculated with a single colony of transformed pACA 
forward yCCS hSOD1 BL21(DE3) E.coli and grown overnight at 37 °C with shaking at 180 
rpm. Each 20 mL overnight starter culture was used to inoculate 1 L of main culture (2x LB) 
with carbenicillin (Cb) added to a final concentration of 100 µg/mL. Main cultures were 
grown at 37 °C with shaking at 180 rpm until an OD600 of 0.5 was reached. In the case of 
mutant variants SOD1
A4V
, SOD1
G85R
 and SOD1
G85R-W32S
, main cultures were grown until an 
OD600 of 0.25, after which they were moved to 18 °C until they reached an OD600 of 0.5. At 
OD600 0.5 isopropyl β-D-1thiogalactopyranoside (IPTG), CuSO4, and ZnSO4 were added to 
final concentrations of 0.5 mM, 3 mM, and 40 µM respectively, as well as the addition of 
further Cb to a final concentration of 150 µg/mL. After induction, cultures incubated at 18 °C 
with shaking overnight. Following overnight expression, bacterium were harvested via 
centrifugation (6 200 × g, 10 min at 4 °C) and resuspended in ice cold 50 mM Tris-base 
(pH 7.4) (25 mL per litre of main culture). Samples were lysed by applying the bacterial cell 
suspension 2 times to an Avestin EmulsiFlex-C5-Homogeniser (ATA Scientific, Australia) at 
120 000 kPa. Cellular debris was removed from the lysate via centrifugation 
(40 000 × g, 20 min at 4 °C). The cleared lysate was then subject to heat denaturation by 
incubation in a water bath at either 65 °C (Wild type), 60 °C (Mutants), or 55° C (SOD1
A4V
, 
SOD1
G85R
). Precipitate was cleared from the lysate via centrifugation 
(40 000 × g, 20 min at 4 °C). At this point mutants SOD1
A4V
 and SOD1
G85R
, were 
concentrated using a stirred filtration cell (Millipore, USA) with Ultracel® 10 kDa 
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ultrafiltration disc membranes to a volume of approximately 15 mL after which they were 
subject to size exclusion gel-filtration chromatography (see section 2.5.2 below). Other SOD1 
mutant preparations had their volumes measured and (NH4)2SO4 was added stepwise with 
mild stirring at 4 °C until a final concentration of 60% (w/v) was reached, after which the 
samples were incubated for 2 h at 4 °C with constant stirring. Following incubation, 
precipitated protein was cleared via centrifugation (40 000 × g, 20 min at 4 °C) and 
(NH4)2SO4 was added to a final concentration of 90% (w/v) and samples were incubated 
overnight at 4 °C with stirring. Following overnight incubation, the precipitated protein 
fraction containing SOD1 was harvested via centrifugation (40 000 × g, 20 min at 4 °C) and 
the pellets were rinsed with dH2O and resuspended in 2 mL of 50 mM Tris-base 150 mM 
NaCl (pH 7.4) per 1 L of main culture. Resuspended pellets were filtered through a 0.22 µm 
filter and either immediately subject to gel-filtration chromatography (see section 2.5.2 
below) or snap frozen in liquid nitrogen for subsequent purification. 
2.5.2 SOD1 purification via gel-filtration and ion-exchange chromatography 
SOD1 samples that were (NH4)2SO4 precipitated, or filtrator concentrated, were injected onto 
a Hiload 16/600 Superdex™-75 prep-grade column equilibrated in 50 mM Tris-base 500 mM 
NaCl (pH 7.4) at volumes no more than 4% total column volume (120 mL). The protein was 
eluted at a flowrate of 1 mL/min and collected in fractions of 1 mL volume. Fractions 
containing SOD1 were determined by SDS-PAGE (see section 2.5.3 below) and pooled. The 
pooled eluent was transferred to Snakeskin® pleated dialysis tubing (3 500 MWCO) 
(ThermoFisher Scientific, USA) and dialysed at 4 °C with stirring into 20 mM Tris-base 
(pH 8.0). The dialysed sample was then loaded onto a HiPrep™ DEAE FF 16/10 anion-
exchange column equilibrated in 20 mM Tris-base (pH 8.0). After the protein was loaded, the 
column was washed with two column volumes of 20 mM Tris-base (pH 8.0) and the protein 
eluted with a gradient from 0-200 mM NaCl across 240 mL at a flow rate of 2 mL/min. 
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Fractions containing pure SOD1 were determined by SDS-PAGE (see section 2.5.3 below), 
concentrated using Vivaspin™ 20 centrifugal concentrators (10 000 MWCO), and frozen at -
20 °C in aliquots for later use. Impure fractions were pooled and frozen at -20 °C for further 
purification via use of the above methods. 
2.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SDS-PAGE analysis was used routinely to analyse and confirm protein expression and 
purification. Resolving gel components were generated by pouring Acrylamide gel mixtures 
ranging from 7-12% acrylamide (v/v) into a MINI PROTEAN® system (Bio-Rad, USA) and 
overlaying with 70% ethanol. Resolving gels were allowed to set for 30 min, after which the 
overlayed 70% ethanol was removed by absorption into filter-paper. A 4% stacking gel mix 
was then overlayed, and a comb inserted to form wells. The stacking gel was allowed to set 
for 30 min. Gels to be stored for later use were wrapped in wet paper towel and plastic wrap, 
and stored at 4 °C for a maximum of two days. Protein samples were mixed with an 
appropriate volume of reducing “sample” buffer, and boiled for 5 min. Samples were loading 
into wells and the gel was run at 150 V in 1 × SDS running buffer, until the dye front ran off. 
Protein bands were visualised by incubation in Coomassie stain solution 1-24 h with shaking 
(50 rpm). Gels were destained using rapid de-stain solution until protein bands were resolved. 
Protein bands of interest were identified using Precision Plus Protein™ dual colour standards 
(Bio-Rad, USA) as a reference. 
2.5.4 Native PAGE 
Native PAGE was used to assess SOD1 oligomeric distribution. Either a 10% acrylamide gel 
(generated as per section 2.5.3), or an Any-kD™ Mini-PROTEAN® TGX Stain-Free™ 
(Bio-Rad, USA) was set up for electrophoresis in a MINI PROTEAN® system (Bio-Rad, 
USA). Protein samples were mixed with an appropriate amount of native PAGE loading 
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buffer and dispensed into wells, with the gel being run at 100 V at 4 °C for 210 min in 
25 mM Tris-base 192 mM Glycine (pH 8.3). In-house 10% gels were stained using 
Coomassie. Stain-Free™ gels were analysed using a Gel Doc™ EZ System (Bio-Rad, USA). 
Stain-Free™ gels were placed onto the stain-free tray with a thin layer of dH2O, and activated 
for 5 min prior to final imaging. Quantification and analysis of gel bands was performed 
using ImageJ software (Abramoff et al., 2004).  
2.5.5 Protein quantification  
Owing to the removal of tryptophan-32 in some of our SOD1 variants, and the generation of 
structurally destabilised variants of SOD1, we typically determined protein concentration 
using BCA protein assay (Sigma Aldrich, USA). A 25 µL sample of each protein sample 
(diluted if necessary) was added, in triplicate, to a 96-well microtitre plate. Bovine serum 
albumin (BSA) standards of known concentrations (0–2 mg/mL), in the same buffer as the 
samples to be determined, were also added to the plate in triplicate. The reaction was initiated 
by addition of 196 µL of reagent A, and 4 µL of reagent B to each well. Plates were gently 
agitated to ensure proper mixing of reagents, after which they were incubated at 37 °C for 
30 min. Following incubation, plates were analysed using a POLARstar Omega Plate Reader 
Spectrophotometer (BMG Labtech, Germany) using absorbance at 560 nm. Protein 
concentrations were interpolated from a BSA standard curve. Protein quantification was also 
determined via molar absorption, analysed using a UV mini 1240 UV/Vis spectrometer 
(Shimadzu, Japan) when appropriate. Briefly, SOD1 samples were diluted in appropriate 
buffer and 100 µL was loaded into a quartz cuvette which was read using a UV/Vis 
spectrophotometer zeroed to the appropriate buffer at wavelength of 265 nm. Concentration 
was determined using a coefficient of 18 700 M
-1
cm
-1
 (Stansell and Deutsch, 1966). 
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2.5.6 Buffer exchange of proteins 
Purified SOD1 and commercial proteins were buffer exchanged, by either gel-filtration 
chromatography or spin columns, into appropriate buffers prior to certain analyses. Gel-
filtration buffer exchange was achieved using either a HiLoad™ Superdex™-75 10/300 GL 
or HiLoad™ Superdex™-200 10/300 GL (GE Life Sciences, USA). Protein samples were 
injected onto the column, equilibrated with appropriate buffer, and eluted at a flow rate of 
0.5 mL/min. Spin column buffer exchange was achieved using Vivaspin™ (500 or 20) 
centrifugal concentrators (10 000 MWCO). Protein samples were aliquoted into the 
concentrators and concentrated via centrifuge (8 000 × g, 10 min). The buffer to be 
exchanged into was added to the max volume of the concentrator unit and centrifuged again 
(8 000 × g, 10 min). This process was repeated 3 times prior to removing the protein sample 
for subsequent experimentation. 
2.6 Mass spectrometry 
2.6.1 General mass spectrometry apparatus and settings 
A SYNAPT® G1 High Definition MS™ mass spectrometer (Waters, UK), in positive ion 
mode, with a nano-electrospray source was used for all mass spectrometry based experiments 
in this work. All nano-capillaries were created in-house from borosilicate capillaries 
(100 mm length, 1.0 mm outer diameter, 0.78 mm internal diameter) (Harvard Apparatus, 
USA) using a P-97 Flaming/Brown Micropipette Puller (Sutter Instrument, USA), at a 
pressure of 85, with a three step method ((i) Pull = 0, Velocity = 6, Time = 45, Heat = 585 
(ii) Pull = 0, Velocity = 6, Time = 45, Heat = 585 (iii) Pull = 120, Velocity = 100, 
Time = 100, Heat = 585). Pulled capillaries were gold-coated using a K500X sputter coater 
(Quorom Tech., UK) at 50 mA for 2 min. The parameters used for all mass spectrometry 
based experiments were generally the same unless stated otherwise elsewhere. All native 
mass spectrometry protein samples were analysed in 200 mM NH4OAc (pH 6.8) unless stated 
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otherwise. All spectra were externally calibrated using a solution of 10 mg/mL caesium 
iodide in 50% n-propanol. All spectra were analysed and processed using MassLynx 4.1 
software (Waters, UK) and other programs where stated. 
Table 2. 2: General system parameters for the SYNAPT G1 HDMS. 
Parameter Experimental Setting 
Capillary voltage 1.52 (kV) 
Sampling Cone 80 V 
Extraction Cone 4.0 V 
Source Temperature 25 °C 
Low Mass Resolution 4.7 
High Mass Resolution 15.0 
Trap Collision Energy 6 V 
Transfer Collision Energy 4 V 
Trap Gas Flow 2.9 mL/min 
Source Gas Flow 1 mL/min 
Detector  1800 V 
Backing Pressure 4.0e
0
 mbar 
Trap Pressure 1.21e
-1
 mbar 
Time-of-Flight Pressure 8.41e
-2
 mbar 
2.6.2 Denatured mass spectrometry and zip-tip protocol 
In order to assess the extent of modification on the purified SOD1 in this work, acid 
denaturing mass spectrometry was performed either through direct addition of acid and 
denaturant, or through a zip-tip protocol. Proteins buffer exchanged into 200 mM NH4OAc 
(pH7.0) (as per section 2.5.7) were denatured by the addition of acetonitrile and formic acid 
to final concentrations of 49% and 1% respectively. Following denaturing, 2 µL of sample 
was loaded into a gold-coated borosilicate capillary and nano-electrosprayed into the mass 
spectrometer. Protein samples in salt based buffers were desalted using ZipTip®C18 tips 
(Millipore, USA) prior to denaturing mass spectrometry. Zip-tips were wetted with a solution 
of 100% MeOH and equilibrated with a solution of 1% formic acid, before aspirating the 
protein sample at least 5 times into the tip. Following binding of the protein sample, the zip-
tip was washed by aspirating 1% formic acid at least 5 times. Protein was eluted from the tip 
using a solution of 1% formic acid 70% acetonitrile. A volume of 2 µL of the eluted protein 
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sample was loaded into a gold-coated borosilicate capillary and analysed by mass 
spectrometry. 
2.6.3 Dimer dissociation constant determination 
Solution phase dimer dissociation constants were determined by methods previously 
published (Rose et al., 2011). SOD1 variants, at concentrations ranging from 20 – 0.6 µM 
were nano-electrosprayed and an acquisition range of m/z 1000 – 5000 was analysed. 
Dissociation constants were determined using the integrated peak areas of the ions detected. 
The total monomer abundance was defined as IM, total dimer abundance defined as ID, and 
the sum of both previous values equalled total signal, which was defined as ITS. 
𝐼𝑀 + 𝐼𝐷 =  𝐼𝑇𝑆 
The proportion of monomer signal (PM) was determined by dividing monomer abundance 
(IM) by total signal (ITS). 
𝐼𝑀
𝐼𝑇𝑆
=  𝑃𝑀 
The concentration of monomer at equilibrium ([M]eq) was determined by multiplying the 
proportion of monomer signal (PM) by the total protein concentration in µM as determined by 
UV/VIS spectroscopy or BCA ([Po]) 
𝑃𝑀  ×  [𝑃𝑜] =  [𝑀]𝑒𝑞 
The concentration of dimer at equilibrium ([D]eq) is defined as: 
( [𝑃𝑂] −  [𝑀]𝑒𝑞)
2
=  [𝐷]𝑒𝑞 
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The KD of dimer dissociation was derived from the gradient of plotting [D]eq against ([M]eq)
2
. 
In each case at least 5 data points were plotted with repeat experiments being performed if the 
line of best fit gave least-squares-regression, r
2
 = < 0.75. At least n = 3 nano-electrosprays 
were performed at each concentration for each SOD1 variant.  
2.6.4 Tandem mass spectrometry 
Protein samples buffer exchanged (as per section 2.5.6) into 200 mM NH4OAc (pH 7.0) had 
their concentration determined (as per section 2.5.6) prior to all mass spectrometry 
experiments. SOD1 samples were diluted to a concentration of 7.5 µM, and 2 µL was loaded 
into gold-coated borosilicate capillaries. Samples were nano-electrosprayed and acquired in a 
mass range of m/z 1000 – 5000 with a scan time of 2 seconds. Tandem mass spectrometry 
(MS/MS) was used to isolate specific ions, by limiting the peak window, for subsequent 
collisional activation. Gas phase unfolding and dissociation were promoted by raising the 
voltage of the Trap cell, typically from 6 – 100 V in 5 V increments. In cases where MS/MS 
was coupled with ion mobility, the MS/MS parameters remained consistent but particular 
system parameters were changed (see section 2.6.4 and table 2.3 below). 
2.6.5 Ion mobility - mass spectrometry 
Ion mobility-mass spectrometry (IM-MS) was used to determine the collision cross sections 
(CCS) of SOD1 variants, and to monitor dissociation and unfolding of ions in the gas phase. 
System parameters were similar to above (Table 2.2), with exceptions that were based on 
(Ruotolo et al., 2008a) (Table 2.3). 
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Table 2.3: Ion mobility system settings for the SYNAPT G1 HDMS.  Shown are parameters that 
were changed for IM-MS. 
Parameter Experimental Setting 
Trap DC Entrance 5.0 
Trap DC Bias 22.0 
Trap DC Exit 5.0 
Trap Manual Control ON 
Trap Wave Velocity 250 m/s 
Trap Wave Height 0.2 V 
IMS Manual Control ON 
IMS Wave Velocity 250 m/s 
IMS Wave Height 3.0 V 
Transfer Wave Velocity 200 m/s 
Transfer Wave Height 8.0 – 10.0 V 
Calibrants for CCS area determination were horse heart myglobin and cytochrome c (Sigma-
Aldrich, USA). Calibrants were resuspended into a solution of 50% MeOH and 2% acetic 
acid in dH2O, and diluted to a concentration of 10 µM. Each calibrant was 
nano-electrosprayed separately at IM wave heights of 8, 9, and 10 V. Calibrants were made 
fresh and sprayed every day that CCS experiments were being performed. SOD1 variants that 
had their CCS areas determined were diluted to a concentration of 10 µM prior to 
nano-electrospray. MassLynx (Waters, UK) and DriftScope (Waters, UK) software was used 
to analyse the ions and determine ion drift time. Calibration curves were generated from the 
drift times of the calibrants, and SOD1 drift times were interpolated from a standard curve of 
the calibrant CCS areas (Appendix C).   
2.7 SOD1 unfolding and aggregation 
2.7.1 Thioflavin T based aggregation assays 
Purified SOD1 variants were buffer exchanged into 1 × PBS (pH 7.4) (section 2.5.7) prior to 
all aggregation assays. Prior to incubation at 37°C, the final reaction mixture was 30 µM 
SOD1, 20 mM DTT, 5 mM EDTA, 10 µM thioflavin T (ThT) in 1 × PBS (pH 7.4). Reaction 
mixtures were vortexed for 5 sec, and 50 µL per well was aliquoted into 384-well clear 
bottomed plastic plate (Greiner, Germany). Loaded plates were incubated inside a 
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POLARstar Omega Plate Reader Spectrophotometer (BMG Labtech, Germany) at an internal 
temperature of 37 °C and incubated for 20 min to equilibrate, following which the plates 
were covered with adhesive film. Plates were shaken at 300 rpm, in a double-orbital pattern, 
for 330 sec at the start of a 900 sec cycle, for at least 200 cycles. ThT was excited at 450 nm 
and its emission read at 480 nm using the bottom optic of the plate reader. Seeded 
aggregation assays were carried out similarly, with the exception that the reaction mixture 
was 30 µM SOD1, 10 mM DTT, 1 mM EDTA, 10 µM ThT, in 1 × PBS (pH 7.4). Seeded 
assays also contained 0.3% (w/w) of total protein as seed from a previous aggregation assay. 
The kinetics of aggregation were analysed using derivation of the equation for the 
Boltzmann-sigmoidal curve. The main parameters used in this equation are final fluorescence 
(Ff), initial fluorescence (Fi), time to half maximal fluorescence (t50), and the slope of the 
curve (k). From this equation we could determine lag-phase and fibril elongation rate. The 
equations are as follows based on previous work (Nielsen et al., 2001) 
The equation of the Boltzmann curve is given as: 
𝐹 = 𝐹𝑖 +
(𝐹𝑓 − 𝐹𝑖)
1 + 𝑒
(𝑡50−𝑡)
𝑘
  
The slope of the line at any point is:  
𝑑𝐹
𝑑𝑡
=
(𝐹𝑓 − 𝐹𝑖)
𝑘
 × 𝑒
(𝑡50−𝑡)
𝑘
(1 +  𝑒
(𝑡50−𝑡)
𝑘 )
2   
When t = t50 (i.e. the inflexion point, when the elongation rate is maximal), the elongation 
rate is: 
𝑑𝐹
𝑑𝑡
=  
(𝐹𝑓 − 𝐹𝑖)
𝑘
 × 𝑒0
(1 +  𝑒0)2
 
               
=  
(𝐹𝑓 − 𝐹𝑖)
4 × 𝑘
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The lag phase is when  
{
(𝐹𝑓 − 𝐹𝑖)
4 × 𝑘
}  × 𝑡50 + 𝑏 =  𝐹𝑖  
          
To solve for b, at t50 (i.e. the mid-point between Ff and Fi): 
𝐹𝑡50 =  
(𝐹𝑓 − 𝐹𝑖)
2
 
  
𝑏 =  {
(𝐹𝑓 − 𝐹𝑖)
2
} −  {
(𝐹𝑓 − 𝐹𝑖)
4 × 𝑘
} × 𝑡50 
So, substituting b into equation (ii): 
𝐹𝑖 =  {
(𝐹𝑓 − 𝐹𝑖)
4 × 𝑘
}  × 𝑡𝑙𝑎𝑔 +  {
(𝐹𝑓 − 𝐹𝑖)
2
} −  {
(𝐹𝑓 − 𝐹𝑖)
4 × 𝑘
} × 𝑡50 
Solving for tlag: 
4 × 𝑘 × 𝐹𝑖 =  {(𝐹𝑓 − 𝐹𝑖) × 𝑡𝑙𝑎𝑔} + {2 × 𝑘 (𝐹𝑓 − 𝐹𝑖)} −  {(𝐹𝑓 − 𝐹𝑖) × 𝑡50} 
(𝐹𝑓 − 𝐹𝑖) × 𝑡𝑙𝑎𝑔 =  4 × 𝑘 × 𝐹𝑖 + {(𝐹𝑓 − 𝐹𝑖) × 𝑡50} −  {2 × 𝑘 (𝐹𝑓 − 𝐹𝑖)} 
𝑡𝑙𝑎𝑔 =  
4 × 𝑘 × 𝐹𝑖
(𝐹𝑓 − 𝐹𝑖)
+  𝑡50 −  {2 × 𝑘 } 
 
2.7.2 Transmission electron microscopy 
A volume of 2 µL of aggregated SOD1 from plate reader based aggregation assays (section 
2.7.1) was loaded onto a carbon coated 400 mesh Nickel TEM grid (ProSciTech, Australia). 
Loaded samples were then diluted with 10 µL of 0.22 µm filtered milli-Q H2O and left to 
stand for 1 min. Grids were then dried with fine fibre blotting paper by dabbing the side 
gently. The addition of milli-Q and drying was repeated three times, after which 10 µL of 
2% uranyl acetate (w/v) was added and left to stand for 1 min. Uranyl acetate was dried off 
the grid gently with blotting paper, and the grid was left to air dry, upside down, for 5 min 
before being stored. Grids were stored at room temperature in sealed plastic container. 
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Prepared grids were imaged at the Australian Institute of Innovative Materials using a JEOL 
JEM-2011 transmission electron microscope (JEOL, Japan). Images were processed using 
Image J software (Abramoff et al., 2004). 
2.7.3 Generation of destabilised conformations of SOD1 
Purified SOD1 variants were buffer exchanged into 1 × PBS (pH 7.4) (section 2.5.7) and 
diluted to 30 µM, after which DTT and EDTA were added to concentrations of 20 mM and 
5 mM respectively. Samples were incubated at 37 °C for 2 hours and then concentrated using 
Vivaspin™ 500 centrifugal concentrators (10 000 MWCO) at 4 °C. Concentrated samples 
were diluted to 100 µ and loaded onto a Hiload Superdex™-75 10/300 GL column (GE Life 
Sciences, USA) equilibrated in 200 mM NH4OAc (pH 7.0). The samples were injected and 
eluted at 0.5 mL/min with 0.5 mL fractions being collected.  Volumes of 10 µL from each 
fraction containing protein were pooled to create a sample representative of the total 
conformational distribution of destabilised SOD1. All destabilised SOD1 was quantified via 
BCA (section 2.5.6) and subject to native mass spectrometry (section 2.6.1) on the day of 
generation.  
2.8 Secondary tissue culture and fluorescent imaging 
2.8.1 Preparation of NSC-34 cells 
Mouse neuroblastoma/motor neuron hybrid cells (NSC-34) (Cashman et al., 1992) were 
cultured in Dulbecco’s modified Eagles medium-F12 (DMEM-F12) (Invitrogen, Australia), 
supplemented with 10% (v/v) heat inactivated foetal bovine serum (FBS) (Bovogen 
Biologicals, Australia). In order to passage and plate cells, they were washed once with 
DMEM-F12 and treated with 0.25% Trypsin, 0.02% EDTA (Sigma-Aldrich, Australia) to lift 
off the adherent cells. The cells were pelleted via centrifugation (500 × g, 5 min) and 
resuspended in pre-warmed DMEM-F12, supplemented with 10% FBS. Following washing, 
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plates and chamber-slides were seeded at a confluency of 40% and cultured at 37 °C in a 
humidified incubator with 5% atmospheric CO2 for 24 h prior to transfection. 
2.8.2 Transfection of NSC-34 cells 
 NSC-34 cells were transfected, 24 h post-plating into either multi-well plates or chamber-
slides, using Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer’s 
instructions. Lipofectamine 3000 reagent was added to pre-warmed DMEM-F12 to a 
concentration of 6% (v/v). P3000 reagent and plasmid DNA were added to a separate 
DMEM-F12 volume to concentrations of 4% (v/v) and 20 ng/µL respectively. The 
DNA/lipofectamine complex was generated by mixing one volume of 6% (v/v) lipofectamine 
in DMEM-F12, with one volume of DNA/P3000 mix in DMEM-F12. The 
DNA/lipofectamine mixture was incubated for 30 min at room temperature, after which it 
was dispensed onto cultured cells. For cells that were co-transfected, the total amount of 
DNA was halved between plasmid constructs. After 24 h incubation, transfection was 
assessed using an Eclipse TE2000-E fluorescent microscope (Nikon, Japan).  
2.8.3 Laser scanning confocal imaging 
All cell imaging was performed using a Leica TCS SP5 Confocal microscope (Leica, 
Germany). Cells were imaged live in 5% atmospheric CO2, with the incubation unit set to a 
temperature of 37 °C. For all confocal experiments, the argon laser power was at 20%, with 
the DPSS 561 nm, and HeNe 633 nm lasers being turned on when necessary. All green-
fluorescent protein (EGFP) tagged constructs were excited with 10% laser power at 488 nm 
and emission was analysed from 507-550 nm. TdTomato protein tagged constructs were 
excited with 7% laser power at 561 nm and emission was analysed from 581-700 nm. Images 
were acquired using or a HCX PL APO 63.0 × 1.20 water immersion objective, using PMT 
detectors, with a pin-hole of 100 µm. 
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2.8.4 Z-stack imaging for inclusion quantification 
To quantify inclusion formation of our SOD1 fluorescent constructs, z-stacks of transfected 
cells were acquired. Cells were cultured (section 2.8.1) into µSlide 8-well chamber slides 
(Ibidi, Germany) and transfected with either EGFP or tdTomato fluorescent SOD1 constructs 
(section 2.8.2). Imaging was performed 48 h post-transfection using a HCX PL APO 63.0 × 
1.30 water immersion objective. Z-stacks series were acquired at 512 × 512 pixels, laser 
scanning speed 400 Hz, line and frame averaging  = 1, where each image was a 400 – 500 nm 
slice of the z-axis. At least five z-stack series were acquired per well of a chamber slide, 
accounting for at least 100 transfected cells imaged per well. Z-stacks were processed into a 
single image using LAS-AF Lite software (Leica, Germany), where cells containing 
inclusions were determined by the presence of bright fluorescent puncta in the cytoplasmic 
region greater than 2 µm in diameter 
2.8.5 Dual colour transfection for in cell aggregation seeding analysis 
In order to examine the ability of SOD1 variants to template onto aggregates in a cellular 
context, NSC-34 cells were cultured (section 2.8.1) in µSlide 8-well chamber slides (Ibidi, 
Germany) and transfected with both EGFP and tdTomato fluorescent SOD1 constructs 
(section 2.8.2). tdTomato-SOD1 fusions are less likely to aggregate than EGFP fusions, likely 
due to the larger size of the fusion protein (Fig. 5.1 B). As a result, we used EGFP as a non-
aggregating control, and in our analyses, tdTomato constructs were defined as the template 
for the aggregation of SOD1-EGFP variants. Co-transfected cells were identified by the 
presence of both EGFP and tdTomato fluorescent signal.  Individual co-transfected cells were 
magnified and imaged at 1024 × 1024 pixels, laser scanning speed 1000 Hz, line averaging 1, 
using frame by frame sequential scanning with averages calibrated to minimise bleed-through 
of EGFP emission reading into the tdTomato emission window. Both EGFP and tdTomato 
channels were gain adjusted in over-glow mode to avoid saturation of the images acquired. 
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Images were processed for analysis using LAS-AF Lite software (Leica, Germany), and 
image analysis was performed using Image J software (Abramoff et al., 2004). Using Image 
J,  the area within a cell that was composed of aggregated SOD1 was determined by setting a 
‘max entropy’ threshold in the tdTomato channel, followed by then applying this selected 
area to the green channel and measuring the pixel area (AP) and mean pixel intensity (IP) 
of both channels. The AP and IP of the diffuse fluorescent protein was determined in the 
tdTomato channel, and applied to the EGFP channel, by setting the maximum threshold to 
the value of the minimum threshold determined for the aggregated fluorescent protein, 
followed by setting the minimum threshold to a value that selected the cell cytoplasm.   
Using AP and IP values for both diffuse and aggregated protein, in both the EGFP and 
tdTomato channels, we determined the ratio of EGFP to tdTomato signal that was 
aggregated per cell.  
Firstly, since intracellular SOD1 aggregates are noted to be porous (Farawell et al., 2015, 
Matsumoto et al., 2006, Matsumoto et al., 2005), corrected aggregate fluorescence intensity 
(Aggregated IC) was determined by subtracting the diffuse mean pixel intensity (Diffuse IP) 
from aggregated mean pixel intensity (Aggregated IP).  
1. (𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝑃) − (𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝐼𝑃) = 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝑃 (𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝐶) 
Total aggregated signal (SA) was determined by multiplying the corrected aggregated 
fluorescence intensity (Aggregated IC) by the aggregated pixel area (Aggregated AP).  
2. (𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝐶) ×  (𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐴𝑃) = 𝑇𝑜𝑡𝑎𝑙 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝑆𝑖𝑔𝑛𝑎𝑙 (𝑆𝐴) 
Total diffuse signal (SD) was determined by multiplying the mean diffuse fluorescence 
intensity (Diffuse IP) by the diffuse pixel area (Diffuse AP).  
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3. (𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝐼𝑃) × (𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝐴𝑃) = 𝑇𝑜𝑡𝑎𝑙 𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝑆𝑖𝑔𝑛𝑎𝑙 (𝑆𝐷) 
Total cell fluorescence signal (SC) was determined by the addition of total diffuse signal (SD) 
and total aggregated signal (SA). 
4. 𝑆𝐷  +  𝑆𝐴 = 𝑇𝑜𝑡𝑎𝑙 𝐶𝑒𝑙𝑙 𝑆𝑖𝑔𝑛𝑎𝑙 (𝑆𝐶) 
The proportion of aggregated fluorescent signal (PA) was determined by dividing the total 
aggregated signal (SA) by total cell fluorescence signal (SC). 
5. 
𝑆𝐴
𝑆𝐶
= 𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 (𝑃𝐴) 
The proportion of aggregated EGFP (EGFP PA) was then divided by the proportion of 
aggregated tdTomato (tdTomato PA) to determine the ratio of EGFP to tdTomato 
fluorescence signal that was contributing to the intracellular aggregates. 
6. 
(𝐸𝐺𝐹𝑃 𝑃𝐴)
(𝑡𝑑𝑇𝑜𝑚𝑎𝑡𝑜 𝑃𝐴)
= 𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝐸𝐺𝐹𝑃 𝑡𝑜 𝑡𝑑𝑇𝑜𝑚𝑎𝑡𝑜 𝑎𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 
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3. SOD1 in vacuo Dissociation and 
Unfolding 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Note: This chapter is written in a style that makes it stand-alone and ready for publication, as a 
consequence there is some repetition with the Introductory Chapter 1. 
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3.1 Introduction 
 
The structures of protein assemblies are increasingly being interrogated using native mass 
spectrometry (MS). When optimised to maintain a native-like state, this technique can reveal 
attributes of protein complexes such as oligomeric distribution, topology, and protein-protein 
interactions, even in complex systems (Bich et al., 2010b, Daniel et al., 2002, Hilton and 
Benesch, 2012, Mehmood et al., 2015, Smith and Zhang, 1994). This is further enhanced 
with the use of tandem mass spectrometry (MS/MS), in which discrete ions can be isolated 
and subjected to collision-induced dissociation (CID) (Benesch et al., 2006), thereby 
providing insight into the underlying composition of narrow m/z (mass to charge) regions 
within multi-component spectra. Ion mobility-mass spectrometry (IM-MS) makes analysis 
three dimensional by determining ion drift-time, which is correlated with the collisional 
cross-section of the ion, providing constraints for downstream in silico modelling of oligomer 
packing (Hall et al., 2012). IM-MS is also useful for analysing the induced unfolding of 
biological molecules in vacuo, either in the absence or presence of binding partners (Hopper 
and Oldham, 2009). In native protein mass spectrometry, charge is added to solvent exposed 
basic amino acids, typically via electrospray ionisation (ESI), where proteins in a volatile 
buffer are subjected to high voltage to create an aerosol. The aerosol droplets containing the 
protein progressively evaporate with the final evaporation leaving behind charge on the 
protein to generate a gas phase ion (Nguyen and Fenn, 2007). ESI is described as a ‘soft 
ionisation’ technique owing to the small amount of fragmentation that occurs to analytes, 
making it especially useful for the study of multimeric protein complexes (Hilton and 
Benesch, 2012). Most identified proteins exist as components of a complex in vivo and it is 
important for structural and functional analysis to dissociate these complexes into subunits to 
characterize them (Kuriyan and Eisenberg, 2007).  In MS based-assays, dissociation is 
typically achieved in vacuo, where charged ions of protein assemblies are subject to 
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increasing energy to promote dissociation into subunits. Dissociation of a complex is defined 
as asymmetric when a small subunit or monomer, carrying a high proportion of charge 
relative to their mass, is ejected from the protein complex (dimer
n+
 = monomer
>(n/2)+
 and 
monomer
<(n/2)+
). Dissociation is defined as symmetric when the proportion of charge on 
fragment ions is equal to the proportion of mass it represents (dimer
n+
 = 2 × monomer
(2/n)+
); 
i.e. in the case of dimer
n+
, the monomer charge state distribution will be unimodal and 
centred on monomer
(2/n)+
, but if asymmetrical it will lead to bimodal distribution of charge 
states. In the asymmetric model, the disproportionately high charge on the ejected monomer 
has been explained as a consequence of unfolding during dissociation in the gas phase. 
Unfolding of a subunit in a multimeric complex increases the surface area on the subunit to 
balance the charge to surface area distribution, a result of an increase in the number of 
chargeable sites accessible to the existing charges on the ion. (Benesch et al., 2007, Benesch 
et al., 2006, Wanasundara and Thachuk, 2007b). Asymmetric dissociation is typical of most 
multimeric protein complexes (Felitsyn et al., 2001, Jurchen and Williams, 2003a, Versluis et 
al., 2001). Another proposed model for the asymmetry observed during dissociation is 
explained by Coloumbic repulsion, where the charges on each subunit in a complex repulse 
each other. In this model, the charges on subunits exist in an equilibrium state where total 
charge of the complex is divided amongst subunits, and the complexes with the most unequal 
charges are thought to present a higher barrier to dissociation, dependent upon charge isomers 
and charge migration during unfolding (Sinelnikov et al., 2007, Wanasundara and Thachuk, 
2007a).  
If we wish to interrogate the utility of gas phase dissociation in biomolecular analyses, we 
need to first broaden our understanding of the mechanisms of this process. Recently, Zhuang 
and colleagues investigated the in vacuo unfolding and dissociation of bovine superoxide 
dismutase-1 (SOD1) (Zhuang et al., 2014), postulating that dissociation and unfolding in 
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vacuo, could be used to analyse disease-associated mutants of human SOD1. SOD1 
misfolding and aggregation is involved in the neurodegenerative disease amyotrophic lateral 
sclerosis (ALS), as evidenced by a misfolded conformation specific antibody being 
immunoreactive to SOD1 in both sporadic ALS and SOD1-associated familial ALS post-
mortem tissue (Bosco et al., 2010). Taken together, these data suggest that SOD1 
conformation may play a role in the toxicity responsible for motor neuron death. 
SOD1 is a 32 kDa homodimeric enzyme that converts superoxide to either O2 or H2O2 
(McCord and Fridovich, 1969). Each SOD1 monomer contains a catalytically active copper 
atom, a zinc atom, and an intramolecular disulfide bond that links loop-IV with β-strand-VIII 
(Fig. 3.1). These post-translational modifications impart a high level of stability to the 
protein, making it resistant to proteolytic digestion (Senoo et al., 1988) and heat denaturation 
(Rodriguez et al., 2002).  Protein inclusions composed of SOD1 and soluble misfolded 
SOD1, have been observed in both sporadic and SOD1 familial patients (Bosco et al., 2010, 
Forsberg et al., 2010, Pokrishevsky et al., 2012b), pointing to a putative common pathway 
responsible for toxicity whereby both the wild-type and mutant variants assume a common 
misfolded and/or aggregated conformation. Research has historically been focused on 
disease-causing SOD1 mutants, of which there are over 183 linked to the familial form of 
ALS (fALS) (http://alsod.iop.kcl.ac.uk (Abel et al., 2013a). These mutations are found 
throughout the SOD1 primary structure and result in variation in protein stability (Khare et 
al., 2006), post-translational modification states (Arnesano et al., 2004, Goto et al., 2000, 
Hayward et al., 2002), and even disease progression (Wang et al., 2008). A suggested 
pathway through which SOD1 may cause ALS is that structural destabilisation (via mutation, 
metal deficiency, disulfide reduction) leads to increased abundance of SOD1 monomers, 
which are increasingly prone to misfolding and subsequent aggregation (Rakhit et al., 2004). 
It is currently unclear if toxicity can be attributed to misfolded SOD1 monomers, small 
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oligomers, or larger SOD1 aggregates; however, it is evident that misfolding precedes 
aggregation.  
 
Figure 3.1: SOD1 showing mutation locations and post-translational modification. The native 
structure of the SOD1 homodimer is reliant upon the correct coordination of Zn
2+
 (brown sphere) in to 
the zinc loop, and Cu
2+
 (light blue sphere) into the electrostatic loop, as well as the formation of an 
intramolecular disulfide bond (black) between C57 and C146. The mutations examined here were 
chosen due to variable effects upon SOD1 structural stability, including destabilisation of the dimer 
interface (A4V-grey and V148G-orange), destabilisation of monomeric structure (G37R-red, D90A-
dark blue, G93A-green), perturbation of copper binding (H46R-magenta). Disease severity of these 
mutants ranges from 0.9 – 17.6 years on average post-diagnosis (Wang et al., 2008). 
 
As stated previously, Zhuang and co-workers (2014) have reported on the in vacuo 
dissociation and unfolding of bovine SOD1 using IM-MS to examine the ion species 
generated from increasing acceleration potentials in CID (Zhuang et al., 2014).  IM-MS has 
also been performed on SOD1 purified from sporadic ALS patient erythrocytes, showing that 
sporadic patients had increased SOD1 monomer abundance compared to healthy controls 
(Borges-Alvarez et al., 2012). In this work, we used MS/MS, and IM-MS, coupled with CID 
to gain an understanding of how the in vacuo environment affects SOD1 quaternary and 
tertiary structure with respects to in vacuo dissociation models, and how this relates to 
disease. To this end, we performed the above techniques on a set of recombinantly expressed 
SOD1 ALS-associated variants (Fig. 3.1) chosen for their differential effects upon the 
stability of the SOD1 dimer, monomer and metal-binding. The results demonstrate that 
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collision-induced dissociation and unfolding of the SOD1 dimer and monomer in vacuo 
follows a symmetrical pathway for the most part, with the exception of SOD1
G37R
, which 
presents a more asymmetric dissociation. We find this is at odds with the conformational 
changes, observed using IM-MS, in the dimer over increasing acceleration potentials. 
Analysis of a heterodimer, composed of SOD1
WT
 and SOD1
G37R
, suggested that, in the case 
of SOD1, charge partitioning seems to be uncoupled from the unfolding of subunits in the 
dimer. This suggests an allosteric effect of the SOD1
G37R
 mutant is largely affecting its 
interesting in vacuo properties. Furthermore, we did not observe substantial differences in 
dimer dissociation or unfolding, of our SOD1 variants, when compared to previously 
published solution-phase work, suggesting that in vacuo dissociation and unfolding is not 
reflective of the solution states of SOD1. 
3.2 Results 
3.2.1 Tandem mass spectrometry (MS/MS) of SOD1 variant dimers 
 
It has been previously established that when SOD1 is subjected to collisional activation, the 
abundant dimer 10+ and 11+ ions (denoted as D
10+
 and D
11+
 from hereon) dissociate 
primarily into monomer ions of charge states 5+ and 6+ (denoted as M
5+
 and M
6+
 from 
hereon) (Zhuang et al., 2014). The M
6+
 and M
5+
 product ions can overlap with D
12+
 and D
10+
 
ions respectively, since, for example, the m/z of M
5+
 is the same as D
10+
 (twice the mass and 
twice the charge). To overcome this we employed MS/MS, with a peak window centred on 
the unique D
11+
 ion at m/z ~2900. By increasing the acceleration potential into the “Trap” 
collision cell, we prompted the dissociation of D
11+
 into product ions ranging from M
4+
 to 
M
7+
 (Fig. 3.2). Considering charge conservation, the dissociation of D
11+
 into these 
monomeric ions indicates that SOD1 can dissociate via two routes, resulting in either M
5+
 
and M
6+ 
(termed symmetric dissociation considering non-integer charge states are 
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impossible), or M
4+
 and M
7+
 (asymmetric dissociation).  Across the acceleration ramp, D
11+
 
of each SOD1 variant decreased in relative abundance (Fig. 3.3 A). Application of a 
logarithmic function (log values of the abundances measured in Fig. 3.3 A) to these data 
showed that the dissociation of the D
11+
 ion was biphasic, with two separate rates of 
dissociation, where phase 1 was from 6 – 70 V, and phase 2 was from 70 – 100 V (Fig. 3.3 
B). Comparing the rates of dissociation in the two phases separately, revealed significant 
differences between some of the SOD1 variants when compared to SOD1
WT
 (Fig. 3.3 C and 
D). However, these differences are at odds with previously well-established SOD1 dimer 
dissociation work in solution, for example, SOD1
A4V
 (dimer dissociation constant = ~1 µm) 
is well known to have an increased dimer dissociation propensity when compared to SOD1
WT
 
(dimer dissociation constant = ~10 nM) (Doucette et al., 2004, Ray et al., 2004, Redler et al., 
2011), yet here we see no significant difference in dissociation between SOD1
A4V
 and 
SOD1
WT
 in either phase. This highlights the difference between the gas phase and solution 
phase dynamics, where the apparent effect of mutation is not the same, most likely due to the 
change in physical forces that direct the non-covalent interaction between subunits. 
The biphasic dissociation of our SOD1 variants were consistent with the dissociation through 
the two observed routes, where in phase 1 (0 – 70 V) we observed primarily M
5+
 and M
6+
 
product ions, but in phase 2 we saw an increase in M
4+
 and M
7+
 ions (Fig. 3.4 B). 
Interestingly, we observed a substantially increased relative abundance of the M
7+
 and M
4+
 
ions for SOD1
G37R
 at high acceleration potentials (Fig. 3.4 A). When comparing the ratio of 
M
6/5
 ions to the ratio of M
7/4
 ions, we observed that from 65 – 100 V SOD1
G37R
, had a 
substantially increased abundance of M
7/4
 ions, suggesting that a higher abundance of 
SOD1
G37R
 dimers are following the asymmetric dissociation pathway during phase 2. X-ray 
crystallography of SOD1
G37R
 has suggested that dimers of this variant can be composed of 
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asymmetrically folded subunits, and that the monomer is more flexible than that of SOD1
WT
 
(Hart et al., 1998).  
 
 
Figure 3.2: MS/MS dissociation profile of the D
11+
 ion of SOD1
WT
. Increasing acceleration 
potentials (collision energy; CE) prompted the dissociation of the D
11+
 ion into species M
4+
, M
5+
, M
6+
, 
and M
7+
. Oligomeric size is denoted by the ellipsoids (1 = monomer, 2 = dimer), and charge state by 
the accompanying number. 
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okk 
Figure 3.3: In vacuo dimer dissociation of SOD1 variants analysed by IM-MS/MS. The unique 
D
11+
 ion of each SOD1 variant was selected using MS/MS and subject to increasing accelerating 
potentials (collision energy) in the Trap. (A) The relative abundance (as determined by peak area) of 
the D
11+
 ion decreased for all SOD1 variants as acceleration potential was raised. The relationship was 
similar for all SOD1 variants, although a difference in rate for SOD1
G93A
 and SOD1
V148G
 was 
apparent. (B) Application of a logarithmic function (log of the percentage values in panel A) to the 
dissociation curves revealed two discreet linear relationships for the dissociation of the D
11+
 ion, 
indicating that it was biphasic. (C) Plotted dissociation rates of the first phase of dissociation showed 
significant differences in the dissociation rate of SOD1
H46R
, SOD1
D90A
, SOD1
G93A
, and SOD1
V148G
 
when compared to SOD1
WT
. (D) Plotted dissociation rates of the second phase of dissociation showed 
significant differences in the dissociation rate of SOD1
H46R
 and SOD1
G93A
 when compared to 
SOD1
WT
. Error bars represent SD of the mean of at least 3 nano-electrosprays. Statistical significance 
was determined using a non-paired t-test, (* = P < 0.05).  
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Figure 3.4: MS/MS of D
11+
 resulted in the evolution of four main product ions. The D
11+
 ion was 
dissociating into either M
6+
 and M
5+
, or M
7+
 and M
4+
. (A) Base peak (BP) normalised mass spectrum 
of the m/z region where the M
7+
 ion was evolving at 80 V acceleration potential, showing the 
substantially higher relative abundance of SOD1
G37R
. (B) Plotting the ratio of M
7/4
 to M
6/5
 shows that 
from 60-100 V acceleration potential, the abundance of the M
7+
 and M
4+
 ions increases substantially 
for SOD
G37R
 compared to other variants. (C) Plot showing the mean monomer charge state across 
acceleration potentials where SOD1
G37R
 presents a higher mean charge state from 70 – 100 V. 
 
3.2.2 Ion mobility-mass spectrometry of SOD1 variants 
 
The advent of ion mobility analysis coupled to mass spectrometry has provided another 
mechanism to investigate biomolecular ions, as collisional cross-sections (CCS) can be 
determined by the relative drift times of ions. In order to investigate if there were any 
differences in the unfolding of our SOD1 variants in vacuo, we employed IM-MS with 
increasing acceleration potentials to induce unfolding and dissociation. The main ion species 
arising, at low acceleration potential, from our IM-MS analysis were D
11+
 and D
10+
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(Fig. 3.6 A), indicating that under IM conditions the charge state distribution of SOD1 was 
not significantly altered. The IM-MS of SOD1, under low acceleration potential, showed ion 
drift times that were typical of folded conformers, as there was only one drift time population 
per ion species (Fig 3.6 B) (conformers are labelled with oligomeric state [M = monomer, 
D = dimer], charge, and subscript = conformer, i.e. D11+[2]  is the second conformer to evolve 
from the dimeric 11+ charge state ion).  When acceleration potential was increased, evolution 
of new conformers for all of the ions was observed (CCS values in Tables 3.1 and 3.2). Of 
interest was the D
11+
 ion which transitioned into two conformers, with higher drift times, as 
acceleration potential was increased (D11+[1]  > D
11+
[2]  > D
11+
[3]  at respective drift times of 9 > 11.5 > 
13.2 ms) (Fig 3.6 C). As stated previously, there is signal overlap between SOD1 dimers and 
monomer products. As such, we were unable to reliably identify the existence of particular 
conformers in both the D
12+
 and D
10+
 m/z regions. Due to this signal overlap we once again 
focused our analysis on the D
11+
 ion. 
Table 3.1: The interpolated CCS (Å
2
) values of monomeric conformers of SOD1 variants 
determined using IM-MS. Calibration curves were generated using cytochrome c and myoglobin, 
and SOD1 CCS values were interpolated from these curves (calibration curves can be found in 
appendix C) 
Variant M
8+
[1]
 
M
8+
[2]  M
7+
[1]  M
7+
[2]  
WT 957 ± 90 1292 ± 122 970 ± 70 1243 ± 116 
A4V 969 ± 88 1321 ± 112 954 ± 72 1254 ± 120 
G37R 969 ± 75 1315 ± 126 954 ± 65 1243 ± 126 
H46R 957± 99 1303 ± 118 964 ± 80 1264 ± 110 
D90A 969 ± 86 1351 ± 115 987 ± 76 1286 ± 107 
G93A 969 ± 82 1363 ± 125 954 ± 79 1307 ± 131 
V148G 957 ± 80 1351 ± 120 975 ± 70 1259 ± 124 
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Table 3.2: The measured CCS (Å
2
) values of dimeric conformers of SOD1 variants determined 
using IM-MS. (calibration curves can be found in appendix C) 
Variant D
9+
[1]  D
9+
[2]  D
10+
[1]  D
10+
[2]  D
10+
[3]  D
11+
[1]  D
11+
[2]  D
11+
[3]  D
12+
[1]  D
12+
[2]  
WT 
1478 ± 
120 
1761 ± 
136 
1393 ± 
121 
1728 ± 
134 
1995 ± 
147 
1347 ± 
121 
1727 ± 
129 
1956 ± 
137 
1331 ± 
122 
1491 ± 
140 
A4V 
1499 ± 
110 
1787 ± 
132 
1397 ± 
115 
1729 ± 
133 
1958 ± 
150 
1397 ± 
115 
1714 ± 
124 
1958 ± 
148 
1279 ± 
112 
1499 ± 
150 
G37R 
1505 ± 
125 
1751 ± 
140 
1437 ± 
118 
1703 ± 
129 
1944 ± 
142 
1354 ± 
129 
1714 ± 
120 
1944 ± 
144 
1293 ± 
123 
1478 ± 
145 
H46R 
1446 ± 
127 
1787 ± 
129 
1370 ± 
119 
1729 ± 
140 
1958 ± 
143 
1339 ± 
120 
1728 ± 
118 
1958 ± 
141 
1357 ± 
122 
1478 ± 
143 
D90A 
1434 ± 
114 
1763 ± 
139 
1357 ± 
126 
1729 ± 
141 
1944 ± 
148 
1296 ± 
126 
1714 ± 
134 
1944 ± 
135 
1365 ± 
128 
1485 ± 
136 
G93A 
1499 ± 
118 
1716 ± 
138 
1423 ± 
129 
1796 ± 
137 
1987 ± 
148 
1339 ± 
118 
1771 ± 
132 
1987 ± 
139 
1350 ± 
114 
1513 ± 
138 
V148G 
1505 ± 
120 
1763 ± 
119 
1397 ± 
122 
1716 ± 
135 
1958 ± 
140 
1354 ± 
119 
1692 ± 
120 
1958 ± 
146 
1350 ± 
119 
1485 ± 
133 
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Figure 3.5: IM-MS chromatogram of SOD1 under different acceleration potentials. SOD1 
variants were subject to IM-MS with increasing acceleration potentials in the Trap to prompt 
unfolding and dissociation. (A) Typical native spectrum of SOD1
WT
 with ellipsoids representing the 
oligomeric state (1 = monomer, 2 = dimer) with charge states above. The maxima observed on the 
10+ and 11+ labelled peaks are representative of glutathionylation state (discussed later in section 
4.2.3). (B) IM chromatogram of SOD1
WT
 at an acceleration potential of 15 V, showing singular 
conformers for each ion. (C) IM chromatogram of SOD1
WT
 at an acceleration potential of 50 V, 
showing the evolution of multiple conformers at each charge state. Conformers are labelled with 
Oligomeric state (M = monomer, D = dimer) charge, and subscript = conformer, i.e. D
11+
[2]  is the 
second conformer to evolve from the dimeric 11+ charge state ion. 
 
Using a combination of MS/MS and IM-MS, we monitored the change in drift time for the 
D
11+
 ion as a function of acceleration potential to generate CIU fingerprints using CIUSuite 
(Eschweiler et al., 2015) (Fig 3.7),as well as measurements of standard deviation between 
nano-electrospray replicates (Fig 3.8).From these fingerprints it was apparent that the D
11+
 
ion species of all of our SOD1 variants shared similar unfolding pathways, with the exception 
of SOD1
G37R
, which preferentially remained in the D11+[2]  conformer state at high accelerating 
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potentials, rather than transition to the D11+[3]  state. To further analyse differences in the SOD1 
variants CIU fingerprints, we utilised the CIUSuite ‘compare’ feature which generates heat 
maps, where differences between fingerprints are colour coded, and root-mean-square 
deviation (RMSD) values. All SOD1 variants CIU fingerprints were compared to SOD1
WT
 
(Fig 3.9) showing low RMSD values with the exception of SOD1
G37R
 which gave a value 
approximately 4 times that of the other SOD1 variants (SOD1
G37R
 = 19.99%, average of other 
variants = 5.88 %). The heat map of SOD1
WT
  and SOD1
G37R
 showed that SOD1
G37R
 was 
remaining in the D11+[2]  conformation throughout the acceleration ramp, whereas SOD1
WT
 was 
transitioning to the D11+[3]  conformation. An IM-MS study performed with bovine SOD1 
showed similar results to most of the SOD1 variants examined here, where the bovine D
11+
 
transitioned into three conformers with increasing accelerating potential (Zhuang et al., 
2014). The authors described the three diferent conformers as the result of the fold of the 
monomeric subunits, which suggests in our case D11+[1]
 
is a dimer with two folded subunits, 
D11+[2]  may be a dimer with one unfolded (or less compact) subunit, and D
11+
[3]  may be a dimer 
where both subunits are unfolded. However, it is possible that only one subunit in the dimer 
is transitioning through multiple conformational states. This, like the dissociation data 
presented earlier, suggests that in vacuo dynamics are having a significant effect upon both 
unfolding and dissociation pathways, as one would expect dissociation to occur prior to 
unfolding of both monomers in a dimer when in solution. 
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Figure 3.6: Mean CIU fingerprints for the D
11+
 ion of SOD1 variants. The conformational change 
of D
11+
 in response to increasing acceleration potentials was monitored using IM-MS and plotted as a 
heat-map using CIUSuite. All SOD1 variants showed similar gas phase unfolding, transitioning 
through 3 conformers (D
11+
[1] , D
11+
[2] , and D
11+
[3])  with the exception of SOD1
G37R
, which transitioned 
primarily into the D
11+
[2]  conformer. All unfolding plots are averages of 3 separate nano-electrosprays. 
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Figure 3.7: The standard deviation of CIU fingerprints of the D
11+
 ion of SOD1 variants. Using 
CIUSuite it was possible to determine the standard deviation between replicates for each SOD1 
variant. Deviation was minimal in each case with the exception of SOD1
G37R
. This data was generated 
from 3 separate nano-electrosprays. 
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Figure 3.8: The difference in the mean CIU fingerprint between SOD1 variants and SOD1
WT
. 
The average CIU fingerprint of each SOD1 variant (blue) was compared to the SOD1
WT
 (red) 
fingerprint to determine differences in CIU. Root-mean-square deviation was calculated to determine 
difference showing that SOD1
G37R
 was the most different (RMSD = 19.99 %). The differences were 
apparent with SOD1
WT
 inhabiting the D
11+
[3]  conformer, whilst SOD1
G37R
 inhabited the D
11+
[2]  conformer 
for the majority of the acceleration ramp. 
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When comparing the unfolding rates of D
11+
, we observed that all SOD1 variants showed 
similar rates of transition from D11+[1]  to D
11+
[2]  (Fig 3.7), suggesting that mutation was having 
little effect upon the unfolding of a single SOD1 subunit within a dimer. Conversely, the 
relative abundances of the D11+[2]  and D
11+
[3]  conformers (Fig. 3.10 B and C, respectively) showed 
that SOD1
G37R
 was behaving differently. SOD1
G37R
 preferred to remain in the D11+[2]  state 
across the acceleration ramp, whereas the other SOD1 variants transitioned rapidly into the 
D11+[3]  state. This suggests that the unfolding of a second subunit, or increased unfolding of a 
single subunit, in a SOD1
G37R
 dimer is not occurring, and that the dimer is potentially 
dissociating prior to, or concomitantly with, the secondary unfolding event. After examining 
the dimer, we performed the same analysis on the solution M
7+
 ion (therefore we did not use 
MS/MS) to determine if there were signficant differences in the in vacuo unfolding of the 
solution-phase monomer (Fig 3.7 D). There were no observable differences between the 
SOD1 variants in terms of M
7+
 abundane as it transitions to M7+[2]  over increasing acceleration 
potentials, again suggesting that in vacuo dynamics are overpowering the effect of mutation. 
For example, SOD1
D90A
 has a destabilised tertiary structure but not quaternary structure 
(Lindberg et al., 2005), yet in our assay the unfolding of monomeric SOD1
D90A
 required 
energies similar to that of monomeric SOD1
WT
 to induce unfolding.  
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Figure 3.9: In vacuo unfolding of the D
11+
 ion and M
7+
 ion for all SOD1 variants.  (A) The 
relative abundance of the D
11+
[1]  conformer, compared to the abundance of the D
11+
[2]
 
and D
11+
[3]  
conformers, decreased across the acceleration series, with all SOD1 variants showing a similar 
relationship. (B) The relative abundance of D
11+
[2]
 
showed a similar relationship for all SOD1 variants, 
with the exception of SOD1
G37R
, increasing in abundance until 40 V in the Trap, after which relative 
abundance decreased. SOD1
G37R
 showed no decrease in relative abundance across the acceleration 
series, rather an increase in abundance plateauing at 60 V in the Trap. (C) The relative abundance of 
D
11+
[3]  increased to ~80% for all SOD1 variants, with the exception for SOD1
G37R
 which plateaued at 
~20%. (D) The relative abundance of the M
7+
[1]conformer decreased across the collision series in a 
similar relationship for all SOD1 variants. Error bars represent SD of the mean of 3 separate nano-
electrosprays. 
 
3.2.3 Analysis of a SOD1
WT/G37R
 heterodimer 
The previous analyses highlighted SOD1
G37R
 as a clear outlier, compared to other variants, 
especially when considered in the light of current models of in vacuo dissociation and 
unfolding. In simple terms, current models of in vacuo unfolding and dissociation suggest 
that the more unfolding there is in a protein multimer, the more asymmetric the dissociation 
of the multimer will be (Wanasundara and Thachuk, 2009). In order to more accurately 
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determine the differences in dissociation and unfolding of SOD1
G37R
, we generated a 
SOD1
WT/G37R
 heterodimer by mixing both variants at equal concentration (10 µM) and 
incubating the mixed sample at 37 °C overnight to ensure sufficient subunit exchange had 
taken place before performing similar analysis to that described above. Since mixing of 
SOD1
WT
 and SOD1
G37R
 generates heterodimer as well as homodimers of both variants (Fig. 
3.10 A), we again utilised MS/MS to isolate the D
11+ 
ion, focusing on the heterodimer peak at 
m/z ~2915, and subjected it to increasing accelerating potentials. We first assessed the 
symmetry of dissociation by comparing the ratio of M
7/4
 to M
6/5
 dimer, observing that the 
dissociation was closer to the symmetrical dissociation of SOD1
WT
 than that of SOD1
G37R
 
(Fig 3.10 B). This suggests that the asymmetry of the SOD1
G37R
  dimer dissociation is reliant 
upon both subunits having an arginine at position-37. The SOD1
WT/G37R
 heterodimer can 
dissociate through four main routes dependent upon the monomer and charge composition 
(WT
6+
/G37R
5+
, G37R
6+
/WT
5+
, WT
7+
/G37R
4+
, G37R
7+
/WT
4+
) (Fig 3.10 C). Plotting the 
relative abundance of these dissociation routes revealed a preference for the symmetric 
pathway, indicating that a single SOD1
G37R
 subunit does not affect the dissociation route. 
Although the dissociation of the SOD1
WT/G37R
 heterodimer was similar to SOD1
WT
, we 
observed differences in the unfolding of the D
11+
 ion. The SOD1
WT/G37R
 heterodimer still 
proceeded to evolve the three main D
11+
 conformers across acceleration potentials 
(Fig. 3.11 A), with the D
11+
[2]  and D
11+
[3]  conformers being abundant from approximately 35 and 
45 V acceleration potential respectively (there was low standard deviation between repeats – 
Fig. 3.11 B). The D
11+
[2]  and D
11+
[3]  conformers both remained abundant across the acceleration 
ramp, indicating that the in vacuo unfolding of the SOD1
WT/G37R
 heterodimer was a mix of 
both SOD1
WT
 and SOD1
G37R
 unfolding dynamics. By comparing the ratio of D
11+
[3]  to D
11+
[2] , 
we can determine the similarity of the unfolding dynamics between homodimer and 
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heterodimer. The SOD1
WT/G37R
 heterodimer unfolding was much closer to that of the 
SOD1
WT
 homodimer (Fig. 3.11 C and D), however, there were significant differences 
between each variant at 70 V accelerating potential (Fig 3.11 E). These unfolding data, in 
conjunction with the dissociation symmetry data, suggest that the effect of the SOD1
G37R
 
subunit on the heterodimer unfolding is independent of charge as we still observe a high 
abundance of D
11+
[2]  conformer, yet no significant difference in dissociation symmetry when 
compared to a SOD1
WT
 heterodimer.  
 
Figure 3.10: IM-MS/MS analysis of a SOD1
WT/G37R
 heterodimer. (A) MS/MS selection of the 
SOD1
WT/G37R
 heterodimer. (B) The ratio of M
7/4
 to M
6/5
 shows that the charge partitioning of the 
heterodimer is closer to that of a SOD1
WT
 homodimer than a SOD1
G37R
 homodimer. (C) The four 
dissociation routes (black = WT
6+
/G37R
5+
, blue = G37R
6+
/WT
5+
, grey = WT
7+
/G37R
4+
, red = 
G37R
7+
/WT
4+
) by which the heterodimer can dissociate reveal that no particular dissociation channel 
is favored. Error bars represent SD of the mean from 3 nano-electrosprays. 
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Figure 3.11: IM-MS/MS analysis of a SOD1
WT/G37R
 heterodimer. (A) The mean CIU finger print of 
D
11+
 of the SOD1
WT/G37R 
heterodimer. (B) The standard deviation between replicates of the 
SOD1
WT/G37R
 heterodimer. (C) The difference in CIU fingerprint between a SOD1
WT
 homodimer 
(blue) and a SOD1
WT/G37R
 heterodimer (red). (D) The difference in CIU fingerprint between a 
SOD1
G37R
 homodimer (blue) and a SOD1
WT/G37R
 heterodimer (red). (E) The ratio of D
11+
[2]  to D
11+
[3]  
showing that the D
11+
 ion of the heterodimer unfolds with a relationship closer to SOD1
WT
 than 
SOD1
G37R
. All data were averaged from 3 separate nano-electrosprays of different samples, error bars 
represent SD of the mean. 
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Owing to the substantial difference in the dissociation and unfolding profile of SOD1
G37R
 
compared to all other variants we next examined the packing of the dissociated monomer ions 
across acceleration potentials to determine if there were any differences. Using the CIUSuite 
compare function we quantified where the differences were for each variant compared to 
SOD1
WT
. We found a major difference when comparing the SOD1
WT
 and SOD1
G37R
 M
7+
 
ions, where SOD1
G37R
 presented a more compact dissociation product, as measured by the 
drift time (SOD1
G37R
 = 10.3, SOD1
WT
 = 11.2) (Fig 3.12). Further analysis, comparing the 
drift times of the SOD1
WT
 and SOD1
G37R
 M
7+
 ions dissociated from the SOD1
WTéG37R
 
heterodimer showed similar results, where the SOD1
G37R
 ion was more compact than the 
corresponding SOD1
WT
 ion in the same assay (Fig. 3.12). Quantification of this was carried 
out and it was observed that there was no difference between mean RMSD values for each 
monomer ion dissociated from each variant (Fig. 3.13 A, C, and E), and no difference 
between all replicates when comparing the M
5+
 ion from each variant against SOD1
WT
 (Fig. 
3.13 B). Only a small difference was observed for the M
6+
 ion when SOD1
G93A
 was 
compared to SOD1
WT
 (Fig. 3.13 D), however a large difference in RMSD was observed for 
the M
7+
 ion for only SOD1
G37R
 (Fig. 3.13 F). These results taken in conjunction with the 
different unfolding and dissociation of SOD1
G37R
 indicate that this variant is dissociating 
prior to unfolding in this CID-CIU assay. 
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Figure 3.12: The difference in the compactness of the dissociating M
7+
 ion during IM-MS/MS 
analysis.  The average CIU fingerprint of the dissociated M
7+
 from each variant (blue) was compared 
to the SOD1
WT
 (red) fingerprint to determine differences in the packing of dissociated monomer ion. 
Root-mean-square deviation was calculated to determine difference showing that SOD1
G37R
 was the 
most different (RMSD = 15.16 %), having a more compact ion at ~10.3 ms drift time across 
acceleration potentials. 
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Figure 3.13: Analysis of the differences between replicates and variants for the dissociated 
monomeric conformers. (A) The variance in replicates for the dissociated M
5+
 conformer showing 
minimal difference for all variants. (B)  The difference between WT and other variants for the 
dissociated M
5+
 conformer (black dotted line = total average across all variants). (C)  The variance in 
replicates for the dissociated M
6+
 conformer showing minimal difference for all variants. (D) The 
difference between WT and other variants for the dissociated M
6+
 conformer where only G93A was 
significantly different (black dotted line = total average across all variants). (E) The variance in 
replicates for the dissociated M
7+
 conformer showing minimal difference for all variants. (F) The 
difference between WT and other variants for the dissociated M
7+
 conformer where G37R and H46R 
were both significantly different (black dotted line = total average across all variants). When 
comparing to WT, means were calculated by comparing all replicates on a single basis (3x3 replicates 
= 9 data points). Significance was determine by students t-test against the total average (*** = P 
<0.001, * = P < 0.01). 
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3.3 Discussion 
 
In the present study, we have investigated the gas phase dissociation and unfolding of several 
ALS-associated SOD1 variants. Our data clearly show that CID-directed dimer dissociation 
of SOD1 in vacuo does not reflect its solution-state dissociation dynamics regardless of 
mutation. Previous work has determined the dimer dissociation constants of several SOD1 
variants, finding specific mutants to have significantly altered dissociation constants 
compared to the wild-type (Byrstrom et al., 2010, Khare et al., 2004, Redler et al., 2011). 
Here, our CID-based dissociation of SOD1 dimers did not correlate with the substantial 
differences between variants that have been previously observed in solution. For example, the 
dimer dissociation constant of SOD1
A4V
 was found to be ~ 1 µM, as determined by analytical 
size-exclusion chromatography (Redler et al., 2011), compared to a value of 10 nM for 
SOD1
WT 
as determined by analytical ultracentrifugation (Doucette et al., 2004). The 
usefulness of MS, coupled with analyses that are performed in the gas-phase, to study protein 
structure and dynamics in a manner relevant to disease, therefore, is model/protein specific. 
Solution methods that measure equilibrium dissociation constants may themselves require 
different observation conditions that affect equilibrium. In an MS/MS experiment, in the 
absence of solvent, the mechanism of dissociation may be different from those which occur 
in solution. In the context of the SOD1 dimer, the driving force behind dimer association is 
reported to be hydrophobic interaction, as well as electrostatic attraction between subunits 
(Mozo-Villarías et al., 2014). It is known that forces that affect the non-covalent binding of 
proteins can be modified in the absence of bulk-solvent, leading to a decrease or loss of 
hydrophobic interaction (Bich et al., 2010a), and an increase in the strength of polar and 
electrostatic forces (Sharon and Robinson, 2011). From the work presented here, it is clear 
that in the case of SOD1, the structural perturbations caused by mutations that destabilise the 
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dimer are overwhelmed by the strengthening of the polar and electrostatic interactions 
between subunits in vacuo.  
The substantial difference in tertiary and quaternary structural stabilities observed in solution 
between SOD1 mutants (Byrstrom et al., 2010, Doucette et al., 2004, Khare et al., 2004, 
Redler et al., 2011) lead to the hypothesis that MS might be useful to detect these variations, 
however, there was no real difference observed in gas phase dissociation and unfolding 
between most of the SOD1 mutants. However, it was observed that the D
11+
 ion of SOD1
G37R 
presented a significantly more asymmetrical dissociation relative to the other SOD1 variants. 
From the analysis of the SOD1
WT/G37R
 heterodimer, one could expect the SOD1
G37R
 subunit 
to be disproportionately abundant in the M
7+
 population owing to the existence of one more 
basic residue compared to SOD1
WT
. Our data shows that this is not the case, suggesting that 
charge isomers are not driving unfolding, or that a salt bridge is forming so that the residue 
that it pairs with is not available for neutralisation. This also infers that the asymmetry stems 
not from a change in the formal charge, but rather allosteric effects that modify the dimer 
interface. 
IM-MS can determine CCS values that reflect the packing of the native protein conformation. 
There were no significant differences in CCS values between our SOD1 variants, with and 
without accelerating potential. The SOD1 monomer, in its metal bound disulfide bonded 
form, is a constrained and rigid structure. Given the tight packing of SOD1, in conjunction 
with the dehydration/collapsing effect of the in vacuo environment, and the relatively low 
resolution of IM-MS, we expected no measurable difference in CCS between the variants. 
Instead, the main utility of IM-MS in the current work comes from the additional separation 
provided by the drift time dimension. By separating the variants, not only using m/z ratio, but 
also by CCS, conformational changes provoked by collisional activation were interrogated. 
The energy of activation required to transition the monomeric and dimeric ions into their 
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more unfolded conformations was effectively the same for all SOD1 variants tested. This 
further supports the idea that the effect of mutation on structure is being overshadowed by in 
vacuo forces in the work presented here. The transition of the D
11+
 ion to multiple unfolded 
states has been reported previously by Zhuang and colleagues (Zhuang et al., 2014) when 
they were performing similar IM-MS analysis on bovine SOD1. They proposed a model of 
SOD1 in vacuo destabilisation involving the unfolding of a single subunit in a dimer to 
generate D11+[2]  followed by unfolding of the second subunit to generate D
11+
[3]  as accelerating 
potential increases. Dissociation of the dimer can occur from any point along this model.  Our 
results are in agreement with this model, with the exception of SOD1
G37R
. 
When the results from both the MS/MS and IM-MS experiments are considered, SOD1
G37R
 
stands as a curious outlier with respect to current models of in vacuo dissociation, due to its 
asymmetry and unfolding. The inability to inhabit the D11+[3]  state suggests that the dimer is 
dissociating prior to unfolding of the second subunit. One would expect this difference in 
dissociation state to be reflected in the observed effect of acceleration potential on dimer 
dissociation, however, this was not the case. One might also expect that since SOD1
G37R
 did 
not unfold to the same extent as the other variants, that it might present a much more 
symmetrical dissociation, but again we observe the opposite. Wanansundara and Thachuck 
(2009) suggested that when dimer charge partitioning is symmetric, there is minimal 
structural change to monomers prior to dissociation, and that the asymmetric partitioning of 
charge results in the more charged monomer unfolding at a lower energy prior to 
dissociation. We have observed the opposite here, with SOD1
G37R
, suggesting that current 
modelling may not apply to all proteins. The heterodimer analysis further supports our 
postulation of allosteric effects, with the apparent lack of dissociation asymmetry coupled 
with the high abundance of D11+[2]  across acceleration potentials. 
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Overall, our results show that the in vacuo dynamics of ALS-associated SOD1 variants do 
not reflect observations based on dissociation constants measured in the solution phase. 
Although native-like protein structure can be retained during ESI-MS, any analysis directed 
in vacuo, such as CID or IM-MS, must be performed carefully to ensure relevance when 
making comparisons to the solution-state interactions that are associated with disease. The 
most interesting data produced, involved the decoupling of dissociation asymmetry and 
protein fold in vacuo, suggesting that distribution of charge across a protein multimer alone 
may not dictate dissociation characteristics. Regardless of the biological relevance, the ability 
to separate and resolve samples based upon m/z and cross-sectional size provides an 
invaluable tool for the analysis of heterogeneous samples as evidenced by our ability to 
resolve the SOD1
WT/G37R
 heterodimer, and determine its in vacuo dissociation and unfolding 
dynamics. 
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4. Glutathionylation and Dimer 
Dissociation of SOD1 
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A sub-set of the data presented in this chapter has been peer reviewed and published in 
Scientific Reports (SOD1
WT
, SOD1
A4V
, SOD1
G37R
, SOD1
H46R
, SOD1
D90A
, SOD1
G93A
, and 
SOD1
V148G
 data set) and re-edited to encompass new data (SOD1
G85R
, SOD1
G93D
, SOD1
E100G
, 
SOD1
I112T
, and SOD1
A140G
 data set). 
Reference: 
McAlary, L., Yerbury, J.J., Aquilina, J.A. (2013). “Glutathionylation potentiates benign 
superoxide dismutase 1 variants to the toxic forms associated with amyotrophic lateral 
sclerosis”. Scientific Reports 3, 3275-80. doi:10.1038/srep03275 
4.1 Introduction 
 
Approximately one in five cases of familial amyotrophic lateral sclerosis (fALS) is associated 
with naturally occurring mutations in the gene encoding superoxide dismutase-1 (SOD1). 
Currently, 183 mutations have been identified and are spread throughout the SOD1 amino 
acid sequence (http://alsod.iop.kcl.ac.uk (Abel et al., 2013b). Many of these mutations confer 
a significant level of instability to the native homodimer (Hough et al., 2004), which may 
ultimately lead to unfolding and the formation of insoluble cytoplasmic aggregates – a 
hallmark of SOD1 associated fALS pathology. Concomitant with this, recent evidence has 
suggested that the aggregation or misfolding of wild-type SOD1 is involved in some cases of 
the considerably more prevalent sporadic ALS (Bosco et al., 2010, Forsberg et al., 2010, 
Pokrishevsky et al., 2012b). 
Existing evidence suggests that dissociation of the native homodimer is a key step in the 
aggregation pathway of SOD1, as SOD1 monomers with various post-translational 
modification states have been identified as common misfolding intermediates (Rakhit et al., 
2004, Svensson et al., 2010). This mechanism of aggregation is supported by the 
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extraordinary difference in the dissociation constant (KD) reported for the fALS associated 
SOD1
A4V
 variant dimer (~1 µM) compared to that of SOD1
WT
 (~10 nM) (Doucette et al., 
2004, Redler et al., 2011); i.e. the dissociation of SOD1
A4V
 into monomers is approximately 
100 times more facile at concentrations found in vivo. Furthermore, chemical cross-linking of 
the aggregation prone SOD1
A4V
 monomers, can prevent its aggregation in vitro (Ray et al., 
2004). Similarly, cross-linking experiments performed on other SOD1 variants was shown to 
confer greater thermostability (Auclair et al., 2010). 
A compounding factor in SOD1 dissociation is the post-translational modification (PTM) of 
cysteine at position-111 (Cys111) by the ubiquitous antioxidant glutathione, a modification 
that has been previously identified in SOD1 purified from human erythrocytes (Wilcox et al., 
2009). Although it has been questioned whether this PTM occurs naturally in neuronal tissue 
or rather is an artefact of purification methodology (Auclair et al., 2014). Regardless, the high 
concentration of glutathione within tissue (0.5 - 10 mM) (Schafer and Buettner, 2001), and 
the innate antioxidant activity of SOD1, identifies glutathione as a possible PTM of SOD1. 
Cys111 is proximal to the dimer interface and, not surprisingly, the introduction of a 
glutathione moiety has been shown to augment dissociation (Redler et al., 2011), as well as 
increase the immunoreactivity of antibodies that recognise misfolded SOD1 (Redler et al., 
2014). 
In this work we assess the effect of glutathionylation of Cys111 on the native homodimer of 
multiple fALS associated SOD1 variants, comparing the dissociation of the dimer to the 
reported patient survival times. We report that level of glutathionylation of Cys111 was 
variable across the recombinantly produced SOD1 variants, and that it was consistent with 
increased dimer dissociation, showing a stronger correlation with reduced patient survival. 
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4.2 Results 
4.2.1 Assessment of modification to recombinant SOD1 
 
We first assessed the modification states of our SOD1 variants after purification using acid 
denaturing mass spectrometry, finding that all of our SOD1 variants were glutathionylated to 
some extent, and that, for the most part, it was a major modification for all SOD1 variants. 
We observed for each variant that the full-length protein mass was consistent with metal-free 
disulfide oxidised SOD1 based upon a mass difference of -2 Da which is typically associated 
with the loss of hydrogen from two sulfhydryl groups. Previously, it has been shown that 
glutathionylation of SOD1 purified from E. coli can occur at all cysteine residues (Cys6, 
Cys57, Cys111, and Cys146), as detected by mass spectrometry (Furukawa et al., 2004). We 
observed only one peak corresponding to the addition of a single glutathione (+305 Da) for 
each SOD1 variant. We deduce this to be glutathionylation of Cys111 based upon the 
oxidation of the disulfide (Cys57 and Cys146), and the method by which we express and 
purify SOD1 resulting in a natively folded product where Cys6 is not solvent accessible 
(Strange et al., 2003). Other modifications were observed consistently on each SOD1 variant 
but they were not evident on glutathionylated-SOD1 (gsSOD1), indicating that these 
modifications were occurring to Cys111, which would be protected by addition of a 
glutathione moiety. Due to this, and for the purpose of the analysis, we term any SOD1 
protein species not glutathionylated as unmodified-SOD1 (uSOD1). Modifications to SOD1 
were identified by mass difference (Table 4.1), as has been used previously to identify the 
sulfinic (+32 Da) and sulfonic (+48 Da) acid modifications in vitro (Fujiwara et al., 2007) 
and in vivo (Choi et al., 2005). Another major modification was the peak corresponding to 
+119 Da, which is consistent with cysteinylation, a modification previously observed 
(Auclair et al., 2013b). The modifications of -18 and -36 Da are typically consistent with 
dehydration, however, since they only occurred to Cys111 these identifications are tentative 
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and by mass and chemistry we suspect -18 Da as S-gamma-glutamyl from cysteine, and -36 
as dehydroalanine from cysteine. This conversion of a cysteine to dehydroalanine is known to 
be induced by heat (Wang et al., 2010), and may occur during the purification of SOD1, 
where temperatures of 55 – 65 °C are used to partially clear the bacterial lysate containing 
SOD1 (section 2.5.1).  
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Figure 4.1: Mass transforms showing the modification states of recombinant SOD1. SOD1 
variants were incubated in 2% formic acid 49% acetonitrile and 49% 200 mM NH4OAc for up to an 
hour before being nano-electrosprayed. Mass differences are shown in daltons and FL = full length 
unmodified SOD1 and GS = glutathionylated SOD1. Peaks with similar mass differences are 
observed across all SOD1 variants (-36, -18, +16, +32, +48, +119) but these modifications are not 
observed to occur to glutathionylated SOD1, indicating that these are modifications to Cys111. 
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Table 4.1: Major modifications to SOD1 detected by acid denaturing mass spectrometry. SOD1 
variants were incubated for up to 1 hour in a buffer of 2% formic acid, 50% acetonitrile, and 50% 
200 mM NH4OAc before being nano-electrosprayed.  
Mass difference (Da) Identification 
-36 Dehydroalanine from cysteine 
-18 S-gamma-glutamyl from cysteine 
+16 S-OH on cysteine 
+32 S-O2H on cysteine 
+48 S-O3H on cysteine 
+119 Cysteinylation 
+305 Glutathionylation (GS) 
 
4.2.2 Glutathionylated SOD1 is disproportionately monomeric 
 
Following our determination of the percentage of SOD1 that was glutathionylated for each 
variant, we investigated whether gsSOD1 was disproportionately monomeric. To this end we 
performed mass spectrometry optimised to gentle conditions in the absence of denaturant to 
maintain the native fold, and compared the relative abundance of uSOD1 and gsSOD1 that 
was monomeric for each variant. The charge state distribution of the monomers observed for 
each SOD1 variant were conserved to the 8+ and 7+ charge states, typical of what was 
previously observed (section 3.2.2, Fig. 3.4). The peaks corresponding to gsSOD1 were 
readily apparent for each variant, and in all cases, with the exception of SOD1
D90A
, 
SOD1
E100G
 and SOD1
V148G
, gsSOD1 appeared to be highly abundant (Fig. 4.2). By 
integrating the peak areas of uSOD1 and gsSOD1, from our acid denatured mass 
spectrometry (Fig. 4.1), we were able to determine the percentage of each SOD1 variant that 
was glutathionylated (Fig: 4.3). We compare total gsSOD1 to the relative abundance of 
gsSOD1 within the native monomer ions, finding that in all cases the level of monomeric 
gsSOD1 was disproportionately greater than the total percentage of gsSOD1, indicating that 
glutathionylation was associated with monomerisation. 
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Figure 4.2: Native spectra of SOD1 monomer ions showing high relative abundance of gsSOD1. 
SOD1 variants were nano-electrosprayed under gentle conditions to assess modification state of the 
solution monomer ions. We found that gsSOD1 was highly abundant in the monomer ions detected 
for native SOD1 (M
8+
 = ~ m/z 2000, M
7+
 = ~ m/z 2300). Each spectrum is representative of 3 nano-
electrosprays. 
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Figure 4.3: Monomeric gsSOD1 abundance is disproportionately greater compared to total 
abundance of gsSOD1. Comparison of percentage of SOD1 that is glutathionylated (measured from 
the acid denatured mass spectrometry) and SOD1 monomer that is glutathionylated (from native mass 
spectrometry). The comparison shows, that in all cases, there is a higher abundance of gsSOD1 
monomer relative to the total gsSOD1 abundance. Error bars represent SD of the mean of 3 separate 
dilutions of sample. 
4.2.3 Glutathionylation increases the dimer dissociation constant of SOD1 
 
The observation that gsSOD1 was disproportionately monomeric as detected by mass 
spectrometry, and the fact that previous work has suggested that glutathionylation of SOD1 at 
Cys111 enhances dimer dissociation (Redler et al., 2011), prompted us to investigate the 
dimer dissociation of a range of SOD1 variants in the context of glutathionylation. Mass 
spectrometry is useful for the assessment of non-covalent protein-protein interactions as the 
mass resolution provides a means by which to separate and analyse differentially modified 
protein species. With this in mind, SOD1 dimers could be comprised of two unmodified 
monomers (uSOD1
2
), one unmodified monomer and one glutathionylated monomer 
(uSOD1:gsSOD1), or two glutathionylated monomers (gsSOD1
2
) (Fig. 4.4). The resolution 
provided by native mass spectrometry was different for each SOD1 variant, even when they 
were measured at similar system parameters, which implies that certain mutants may 
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desolvate more efficiently. Due to the necessity of maintaining system parameters, we 
theoretically determined, by expected masses, the areas under the peak that corresponded to 
uSOD1
2
, uSOD1:gsSOD1, and gsSOD1
2
 (Fig. 4.4).  
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Figure 4.4: Native spectra of the SOD1 dimer. SOD1 variants were nano-electrosprayed at a 
concentration of 5 µM under gentle conditions optimised to maintain native interaction. It was 
observed that the main dimer peaks were at 10+ (~3250 m/z) and 11+ (~2950 m/z) charge states. The 
resolution of differential glutathionylation states on these peaks was variable, and seemed to be 
associated with the extent of glutathionylation within the sample, as well as the overall dimer KD 
determined i.e., The greater the effect of glutathionylation on KD, the less gsSOD1 existed as dimer to 
measure. 
 
A dilution series of SOD1 variants was prepared ranging from 20 µM to 620 nM and mass 
spectrometry was used to determine the relative abundance of all species present in solution. 
As a result, it was possible, by plotting the proportion of monomer vs total concentration 
(Fig. 4.5), to calculate discreet dimer dissociation constants for uSOD1
2
 and gsSOD1
2
. 
Owing to the differences in resolution between SOD1 variants, we elected to determine areas 
under the peaks as corresponding to uSOD1
2
, uSOD1;gsSOD1, or gsSOD1
2
 based upon 
expected mass. Unlike the homodimers, which dissociate into their respective and unique 
monomer pairs, products of the heterodimer (uSOD1:gsSOD1) contributed to both 
populations of monomer, and were not so readily estimated. In an effort to account for 
monomers originating from the mixed dimer, we monitored the decline in uSOD1:gsSOD1 
ion intensity with successive dilution, and subtracted an equivalent quantity from each 
monomer signal. Although imprecise, we believe this correction attenuated, to some extent, 
the confounding effects of the mixed dimer species. 
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Figure 4.5: Glutathionylation of SOD1 increases dimer dissociation propensity. Successive 
dilution of SOD1 variants prior to mass spectrometry resulted in an increase in monomeric signal as 
SOD1 concentration decreased. In all cases, uSOD1 (red) monomer abundance was less than that of 
gsSOD1(blue) at all concentrations. Variants with only uSOD1 plots were not sufficiently 
glutathionylated for accurate measurement. Error bars represent SEM of 3 dilutions and nano-
electrosprays. 
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Table 4.2: Dimer KD’s of uSOD1 and gsSOD1 variants as measured by mass spectrometry. 
SOD1 variants dimer KD’s were determined as previously described (Rose et al. 2011). Linear 
regression plots, from which KD’s were calculated, can be found in Appendix C. 
Variant WT A4V G37R H46R G85R D90A 
uSOD1 KD 
(nM) 
9 ± 1 1100 ± 100 10 ± 1 30 ± 4 8 ± 2 25 ± 4 
gsSOD1 KD 
(nM) 
34 ± 5  9600 ± 900 60 ± 9 97 ± 16 - - 
Variant KD 
(nM) 
G93A G93D E100G I112T A140G V148G 
uSOD1 KD 
(nM) 
12 ± 1 54 ± 8 7 ± 2 32 ± 3 86 ± 8 271 ± 40 
gsSOD1 KD 
(nM) 
160 ± 32 395 ± 48 - 622 ± 85 661 ± 81 - 
 
All uSOD1 variants, except uSOD1
G85R
 and uSOD1
E100G
, had dimer KD values greater than 
that of uSOD1
WT
 (9 ± 1 nM), implying that single residue substitutions are sufficient to 
disturb the quaternary structure. uSOD1
G85R
 (8 ± 2 nM) and uSOD1
E100G
 (7 ± 2 nM) both had 
dimer KD values that were not significantly different to that of SOD1
WT
 suggesting similar 
quaternary dynamics between these variants. The most substantial augmentations were 
observed for uSOD1
A4V
 (1.1 ± 0.1 µM) and uSOD1
V148G
 (271 ± 40 nM), being approximately 
112-fold and 28-fold greater than uSOD1
WT
 respectively (Fig. 4.6 A). SOD1
A140G
 showed an 
interesting difference with an 8.9-fold change, which was unexpected due to the location of 
this mutation being localised to loop-VII which is distal from the dimer interface. The 
changes in dimer KD in the other variants ranged from 0.8 to 5.6-fold, which, whilst 
appreciable, were not as substantial as SOD1
V148G
 or SOD1
A4V
. Assessment of the fold-
change in dimer KD between uSOD1 and gsSOD1 for each variant showed that 
glutathionylation of Cys111 was substantially increasing dimer dissociation (Fig. 4.6 B), 
consistent with previous work (Redler et al., 2011). The fold-changes in KD values were 
different for each variant, with the greatest difference being that of SOD1
I112T
 (19.6-fold 
change), which is suggestive of cross-talk between mutated residues, Cys111, and dimer 
interfacing. 
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Figure 4.6: Fold change in dimer KD induced by mutation and glutathionylation. (A) The fold-
change in dimer KD of uSOD1 variants compared to uSOD1
WT
. (B) The fold change in dimer KD when 
comparing uSOD1 to gsSOD1 in variants that were sufficiently glutathionylated. 
 
The fact that monomeric SOD1 is associated with aggregation implicates the monomer as a 
potential toxic form or intermediate. Owing to this, we sought to determine if there was a 
plausible link between patient survival and the dimer KD determined here (Fig. 4.7). To 
achieve this, the log of the KD value of each mutant was plotted against mean disease 
duration (Wang et al., 2008) (Fig. 4.7). We found that there was a weak correlation between 
dimer dissociation rates and disease duration for all uSOD1 variants (r
2
 = 0.12 for all 
variants, r
2
 = 0.18 for the subset that were sufficiently glutathionylated to enable analysis) 
(Fig. 4.7 A and B). In comparison,  the dissociation rate specific to gsSOD1 had a much 
stronger, although still weak, correlation with disease duration (r
2 
= 0.49), suggesting that 
perhaps modification of the Cys111, in this case glutathionylation, may play a role in the 
augmentation of monomerisation and subsequent destabilisation of SOD1 thought to 
contribute to disease severity.   
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Figure 4.7: Dimer dissociation of gsSOD1 has a stronger correlation with patient survival than 
uSOD1. (A) Plot of log uSOD1 (KD/nM) against the mean disease duration of the variant showing a 
weak correlation (r
2
 = 0.12). (B) Plot of log uSOD1 (KD/nM) against mean disease duration of 
variants that had their corresponding gsSOD1 dimer KD values determined, showing a weak 
correlation (r
2
 = 0.18). (C) Plot of log gsSOD1 (KD/nM) against mean disease duration showing a 
stronger correlation than uSOD1 (r
2
 = 0.49). 
 
4.3 Discussion 
 
Post-translational modifications are important features to consider when examining 
biophysical characteristics and dynamics of proteins. Our mass spectrometry-based analysis 
identified several modifications that occurred to recombinantly expressed SOD1 that 
appeared to be localised to residue Cys111. Cys111 has been identified as a site of oxidative 
modification previously (Choi et al., 2005, Fujiwara et al., 2007), and the modifications we 
observed were in agreement with past work.  Although we report on the dimer KD of what we 
here refer to as unmodified SOD1, it is clear from our denaturing mass spectrometry that 
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there is a great extent of modification included within this defined population, and these 
modifications may have potentially augmented the uSOD1 dimer KD reported here. 
It is well documented that patients suffering from SOD1-associated fALS have variable 
survival times (Wang et al., 2008), dependent upon the particular amino acid substitution. 
Our analysis of the dimer KD of the uSOD1 variants and their corresponding mean disease 
durations produced weak a correlation, however the correlation was appreciably increased 
when examining the dimer KD of gsSOD1 variants, inferring that glutathionylation is a 
potential modifier of SOD1-associated ALS. An interesting observation was that specific 
SOD1 variants with stable quaternary structures but rapid disease progression, such as 
SOD1
G93A
 (KD = 12 nM, disease duration = 2.2 years) and SOD1
I112T
 (KD = 32 nM, disease 
duration 0.9 years), had substantial increases in dimer KD when glutathionylated (~13-fold 
and ~20-fold respectively). This effectively highlights the importance of understanding the 
effects of post-translational modifications on proteins in regards to biophysical 
characterisation. Our data can be used to reframe the idea that there is a relationship between 
dimer KD and disease progression: i.e., it is not only the dimer KD of ALS-associated SOD1 
variants that may influence the rate of disease progression, but potentially the extent of 
glutathionylation and the dimer KD of the glutathionylated species. Glutathionylation, 
however, is not a requirement for pathogenicity, as sequence modification alone of SOD1
A4V
 
and SOD1
V148G
 cause ~110-fold and ~30-fold increases in dimer KD over SOD1
WT
 
respectively. These mutations are located deep within the inter-subunit cleft, where small 
molecular volume changes are able to disrupt the dimer interface leading to more facile 
dissociation (Perry et al., 2010). 
In contrast to Val148 and Ala4, Gly37 and Gly93 are spatially remote to the dimer interface, 
being situated in the β3/β4 Greek key loop and the β5/β6 inter-strand loop respectively. It is 
notable that the Gly37 and Gly93 loops are proximal to each other and the Leu38 cork, while 
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Cys111 is within the β6/β7 Greek key loop at the opposite end of the β-barrel. Prior to 
glutathionylation, the G37R and G93A mutations impart a somewhat negligible effect upon 
the KD of SOD1; i.e., in isolation, these mutations appear not to be significantly destabilising 
to natively folded SOD1. Rather, it is the synergy of glutathionylation and point mutation at 
the β-barrel ‘poles’ that accounts for the significantly higher KD of a multitude of individual 
variants in a unique allosteric-like fashion. Even though the work presented here implicates 
post-tranlsational modification to C111 as a possible disease modifier, it is interesting to note 
the existence of the C111Y mutation that is reported to have high penetrance for ALS(Eisen 
et al., 2008). We would postulate that the C111Y mutation would act much in the same 
fashion as other SOD1 mutations, lowering the structural stability of the folding states, 
increasing the propensity for pathogenic aggregation. Indeed, in cell-culture models of SOD1 
aggregation a SOD1
C111Y
 mutant shows a high aggregation propensity comparative to a 
SOD1
C111S
 mutant (Karch and Borchelt, 2008). Taken together, these data are consistent with 
the contemporary notion of SOD1 dimer dissociation being a major factor in SOD1-
associated fALS, and therefore requires further examination. We  
Specifically, it is proposed that the toxicity of a specific variant of SOD1 is a biophysical 
consequence of either, (i) a potent destabilising mutation such as A4V, or (ii) modification of 
Cys111, including glutathionylation as studied here, in a weak or non-destabilising mutation 
such as G93A. Indeed, oxidation of Cys111 has been observed in sporadic ALS in the 
absence of SOD1 mutation (Auclair et al., 2014). In each scenario there is an increase in the 
abundance of monomer, which is more susceptible to misfolding into toxic conformations 
compared to the dimer (Rakhit et al., 2004, Svensson et al., 2010). If the cellular clearance 
rate of misfolded SOD1 is inadequate, increasingly frequent hydrophobic interactions 
ultimately give way to aggregation, forming larger structures that stress the cellular 
machinery (Weisberg et al., 2012). Many neurodegenerative diseases, including ALS, are 
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also associated with oxidative stress (Barber and Shaw, 2010), which in turn can lead to an 
up-regulation of glutathione (Dalle-Donne et al., 2007) increasing the likelihood of gsSOD1. 
Indeed, an increase in GSH levels has been observed in ALS patient CSF (Tohgi et al., 1999), 
marking glutathionylation as a potential modifier of SOD1-associated ALS pathogenesis. 
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5. Aggregation and Unfolding of SOD1 
variants 
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5.1 Introduction 
Amyotrophic lateral sclerosis (ALS) is a disease characterised by the progressive 
degeneration of both upper and lower motor neurons, ultimately resulting in death. The 
symptoms of ALS typically manifest in people aged 55-65 years, with younger patients rarely 
being identified (Gordon, 2011). Post-diagnosis, the average disease duration is 
approximately 3 years, although patients suffering different familial variants can have shorter 
and longer durations. Genetic studies of ALS patients have revealed that 90% of cases are 
sporadic (sALS) and the remaining 10% of cases are familial (fALS) (Renton et al., 2014). 
Several of the fALS associated genes (TDP-43, C9orf72, FUS, ALS2) have roles in the 
biogenesis and trafficking of RNA species, and another clear grouping are associated with 
protein degradation (CCNF, VCP, SQSTM1, UBQLN2, OPTN, TBK1); most are also linked 
to frontotemporal dementia (Peters et al., 2015). The first fALS linked gene discovered, and 
most studied, is the gene encoding superoxide dismutase-1 (SOD1) which is only associated 
with a pure motor neuron disease phenotype. 
SOD1 is a cytosolic 32 kDa homodimeric enzyme that catalyses the dismutation of oxygen 
radicals to either molecular oxygen or hydrogen peroxide (McCord and Fridovich, 1969). 
Each subunit contains a catalytically active copper ion, a zinc ion, and an intramolecular 
disulfide bond. These post-translational modifications confer substantial stability to the native 
fold of SOD1, endowing it with resistance to heat denaturation and maintenance of catalytic 
activity in denaturing conditions (Rodriguez et al., 2002, Senoo et al., 1988). Zinc binding 
occurs spontaneously following synthesis and folding, whereas copper binding and disulfide 
bond formation are mediated by association with the copper-chaperone for SOD1 (Furukawa 
et al., 2004, Rae et al., 2000). Currently, there are known to be over 180 natural mutations 
that can occur within the SOD1 sequence that are associated with fALS 
(http://alsod.iop.kcl.ac.uk - (Abel et al., 2013b). These mutations occur throughout the SOD1 
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structure, and all have the ability to destabilise the native fold, leading to an increased 
propensity to misfold and/or aggregate (Byrstrom et al., 2010, Khare et al., 2006, Munch and 
Bertolotti, 2010). Owing to the high number of mutations associated with SOD1 fALS, and 
the fact that a misfolded/aggregated wild-type SOD1 species has been found associated with 
sALS (Bosco et al., 2010), it has been suggested that there is a common toxic form that exists 
for all SOD1 variants, although it is yet to be elucidated. 
Metal coordination and disulfide bond formation are important for stability of SOD1 tertiary 
and quaternary structures (Hayward et al., 2002, Lynch et al., 2004, Svensson et al., 2010, 
Tiwari and Hayward, 2003), and their absence has been shown to increase the aggregation 
propensity of SOD1 (Arnesano et al., 2004, Ding and Dokholyan, 2008). From this, it has 
been inferred that an immature/unfolded conformation(s) of SOD1 is responsible for 
aggregation.  Investigation of these possible unfolded SOD1 conformations has been difficult 
due to the heterogeneity of non-native protein structures. High resolution analyses, such as X-
ray crystallography, are impeded by the existence of disordered protein regions that can 
assume multiple conformations (Banci et al., 2009), and typical separation techniques such as 
size exclusion chromatography (SEC) do not provide sufficient resolution to separate 
different conformations for downstream analysis (Hong et al., 2012), although use of small-
angle X-ray scattering coupled with SEC can provide valuable insight into the structural 
plasticity of proteins in solution by separating different conformers and oligomeric states 
(Furukawa et al., 2015, Wright et al., 2011, Wright et al., 2016). Nuclear magnetic resonance 
(NMR) spectroscopy has been used to great extent on disordered SOD1, monitoring 
unfolding, refolding, and even identifying a zinc-deficient form of SOD1 proposed as a 
precursor to the toxic species (Luchinat et al., 2014, Szpryngiel et al., 2015). Although NMR 
analysis is an extremely useful tool in structural biology, it requires high concentrations of 
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protein (0.1-3 mM), which can lead to undesirable artefacts, especially in the case of protein-
protein interactions. 
In comparison, native mass spectrometry (MS) is a powerful tool for the analysis of 
structurally heterogeneous protein samples as it allows for the separation of different protein 
species based upon mass, charge, and drift time when coupled to ion mobility (IM-MS) 
(Mehmood et al., 2015), allowing for the resolution of species in solution at variable 
concentrations. This study details the use of native MS to investigate the possible 
misfolded/unfolded conformations SOD1 can occupy when metal binding and disulfide 
bonding are disrupted, and the relationship of these species to SOD1 aggregation. We first 
determined if there was a correlation between isolated recombinant protein aggregation and 
cellular aggregation of different SOD1 variants, focusing on the EGFP fusion proteins 
(described in table 2.1 and section 2.8). Next we attempted to assess the oligomeric state of 
our SOD1 variants under similar aggregation conditions, finding that SOD1 variants had 
differential mobility in both SEC and native PAGE.
 
This was followed by native MS 
analysis, as well as IM-MS to separate and analyse the variably destabilised SOD1 species. 
Our observations indicate that the oligomeric state of the SOD1 variants was primarily 
monomeric and that the monomer assumed 3 conformations based upon mass-to-charge 
distributions. The relative abundances of the conformations were dependent upon the SOD1 
variant being analysed. 
5.2 Results 
5.2.1 Cellular and isolated protein aggregation of SOD1 variants 
 
It has been established that SOD1 variants expressed in cultured cells have differing 
propensities to aggregate (Turner et al., 2005). This variation in aggregation may offer an 
explanation to the large disparity in average length of disease duration between SOD1 
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mutations. We first sought to determine the aggregation propensities of our chosen SOD1 
variant EGFP fusion proteins in cultured cells using microscopy. To this end, mouse 
neuroblastoma/motor neuron hybrid cells (NSC-34) (Cashman et al., 1992) were transfected 
with SOD1-EGFP and imaged 48 hours post-transfection, to count the number of transfected 
cells that formed inclusions. We observed that variants SOD1
A4V
, SOD1
G37R
, SOD1
G85R
, 
SOD1
G93A
, and SOD1
V148G
 had significantly increased populations of transfected cells 
containing inclusions when compared to SOD1
WT
 (Fig. 5.1 A, B). In contrast, there was no 
statistical significance between SOD1
WT
 and the variants SOD1
H46R
 and SOD1
D90A
 (Fig. 5.1 
B). We also generated tdTomato fusions of select variants (SOD1
A4V
, SOD1
G85R
, SOD1
G93A
 
and SOD1
V148G
) and assessed the inclusion formation of these constructs. The tdTomato 
fusion proteins generally showed a decrease in numbers of cells with inclusions when 
compared to the corresponding EGFP fusion (Fig. 5.1 C). This observed difference in 
inclusion formation is most likely due to the difference in size between EGFP (~29 kDa) and 
tdTomato (~59 kDa). 
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Figure 5.1: SOD1 variants have differential aggregation propensities in NSC-34 cells. Cells were 
imaged 48 h post-transfection and the number of transfected cells containing inclusions was counted. 
(A) Representative images of NSC-34 cells transfected with SOD1
WT
, SOD1
A4V
, SOD1
G37R
, and 
SOD1
G93A
 showing cells containing bright puncta that were determined to be inclusions. (B) Manual 
counting of images showed that SOD1 variants had differential aggregation propensities when 
expressed in NSC-34 cells. Significance is determined against SOD1
WT
-EGFP. (C) Comparison of 
inclusion formation 48 h post-transfection between EGFP (green) and tdTomato (red) SOD1 fusion 
proteins normalised to the EGFP inclusion count to allow comparison of differences. Error bars 
represent SD of the mean from 3 separate transfections on different days. Statistical significance was 
determined via a one-way ANOVA with a Tukey’s multiple comparison post-test (*** = P < 0.001, 
** = P < 0.01, * = P < 0.05, ns = non-significant). 
 
Following from this, we sought to assess if there was a correlation between isolated 
recombinant protein aggregation and aggregation in cells. We based our aggregation assay of 
isolated protein on previous work (Furukawa et al., 2008), making use of DTT (to reduce the 
intramolecular disulfide) and EDTA (to chelate Cu and Zn), as well as shaking, to promote 
aggregation of the SOD1 variants, as spontaneous aggregation of holo-SOD1 is yet to be 
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observed. Aggregation was measured via thioflavin T fluorescence, which has been used as a 
measure of amyloid formation and is thought to fluoresce when it binds to the β-sheet 
structure characteristic of amyloid. The variants SOD1
WT
, SOD1
G37R
, SOD1
H46R
, SOD1
D90A
, 
SOD1
G93A
 and SOD1
V148G
 were chosen for the remainder of this work owing to their high 
purification yield and variable patient survival time (SOD1
G37R
 = ~17, SOD1
H46R
 = ~17.6, 
SOD1
D90A
 ~8, SOD1
G93A
 ~3.1, SOD1
V148G 
= ~2.1 years) (Wang et al., 2008). The aggregation 
propensities differed between SOD1 variants (Fig. 5.2 A and B), with SOD1
V148G
, SOD1
G93A
, 
SOD1
G37R
, and SOD1
D90A
 obeying Boltzmann-sigmoidal kinetics typical of fibrillar 
aggregation. SOD1 aggregation is noted to be a highly stochastic process, with large variance 
between technical and biological replicates (Abdolvahabi et al., 2016); however, a 
comparison of the rates of fibril elongation (measured as change in ThT fluorescence) (Fig. 
5.2 C) between two assays here showed that inter-assay variation was minimal with the 
exception of SOD1
G93A
.  SOD1
WT
 and SOD1
H46R
 did not fit standard fibrillar aggregation 
kinetics, and as such analysis of the fibril elongation phase was not performed on these 
variants. Rather, SOD1
WT
 and SOD1
H46R
 did not seem to aggregate at all under our assay 
conditions (20 mM DTT, 5 mM EDTA 1 ×PBS 37 °C, shaking agitation), suggesting either 
resistance to the initial denaturing event or aggregation proceeding down an amorphous 
pathway not recognized by ThT. For the most part, our assays suggested that propensity to 
aggregate was dependent upon mutation, and when we plotted the relative final fluorescence 
of each SOD1 variant in first isolated aggregation assay (Fig. 5.2 A) against the inclusion 
formation data from transfected mammalian cells (Fig 5.2 D) we observed a relatively weak 
correlation (r
2
 = 0.6). However, if we omit SOD1
G37R
 as an outlier, due to its interestingly 
high propensity to form inclusion in cells comparative to its patient survival time, the 
correlation is much stronger (r
2
 = 0.86). We also plotted the lag-phase of aggregation against 
the percentage of cells with inclusions (Fig. appendix-C 5) finding a plausible correlation (r
2
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= 0.83), however there were only 4 data points in this analysis, and it would be greatly 
benefitted by expanding the number of mutants investigated. These data taken together 
suggest that in our case, with the exception of SOD1
G37R
, aggregation propensity of isolated 
SOD1 can predict its cellular aggregation. The two models of aggregation (isolated protein 
and cellular) were also compared with regards to the variable disease duration observed in 
SOD1-associated fALS patients. Plotting the maximum relative ThT signal against SOD1 
mutant disease duration showed a relatively strong correlation of r
2
 = 0.77, however when 
plotting the number of cells with inclusions against disease duration the r
2
 value of 0.16 was 
much weaker.    
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Figure 5.2: SOD1 aggregation and its relationship with disease progression. (A) and (B) 
Aggregation of SOD1 was promoted with DTT, EDTA, with shaking at 37 °C, and was monitored by 
ThT fluorescence. Dotted lines represent SEM of 4 technical replicates. (C) Plotting the slope of the 
elongation phase, of the variants that had a sigmoidal fit with an r
2
 > 0.8, showed that inter-assay 
variations in aggregation were low with the exception of SOD1
G93A
.  (D) Plotting the max 
fluorescence of each variant in assay A against the previously shown intracellular aggregation data 
gave an r
2
 value of 0.60 (solid line) for our SOD1 variants. The r
2
 value was 0.86 (dotted line) when 
SOD1
G37R
 was omitted from the data. (E) Plotting maximum ThT signal vs disease duration gives a 
moderately strong r
2
 value of 0.77. (F) Plotting the number of cells with inclusions against disease 
duration gives a relatively weak r
2
 value of 0.16. Error bars represent SD of mean for cells containing 
inclusions and SEM for 4 technical replicates of aggregation assay A for ThT signal. 
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5.2.2 Solution analysis of SOD1 denaturation and aggregation 
 
Since our the protein aggregation assay relied upon disulfide reduction and metal chelation to 
aggregate SOD1, we attempted to assess the consequences of these reactions on the initial 
oligomeric distribution of  SOD1 structure using native PAGE. SOD1 variants were subject 
to aggregation conditions similar to that of our isolated protein assay (30 µM SOD1, 20 mM 
DTT, 5 mM EDTA in 1 × PBS) and aliquots were taken and flash frozen in liquid nitrogen 
for subsequent native PAGE. Native PAGE of our variants at a concentration of 15 µM 
resolved SOD1
WT
, SOD1
H46R
, and SOD1
D90A
 into clear monomer and dimer populations (Fig. 
5.3). The monomeric population of SOD1
WT
 and SOD1
H46R
 decreased as aggregation 
proceeded, whereas SOD1
D90A
 had both its monomer and dimer populations decrease as 
aggregation proceeded, indicating the dimer was dissociating into monomers, or that the 
dimer was taking part in aggregation. Interestingly, we observed no separate monomer or 
dimer populations for SOD1
G37R
, SOD1
G93A
, or SOD1
V148G
. Rather, the bands seem to 
indicate that a large proportion of the protein remained dimeric as aggregation proceeded, but 
the intensity of these bands decreased substantially as aggregation progressed. In particular, 
SOD1
G37R
 showed a substantial difference compared to SOD1
WT
 as there was a large 
proportion of protein that had a lower mobility when compared to the dimer band, suggesting 
the presence of larger oligomeric species. Apparent aggregation (indicated by the red band 
above gel), identified by the presence of protein in the stacking gel or by streaked high 
molecular weight protein species was observed for all variants at 24 and 48 hours. SOD1
D90A 
had substantial abundance of high molecular weight species at 4 hours and onwards, at odds 
with the previous aggregation assay data, although this difference maybe due to the kinetics 
of both systems (eppendorf tube vs microplate well), or the stochastisty of protein 
aggregation, i.e. fibrillar vs amorphous aggregation, as well as potentially capturing 
oligomers that eventually give way to ThT postivie fibrils. Native PAGE has been used 
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previously to investigate the electrophoretic mobility of SOD1 variants following disulfide 
reduction (Tiwari and Hayward, 2003), where it was proposed that increased mobility was 
most likely a result of metal loss, and retarded mobility was most likely a result of a 
conformational change in the protein structure. It is clear that aggregation was occuring for 
each of the SOD1 variants, however we could not accurately quantify aggregation nor 
determine aggregate morphology (amorphous or fibrillar) using this assay. 
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Figure 5.3: Native-PAGE of SOD1 variants under aggregation conditions. SOD1 variants were 
subject to aggregation conditions and aliquots were taken and snap frozen in liquid nitrogen for native 
PAGE. Ellipsoids denote oligomeric state (1 = monomer, 2 = dimer) and the red line indicates 
fractions where protein remains in the stacking gel, indicating large oligomers or aggregates. 
SOD1
WT
, SOD1
H46R
, and SOD1
D90A
 showed the expected monomer dimer distribution, however 
SOD1
G37R
, SOD1
G93A
, and SOD1
V148G
 did not. The 0 time point is shown only for SOD1
WT
 as all 
variants shared the same profile at this point. 
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The apparent structural heterogeneity, induced by DTT and EDTA treatment across SOD1  
variants, likely arising from differential oligomeric distributions, metallation states, and 
disulfide statuses, prompted a secondary approach. We elected to use analytical SEC after a 
2 hour incubation in DTT and EDTA, in order to simultaneously investigate oligomeric 
distribution and desalt samples for native mass spectrometry. We observed that the elution 
profiles of the SOD1 variants corresponded closely to the mobility observed for each variant 
at the 2 hour time point of the native PAGE assay (Fig. 5.4), suggesting similar changes were 
detected by each technique. The dimer and monomer populations were, again, apparent for 
SOD1
WT
, SOD1
H46R
 and SOD1
D90A
, with the dimer eluting at ~12.5 mL, and the monomer at 
~14.3 mL. However, the elution profile of the DTT/EDTA-treated SOD1 dimer was distinct 
to the primarily dimeric non-treated controls (~13.6 mL), indicating a change in the 
hydrodynamic volume of the SOD1 dimer. This shift to a lower elution volume was observed 
for all SOD1 variants, with SOD1
G37R
, SOD1
G93A
 and SOD1
V148G
 having major elution peaks 
at ~12.5 ml, but no peak at ~14.3 mL in contrast to SOD1
WT
, indicating a lack of monomer. 
Interestingly, SOD1
G37R
 showed substantial protein at the void volume indicating the 
presence of oligomeric species with masses greater than or equal to ~100 kDa (S-75 10/300 
GL column). SOD1
G93A
, SOD1
V148G
, and to a lesser extent SOD1
D90A
 showed the presence of 
oligomeric species with peak shoulders ranging from ~ 9 to 11 mL. The high abundance of 
oligomeric species observed, after only 2 hours, is most likely due to the effects of 
concentrating the protein prior to analytical SEC, however it is interesing to note the 
differences between SOD1 variants. The analytical SEC, in conjunction with the native 
PAGE analysis, suggest that after a 2 hour treatment with DTT and EDTA, SOD1 undergoes 
a conformational change that affects the hydrodynamic volume and the packing of the 
protein. It is well known that changes to the structure of molecules can make SEC data 
ambiguous (Hong et al., 2012), potentially making the interpretation of these data 
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complicated. Due to this, native mass spectrometry analysis was performed on fractions 
eluted from analytical SEC assays.   
 
Figure 5.4: Analytical size-exclusion chromatography of SOD1 variants. SOD1 variants were 
incubated at 37 °C, in 1 × PBS, with 20 mM DTT and 5 mM EDTA, for 2 hours. After incubation, 
samples were concentrated at 4 °C to 450 µM in a volume of 100 µl and loaded onto an analytical S-
75 column equilibrated in 200 mM NH4OAc, and eluted at 0.5 ml/min into 0.5 ml fractions. Black is 
control SOD1 which was not incubated in the presence of DTT or EDTA. Blue is SOD1 +DTT 
+EDTA, which showed different elution profiles for all SOD1 variants, with the peak at ~12 mL 
being labelled ‘peak 1’ and the peak at ~14 mL being labelled ‘peak 2’. Inset above each 
chromatogram is native PAGE of the 2 hour incubation time point. 
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5.2.3 Native mass spectrometry analysis of DTT/EDTA-treated SOD1 variants 
 
The previous native PAGE and analytical SEC assays indicated the presence of high 
molecular weight oligomeric species, as well as SOD1 dimer and monomer populations. In 
addition, a potential change in conformation was observed as the dimer peak had a lower 
elution volume after treatment. Native mass spectrometry (MS) can be used to 
simultaneously investigate this dynamic system in simple experiments, giving high-resolution 
mass data that can be used to determine modification states (disulfide status, metal binding, 
oxidative modification). MS was used to analyse the main peaks eluting from the analytical 
SEC from figure 5.4 (MS analysis in Fig. 5.5 and 5.6), finding that in the case of SOD1
WT
, 
(Fig. 5.5 A and B) the oligomeric distribution in the mass spectra matched the oligomeric 
state determined from the SEC (i.e. the peak at 12.5 mL = dimer and the peak at 14.3 mL = 
monomer). The charge state distributions of both monomer and dimer in this assay were 
similar to that observed previously for native SOD1 variants (dimer 9 – 12+, monomer 7 – 
8+) (McAlary et al., 2013a); however, there was a relatively high abundance of monomer in 
peak 1 of DTT/EDTA-treated SOD1
WT 
from the analytical SEC (dimer = 76.5%, monomer = 
23.5% of signal) (Fig. 5.5 A), and also a low abundance of dimer present in the monomer 
peak (dimer = 5.6%, monomer = 94% of signal) (Fig. 5.5 B). The presence of monomer in 
the dimer peak maybe, at least partly, attributed to the effect of diluting the protein from an 
original concentration off the column to a concentration of 10 µM for analysis, as well as 
overlap of monomer and dimer populations as baseline resolution was not achieved during 
SEC separation. Analytical SEC of SOD1
G93A
 resulted in only one major peak from 
DTT/EDTA treatment at 12.5 mL (peak 1), consistent with the elution of the DTT/EDTA-
treated SOD1
WT
 dimer peak (Fig. 5.4). However, when this was analysed via MS, it was 
observed that a substantially higher abundance of monomer ranging from charge states 7+ to 
21+ was present (Fig. 5.5 C). Figure 5.6 shows that this broad monomeric charge state 
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distribution was also observed in the ~12 mL peak for SOD1
G37R
 (peak 1), the ~14.2 mL peak 
for SOD1
D90A
 (peak 2), and the ~12.1 mL peak for SOD1
V148G
 (peak 1), although each 
presented different relative abundances of the highly charged monomer ions (9 – 21+). The 
charge state distribution of proteins in mass spectrometry is dependent upon conformation 
(Prakash and Mazumdar, 2005), and the presence of these highly charged monomeric ions is 
indicative of a variably unfolded protein in the solution phase, due to greater access of 
solvent to chargeable sites during ionisation. SOD1 contains 23 basic amino acids (His = 8, 
Lys = 11, Arg = 4), and when recombinantly expressed and purified from E. coli, the 
methionine at position 1 is cleaved but the N-terminus is not acetylated (see section 4.2.1 and 
(Leinweber et al., 2004), meaning it can theoretically carry 23 positive charges if fully 
unfolded. Figure 5.5 C shows a maximum of 21 charges applied to SOD1
G93A
, and even in 
the case of SOD1
G37R
 (Fig. 5.6), which has 24 chargeable sites, we only see a maximum of 21 
charges, indicating that 2 (3 for SOD1
G37R
) of the basic amino acids are masked from 
protonation.  
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Figure 5.5: Native mass spectrometry of peaks from analytical SEC. Fractions from peaks were 
subject to mass spectrometry under gentle conditions (section 2.6.1). (A) Spectra of the first eluting 
peak of SOD1
WT
 (~12.5 mL) showing dimer (black labels) as the most abundant species with an 
appreciable abundance of monomer (grey labels). The charge state distribution was typical of a 
natively folded SOD1
WT
. (B) Spectra of the second eluting peak of SOD1
WT
 (~14.3 mL) showing the 
major species as monomeric SOD1 at charge states 7+ and 8+, with a low abundance of dimer. (C) 
Spectra of the major peak of SOD1
G93A
 (~12.5 mL) showing a high abundance of monomer ranging 
from charge states 7+ to 21+, with a low abundance of dimer. This broad charge state distribution is 
indicative of the monomer inhabiting several conformations. The SOD1
WT
 spectra also contained 
highly charged monomer signal but it is not visible due to low abundance. Similar spectra from other 
variants are shown in figure 5.6. 
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Figure 5.6: Native mass spectra of peaks from analytical SEC. Other SOD1 variants were subject 
to analysis similar to that in Figure 5.5. Each variant had unique spectral profiles, with SOD1
G37R
 
presenting the most abundant and highly charged monomeric distribution. The first eluting peak of 
SOD1
H46R
 (~12.5 mL) showed a population of trimer (red labels) ranging from 13+ to 15+ charge 
states. 
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 To further investigate the effect of DTT/EDTA-treatment on the SOD1 variants, MS coupled 
with ion mobility (IM-MS) was used to determine the drift times of ions, where these drift 
times are correlated with the collisional cross-section of the ion. The IM-MS analysis 
revealed that the ions carrying lower charge were unfolding in vacuo, suggesting that they 
were maintaining their solution phase conformation for the most part. This is evidenced by 
the existence of low charge monomers (7-8+) partitioning to two populations in the drift-time 
dimension (M7+[2]  and M
8+
[2]) (Fig. 5.7). The monomer ions that had larger collisional cross-
sections (more unfolded; defined by their increased drift times)  ranged from 7 – 11+ across 
all SOD1 variants, however the abundance of these conformers was different for each variant.  
The monomeric fraction from analytical SEC of SOD1
WT 
(taken from a different assay to 
what is shown in Fig 5.5) showed that the monomer fraction of SOD1
WT
 is capable of 
unfolding in solution, as indicated by the highly charged monomer (Fig. 5.7 A), although the 
unfolded species was at a very low abundance (4.3%). This is similar to the presence of 
unfolded monomer in the monomeric fraction of SOD1
D90A
 suggesting that the unfolding 
may occur spontaneously after analytical SEC. SOD1
H46R
 and SOD1
D90A
 (Fig. 5.7 C and D 
respectively) showed monomeric conformers of similar drift time to that of SOD1
WT
, 
although the M
9+
 ion did not evolve a third conformer in the case of SOD1
H46R
. This is most 
likely due to the different relative abundances of ions detected for each SOD1 variant. In 
agreement with previous spectra, SOD1
G37R
, SOD1
D90A
, and SOD1
V148G
  (Fig. 5.7 B, E, and F 
respectively) all produce a monomeric ion ditribution ranging from 7 – 21+, with several 
conformers arising in the 7 – 11+ ion range. Interestingly, the highly charged monomer ions 
(12-21+) showed only one conformer, for all SOD1 variants, at relatively low drift times. 
Owing to the high charge applied to these monomer species during ionisation, we expect this 
difference to be an in vacuo collapse of the solution unfolded monomer conformer, as 
opposed to the in vacuo unfolding we are observing for other monomer ions. From this we 
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can determine that the monomer ions ranging from 7 – 11+ have maintained some structure 
after DTT/EDTA treatment, and that 12 – 21+ ion are representative of a highly unfolded 
monomer. However, even though the system parameters used are gentle, in vacuo forces are 
still quite harsh and we may not be observing a true reflection of the solution cross-section  of 
the high charged monomer ions because they may unfold/collapse in the time between 
electrospray and detection.  
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Figure 5.7: IM-MS of DTT/EDTA treated SOD1 showing different conformers evolving at each 
charge state. (A) Mass spectrum and IM chromatogram of SOD1
WT
 monomer fraction after 
incubation in DTT/ EDTA treatment. (B) IM-MS of SOD1
G37R
 after DTT/EDTA treatment. (C) IM-
MS of SOD1
H46R
 after DTT/EDTA treatment. (D) IM-MS of SOD1
D90A
 after DTT/EDTA treatment. 
(E) IM-MS of SOD1
G93A
 after DTT/EDTA treatment. (F) IM-MS of SOD1
V148G
 after DTT/EDTA 
treatment. For all IM chromatograms the monomer charge states have the various conformers arising 
identified by dotted white lines and labels (i.e. the M
7+
[2]  denotes the second conformer of the 7+ charge 
state monomer). 
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5.2.4 Mass spectrometry of SOD1
G37R
 oligomers  
 
The elution profile of SOD1
G37R
, from analytical SEC, showed a large abundance of protein 
in the void volume, indicating high molecular weight oligomeric species. In order to identify 
oligomeric species mass spectrometry was performed on the void volume fraction as well as a 
second analytical size exclusion analysis with freshly prepared DTT/EDTA treated SOD1
G37R
 
using an S-200 column (1.3 MDa exclusion limit). The S-200 SEC of SOD1
G37R
 (Fig. 5.8 A) 
showed a primary elution peak for DTT/EDTA treated SOD1
G37R
 at ~15.6 mL compared to 
the untreated control SOD1
G37R
 at ~16.5 mL. This lower elution volume was consistent with 
the peaks observed in the S-75 SEC (Fig. 5.4). The absorbance at 280 nm was broad ranging 
from 8 – 21 mL, with 8 – 14 mL corresponding to high molecular weight species, and 18 – 21 
mL likely corresponding to residual DTT from the treatment (MS of this peak showed no 
protein signal – not shown). To identify the main components of the major peak 
(marked by *) from the S-200 analysis, mass spectrometry was performed on this fraction 
(Fig. 5.8 B), which showed the charge state distribution, of primarily monomeric SOD1
G37R
, 
similar to that observed from the S-75 SEC (Fig. 5.6). The fractions at lower elution volumes, 
containing oligomeric SOD1
G37R
, were also subject to MS, however low signal was acquired, 
most likely due to the very low abundance of the oligomers present. To overcome this, the 
void volume fraction of the SOD1
G37R
 S-75 SEC analysis was subject to MS. We observed a 
broad distribution of oligomers ranging from 1 to 12 subunits (Fig. 5.8 C), with the monomer 
being the most abundant species, indicating that the oligomers eluted from the column were 
highly labile. Generation of a theoretical mass spectrum containing the potentially identified 
species allowed for the correct assignment of each ion species (Fig. 5.8 D). We plotted the 
abundance of each oligomer to determine if there was a pattern in the dynamics of 
oligomerization, observing that the large oligomers were assembling in patterns of 4 subunits, 
as shown by oligomers composed of 4, 8, and 12 subunits being relatively abundant, and no 
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7, 9, 10, or 11 subunit oligomers being detected (Fig. 5.8 E). Since the monomer and dimer 
ions detected from this fraction were showing a charge state distribution typical for SOD1 
(monomer = 7-8+, dimer = 9-12+), we plotted the average charge of each oligomeric state 
against the number of subunits in that oligomer finding that the charge added per subunit 
addition was consistent at ~2 charges per subunit added to the complex, indicating that the 
oligomers were forming in an ordered fashion (Fig. 5.8 F). 
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Figure 5.8: Oligomeric distribution of DTT/EDTA treated SOD1
G37R
. (A) SOD1
G37R
 
(blue = DTT/EDTA treated, black = control) was subject to analytical SEC using an S-200 column 
showing the elution of large molecular weight species (arrows above trace are protein standards). (B) 
Mass spectrometry of the peak from the S-200 SEC showing the broad charge state distribution 
observed previously for DTT/EDTA treated SOD1
G37R
. (C) Mass spectrometry of the void volume 
peak from the S-75 SEC showing the broad oligomeric distribution of SOD1
G37R
 from this column 
fraction (oligomers are colour-coded to corresponding peaks). (D) A theoretical mass spectrum of the 
SOD1
G37R
 showing the expected location of observed peaks allowing for the deconvolution of 
overlapping peaks. (E) The relative abundance of each SOD1
G37R
 oligomer (colours match those in 
panel C) showing that oligomerization was mostly proceeding through the addition of 4 subunits (1 > 
4 > 8 > 12). (F) The relationship between the average charge and the number of subunits in an 
oligomer was consistent (r
2
 = 0.99). 
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5.2.5 Determination of the abundances of unfolded SOD1 
 
Due to the broad elution profiles of our DTT/EDTA treated SOD1 in analytical SEC, and the 
IM-MS analysis revealing the existence of different conformational and oligomeric species, it 
was necessary to normalise the conformational and oligomeric distributions to include a 
broad picture of the effect DTT/EDTA treatment. This was achieved by pooling all fractions 
from analytical SEC containing protein (determined by absorbance at 280 nm) into a single 
fraction, and diluting it to a concentration of 10 µM (determined by BCA) for subsequent MS 
analysis. This allowed for direct comparison of the relative abundances of charge states, and 
oligomeric distributions for each variant. 
It was observed, in the pooled fractions of each SOD1 variant that the major species was 
monomeric, ranging from charges of 7+ to 21+ (Fig. 5.9), as previously observed (Fig. 5.5 
and 5.6). The dimer abundance was substantially decreased in all cases, compared to previous 
spectra that were acquired from peak 1 in analytical SEC. This indicates that the pooling and 
dilution of the samples from analytical SEC resulted in dissociation of the dimer. In the case 
of SOD1
G37R
 (Fig. 5.9 B), there was no evidence of any oligomeric species, even though 
fractions thought to contain them were included into the pooled sample. This is most likely 
due to a combination of the biases involved in mass spectrometry based analyses such as this, 
where system parameters determine sensitivity at specific mass ranges, and the previously 
observed labile nature of the oligomers. In contrast to previously acquired spectra from 
fractions corresponding to peaks in the analytical SEC (Fig. 5.5 and 5.6), it was observed that 
highly charged monomer was present for all SOD1 variants, although at different abundances 
for each SOD1 variant. SOD
WT
, SOD1
H46R
, and SOD1
D90A
 (Fig. 5.9 A, C, and D 
respectively) showed relatively low abundances of highly charged SOD1 monomer, instead 
the major ion species was the monomeric 8+ charge state. SOD1
G37R
, SOD1
G93A
, and 
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SOD1
V148G
 (Fig. 5.9 B, E, and F respectively) had considerably increased relative abundances 
of highly charged monomeric species, in comparison to the typical 7+ and 8+ monomeric 
charge states.  
 
 
 
141 
 
 
142 
 
 
Figure 5.9: Mass spectra of pooled column fractions of DTT/EDTA-treated SOD1 variants. 
Fractions, across the elution profile, containing SOD1 were pooled, diluted to a concentration of 
10 µM, and subject to mass spectrometry. (A) SOD1
WT
 showing a high abundance of monomer (grey 
labels) compared to dimer (black labels). Inset is an expansion of the high charged 10 – 21+ monomer 
ions, normalised to the 10+ ion intensity. (B) SOD1
G37R
 spectrum showing that highly charged 
monomer is the major species present. (C) SOD1
H46R
 showing a primarily low charged monomeric 
distribution. Inset is an expansion of the high charge region normalised to the 9+ ion intensity. (D) 
SOD1
D90A
 showing that the most abundant ion species is the 8+ charge state with low abundance of 
highly charged monomer. Inset is an expansion of the high charged region, normalised to the intensity 
of the 16+ ion. (E) SOD1
G93A
 showing a substantial abundance of high charged monomer. (F) 
SOD1
V148G
 showing a substantial abundance of high charged monomer. 
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Since charge state is affected by conformation (Prakash and Mazumdar, 2005), analysis of 
the modification states, including metal binding, disulfide status, and oxidative modification, 
of select monomeric charge states (8+ = M
8+
, 10+ = M
10+
, and 14+ = M
14+
) and the 11+ dimer 
charge state (D
11+
) was carried out (Fig 5.10). As shown in figure 5.10, across all monomeric 
charge states, no evidence of any bound metals was observed with the exception of dimeric 
SOD1
WT
 (Fig. 5.10 D). Indeed, analysis of M
8+
 for each SOD1 variant revealed that the major 
species within that charge state had a mass consistent with disulfide reduced apo-SOD1, 
designated E,E,SH (E for empty metal binding site, SH for intact, reduced cysteines). 
Figures 5.10 A and E are SOD1
WT
 (15804 Da reduced, 15802 Da intact disulfide) and 
SOD1
G93A
 (15818 Da reduced, 15816 Da intact disulfide) respectively. If either copper or 
zinc were present we would expect mass changes of +63 Da and +65 Da respectively. Other 
major species within M
8+
 were determined, by mass, to be an addition of sodium (+22 Da) 
and a +60 modification that is potentially both sodium and potassium, based on the 
incubation of the protein sample in 1 × PBS during DTT/EDTA treatment, however, this is 
uncertain. Interestingly, the major species in both the 10+ and 14+ monomeric charge states 
of SOD1
WT
 was a mass of 15768 Da, which is a loss of 36 Da from reduced apo-SOD1
WT
. As 
stated previously in section 4.2.1, a mass changes of -18 Da and -36 Da are potentially 
successive dehydration (-18 = 1 dehydration, -36 = 2 × dehydration), however it could also 
represent S-gamma-glutamyl (-18 Da) from cysteine and dehydroalanine from cysteine 
(-36 Da). Conversion of cysteine to a dehydroalanine can proceed through heat induced 
β-elimination of the sulphur (Wang et al., 2010), which is possible here due to the protocol 
used for purification utilising heat to denature contaminating proteins from bacterial lysate 
(65 °C for SOD1
WT
, 55 °C for SOD1 mutants). The M
10+
 charge state of SOD1
WT
 also 
showed another modification that was +100 Da of the mass of reduced apo-SOD1
WT
 that is of 
unknown origin. The SOD1
WT
 M
14+
 ion also displayed two peaks that did not match any 
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masses that correspond to known modifications (Fig 5.10 C). Although the dimer was at 
relatively low abundance in the MS assay, there was sufficient signal and resolution to 
distinguish peaks corresponding to differential metalation states for SOD1
WT
 (E,E = empty , 
Cu,E = copper only, Cu, Zn = copper and zinc) of disulfide reduced SOD1 (Fig. 5.10 D). 
Interestingly, a dimer composed of reduced apo-SOD1
WT
 was observed, however, it was at an 
extremely low abundance compared to all species in the spectra. The major species for the 
M
8+
, M
10+
, and M
14+
 ions of other SOD1 variants were also reduced apo-forms where the 
most abundant modifications were the addition of sodium adducts (Fig. 5.10 E). The sodium 
adducts were confined to low charged monomer ions in the case of each variant. In 
comparison, the higher charged monomer ions showed little to no sodium binding. This 
suggests that the lower charge states are potentially binding sodium via the maintenance of 
structural features, even after extensive desalting via column chromatography, which is 
consistent with lower charged ions being more structured than their higher charged 
counterparts. Alternatively, more highly charged ions are less likely to pick up adventitious 
sodium owing to electrostatic repulsion. 
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Figure 5.10: Identification of protein species across the oligomeric and charge state distribution 
of DTT/EDTA-treated SOD1. (A) The M
8+
 ion of SOD1
WT
 showing that the most abundant species 
at that charge state is reduced apo-SOD1 (E,E,SH). (B) The M
10+
 ion of SOD1
WT
 showing the major 
species as being a mass change of -36 Da on reduced apo-SOD1. (C) The M
14+
 ion of SOD1
WT
 
showing the most abundant species is, again, -36 Da from the reduced apo-SOD1. (D) The D
11+
 ion of 
SOD1
WT
 showing a wide distribution with peaks consistent with different metalation states ranging 
from completely apo ((E,E)(E,E)) to completely metallated ((Cu,Zn)(Cu,Zn)). All of the masses were 
consistent with reduced SOD1. (E) The M
8+
 ion of SOD1
G93A
 showing the major species is apo 
reduced with subsequent peaks being sodium adducts. The M
10+
 ion of SOD1
G93A
 showing the major 
species as reduced apo-SOD1
G93A
. 
 
Following the analysis and identification of protein species evident from a close inspection of 
different monomer ions, it was determined that there were three main monomeric 
conformations that were being detected by MS. These conformations were termed compact, 
intermediate, and unfolded due to the major species across the monomeric ions being reduced 
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apo-SOD1 for all variants i.e. no holo-SOD1 was observed. It was also based on the Gaussian 
distribution of peaks (Fig 5.11 A and B) where we determined the relative abundance of each 
peak and plotted the abundance of each charge state. From these Gaussian fits it was possible 
to determine the relative abundance of each conformation for all SOD1 variants (Fig 5.11 C). 
We found that SOD1
WT
, SOD1
H46R
 and SOD1
D90A
 monomers primarily inhabited the 
compact conformation, with much lower abundances of intermediate and unfolded 
conformations. SOD1
G37R
, SOD1
G93A
, and SOD1
V148G
 had far higher abundances of 
intermediate and unfolded monomer, compared to SOD1
WT
, and out of the three variants, 
only SOD1
G37R
 showed a higher abundance of unfolded monomer compared to compact 
monomer. Since SOD1 aggregation has been previously proposed to be dependent upon the 
amount of unfolded/destabilised protein (Byrstrom et al., 2010), the relative ThT intensity 
from previous aggregation data (Fig. 5.2 A) was plotted against the percentage of monomer 
that was destabilised (sum of intermediate and unfolded abundances). The correlation was 
relatively weak (r
2
 = 0.31), however when SOD1
G37R
 was omitted from the linear fit, the 
correlation became much stronger (r
2
 = 0.70). SOD1
G37R
 is a curious outlier as it is defined as 
‘wild-type like’ due to its structural similarities with SOD1
WT
 (Hart et al., 1998) and has a 
long variable disease duration of ~17 years (Wang et al., 2008), yet in our assays presents 
severe structural destabilisation on similar levels as the aggressive SOD1
G93A
 and SOD1
V148G
 
variants (~2.2 and ~2.3 years patient survival respectively). 
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Figure 5.11: Determination of the abundance of monomeric conformations detected by mass 
spectrometry. (A) Representative mass spectrum of SOD1
G93A
. (B) Plotting the abundance of each 
charge state allowed for the determination of 3 Gaussian distributions that correspond to increasing 
charge states and decreasing peak width, indicative of 3 conformations (compact = blue, 
intermediate = green, unfolded = red). (C) The abundance of each specific conformation for each 
SOD1 variant shows the monomeric distribution where SOD1
WT
, SOD1
H46R
, and SOD1
D90A
 present a 
primarily compact monomeric distribution, compared to the other variants which showed high 
abundances of intermediate and unfolded monomer conformations. Error bars represent SD of the 
mean from 3 separate DTT/EDTA treatments of 3 separate nano-electrosprays (D) Plotting the 
percentage abundance of destabilised monomer (unfolded and intermediate conformation) against the 
relative ThT intensity from our aggregation assays showed a weak correlation (r
2
 = 0.31), however 
omission of SOD1
G37R
 from the linear fit gave a much stronger correlation (r
2
 = 0.70). 
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The concepts of aggregate strains and prion-like seeding have recently become prominent 
within the study of neurodegenerative disease, especially relating to ALS (Bergh et al., 2015, 
Bidhendi et al., 2016, Lang et al., 2015). Owing to the high level of unfolded SOD1
G37R
 
observed in the MS-based assay, an experiment was performed to elucidate if this unfolded 
species could template onto other preformed SOD1 aggregates. SOD1
G93A
 was chosen to be 
the ‘seed’ variant, where a minimal amount of preformed aggregate seed (seed was 0.3% total 
protein by mass) was added to the assay. Remarkably, it was observed that SOD1
G37R
 did not 
respond to the addition of seed, whereas SOD1
WT
 showed an appreciable response (Fig. 5.12 
B and D) and SOD1
G93A
 showed significantly altered aggregation kinetics (Fig. 5.12 A and 
D). SOD1
G37R
 showed no difference in either fibril elongation rate (measured as change in 
ThT fluorescence) (Fig. 5.12 C and D), or lag phase (Fig 5.12 D), indicating that the addition 
of the seed was not affecting either the nucleation time, or the generation of fibrillar 
structures. The kinetics of SOD1
WT
 were difficult to determine due to a weak sigmoidal fit, 
however, it was clear from the assay (Fig. 5.12 A) that the addition of SOD1
G93A
 seed 
increased aggregation. Addition of seed to SOD1
G93A
 aggregation significantly increased the 
elongation rate (Fig. 5.12 D) compared to no seed, and also significantly decreased the lag 
phase (Fig. 5.12 E), indicating that the addition of seed was pushing the aggregation reaction 
towards fibril elongation, overcoming the need to form aggregate nuclei. In figure 5.12 F, the 
fold increase in the mean maximum ThT fluorescence was compared between variants after 
seeding showed that SOD1
G37R
 had only a slight increase in max fluorescence, compared to 
SOD1
WT
 which was higher than SOD1
G37R
, and SOD1
G93A
 which was substantially higher 
than both other variants.  Taken together, this work suggests that SOD1
G37R
 may be 
aggregating as a different strain that is dependent upon the substitution of arginine at 
position-37.  
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Figure 5.12: SOD1
G37R
 is resistant to seeding by preformed SOD1
G93A
 aggregates. Aggregation of 
SOD1 was promoted with DTT, EDTA, and shaking, with the formation of fibrillar structures being 
monitored by ThT fluorescence. Preformed SOD1
G93A
 aggregates were added (or not) at a final 
amount of 0.3% total protein. (A) Aggregation assay of SOD1
G93A
 normalised to the maximum signal 
showing the ThT fluorescence over time for each sample. Dotted lines represent the maximum 
fluorescence of SOD1
WT
 (red) and SOD1
G37R
 (blue). (B) Aggregation assay of SOD1
WT
 with and 
without seed, normalised to the maximum fluorescent signal. (C) Aggregation assay of SOD1
G37R
 
with and without seed, normalised to the maximum fluorescence signal (D) Kinetic analysis gave the 
fibril elongation rate (measured as change in ThT fluorescence), showing that seeded SOD1
G93A
 had a 
significantly increased fibril elongation rate compared to other treatments. SOD1
WT
 is not shown here 
due to it not aggregating without seed. (E) Kinetic analysis gave the lag phase of aggregation, 
showing that addition of seed significantly decreased the lag phase of SOD1
G93A
 but not SOD1
G37R
. 
(F) Comparing the fold increase in the max fluorescence (Fmax) values when aggregation was seeded 
for each variant, showing that SOD1
G93A
 and SOD1
WT
 had greater increases compared to SOD1
G37R
. 
Each assay presented here was performed in the same microplate where error bars represent SEM of 4 
technical replicates. Statistical significance was determined using a one-way ANOVA (*** = P < 
0.001). 
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5.3 Discussion 
 
In this work we have shown that the reduction and chelation of SOD1 variants induces 
unfolding into multiple conformational states, and that the major difference between SOD1 
variants is the abundance of each of these states. It is well known that disruption of the metal 
ions and the intramolecular disulfide has severe effects upon SOD1 structural stability (Banci 
et al., 2009, Hayward et al., 2002, Lynch et al., 2004, Svensson et al., 2010, Tiwari and 
Hayward, 2003). Indeed, in the native conformation (metal bound, disulfide bonded form) 
most ALS-associated SOD1 variants have high melting temperatures, however, when reduced 
and metal-free, some variants, such as SOD1
G93A
, melt below physiological temperature 
(Furukawa and O'Halloran, 2005, Rodriguez et al., 2005). Taking this into account, it is clear 
that the conformational distribution we observed in MS assays is a result of the lower thermal 
stabilities of the SOD1 variants when in their reduced apo-form, which was induced via 
incubation in DTT and EDTA at physiological temperature. Take SOD1
G93A
 for example, 
which in its reduced apo-form, has a reported melting temperature of 31.2 ± 0.3 °C 
(Furukawa and O'Halloran, 2005). We observed that SOD1
G93A
 was significantly destabilised 
following DTT/EDTA treatment at physiological temperature, in agreement with this 
previous work. The most interesting aspect of the MS-based assay however, was that it was 
able to further separate the products of destabilisation, determining the existence and relative 
abundance, of several conformational states. Previously published thermal stability data has 
not detected these states (Furukawa and O'Halloran, 2005, Rodriguez et al., 2005), most 
likely due to the low resolution provided by the technique, or that these conformations are in 
a constant state of flux.  Indeed, the absence of unfolded SOD1
WT
, SOD1
H46R
 and SOD1
D90A
 
in peak 1 from analytical SEC which corresponded to the elution of the peaks containing 
unfolded SOD1
G37R
, SOD1
G93A
, and SOD1
V148G
, indicates that the unfolded conformation 
may be dependent upon dilution, as well as temperature. However, upon electrospray, the 
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assay was limited to ambient temperature (~20 °C), well below the previously mentioned 
melting temperature, indicating that any unfolding resulting in the SEC distributions observed 
occurred during DTT/EDTA-treatment, rather than during or immediately prior to MS 
analysis. 
Interestingly, the SOD1 monomer has been defined as having two-state folding dynamics 
(Stroppolo et al., 2000) but here we clearly see evidence of an intermediate state. Previously, 
Khare and colleagues used discrete molecular dynamics to monitor SOD1 unfolding in silico 
finding evidence of an intermediate folding state(Khare et al., 2003), however they discarded 
this result as it did not fit the published experimental data at the time. In order to delineate the 
differences observed by experimentation and modelling, we would propose using atomic 
force spectroscopy on SOD1 dimers and monomers to determine energies of unfolding and 
refolding, as well as using the data acquired to guide in silico modelling towards defining 
specific structures at each point along the folding/unfolding pathways. 
Higher resolution analyses of disordered SOD1 have been conducted using NMR, where 
reduced apo-SOD1
G93A
 was found to be highly unstructured, with little propensity to form 
secondary structure (Luchinat et al., 2014), and reduced apo-SOD1
WT
 was found to assume a 
monomeric native-like β-barrel structure with disordered loops (Sekhar et al., 2015). This 
model of reduced apo-SOD1
WT
 matches the analysis presented here where the relatively low 
charge state distribution and low drift time are indicative of a more compact monomermic 
species, close to what we observed for disulfide oxidised holo-SOD1
WT
 (see section 3.2.2) 
(Sekhar et al., 2015). Likewise, other work has considered reduced apo-SOD1
G93A
 to be 
representative of several other SOD1 variants, including SOD1
G37R
, which is in partial 
agreement with our results (Luchinat et al., 2014). SOD1
G37R
 was the most destabilised 
variant observed, with SOD1
G93A
 a close second. In-cell NMR spectroscopy revealed that the 
levels of unstructured reduced apo-SOD1
G37R
 and reduced apo-SOD1
G93A
 were similar when 
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overexpressed in mammalian cells, failing to detect any tertiary structure (Luchinat et al., 
2014). In contrast, the MS-based assay performed here detected reduced apo-SOD1 species 
inhabiting quaternary, tertiary, and unstructured states, as determined by IM-MS, across all of 
our SOD1 variants. The discrepancy is potentially due to the manner of purification, or 
differences in the generation of destabilised SOD1, where here SOD1 was co-expressed with 
the yeast copper chaperone for SOD1, and the purified holo-protein was destabilised with 
addition of chelator and reductant at the same time. In contrast, Luchinat (2014) and 
colleagues purified recombinant SOD1 without yCCS co-expression and overexpress SOD1 
variants in mammalian cells with only endogenous levels of the human copper chaperone for 
SOD1 to facilitate folding, i.e. the work present here has investigated SOD1 that has been 
unfolded from its native conformation, whereas Luchinat (2014) and colleagues have 
investigated SOD1 structures that are yet to reach a fully folded state. Regardless of the 
order, the removal of post-translational modifications from SOD1 is widely thought to result 
in a product that is similar to the immature polypeptide that can take part in aggregation. 
The isolated protein and cell-based aggregation assays showed a clear difference between 
specific SOD1 variant aggregation propensities. For the most part, aggregation in the cellular 
context correlated with aggregation of isolated protein, with the exception of SOD1
G37R
. 
SOD1
G37R
 was a consistent outlier throughout this work, and even more so when taking into 
account the interesting correlation between patient survival time and SOD1 mutation, where 
SOD1 variants more prone to aggregation are correlated with a more rapid disease 
progression (Wang et al., 2008). Given the association with a long disease course, one might 
expect SOD1
G37R
 to have a low aggregation propensity in cells, as well as a low isolated 
protein aggregation propensity. However, its in-cell aggregation was significantly increased 
compared to SOD1
WT
, similar to that observed for SOD1
G93A
 and SOD1
V148G
. A potential 
explanation for this is the difference between the intracellular environment compared to that 
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of an isolated protein assay. The isolated protein assay contains only purified SOD1 protein 
at a relatively low concentration (uncrowded) of 30 µM dimer, and is optimised to produce 
fibrillar aggregates at a rapid rate with vigorous shaking (section 2.7.1). The cytoplasm 
contains an abundance of protein and other macromolecules in high concentration (~400 
mg/mL), resulting in a crowded environment (Fulton, 1982, Zeskind et al., 2007). This 
crowding effect, along with other cellular processes, are most likely changing the dynamics 
of SOD1 aggregation, when compared to isolated protein. Indeed, transfection of cells 
typically results in variable expression levels of the protein of interest, across the population 
of cells that have taken up the vector. In the case presented here, the highest expressing cells 
are the ones most likely to develop inclusions (data not shown), jjconsistent with the idea that 
protein concentration is an important factor contributing to aggregation. Another explanation 
is the energy driven aggregation that occurs in cells. Previous work has shown that the large 
inclusions (similar to the inclusions we examine here) are dependent upon microtubule 
transport (Farawell et al., 2015) and are not a simply a product of random aggregation. It is 
possible that aggregation occurs after misfolded SOD1 has been transported to the site of an 
inclusion. 
The analytical SEC and MS analysis lends credence to the crowding idea, where destabilised 
SOD1 was concentrated prior to SEC (~450 µM) and the presence of high molecular weight 
species was observed only for SOD1
G37R
 (although peak shoulders were apparent for 
SOD1
G93A
 and SOD1
V148G
 but were unresolvable in MS), indicating a rapid formation of 
oligomeric species for this variant. These oligomeric species were sensitive to dilution, as 
evidenced by the most abundant species in our MS analysis of the SOD1
G37R
 void volume 
being monomeric. This potentially translates into a greater cellular aggregation propensity 
due to the high concentration of SOD1 with certain cells, but a lower propensity of isolated 
protein to aggregate due to the comparatively lower concentration of SOD1 in our assay. 
154 
 
Furthermore, there is a possibility that SOD1
G37R
 forms aggregate nuclei rapidly, leading to a 
decreased pool of available monomer to template onto extending fibrils, although we cannot 
rule out the possibility of a competing amorphous aggregation pathway for SOD1
G37R
.  
Recent work has emphasised the role that different aggregation pathways, leading to the 
formation of different aggregate strains, may play in the role of amyotrophic lateral sclerosis 
(Bergh et al., 2015, Bidhendi et al., 2016, Lang et al., 2015). Using binary epitope mapping, 
Bergh and colleagues (2015) observed that mice overexpressing human SOD1
D90A
 developed 
SOD1 aggregates that were composed of competing strains termed strains A and B. Each 
strain demonstrated differential kinetics and mortality in mice. A follow on from this found 
that the injection of mice expressing human SOD1
G85R
 with either of these strains resulted in 
the development of ALS-like symptoms at different rates, and also presented different 
pathophysiology (Bidhendi et al., 2016). The strain hypothesis may explain, at least in part, 
why different SOD1 mutants present variable disease progression in patients. Indeed, the 
work presented in this chapter indicates that SOD1
G37R
 may be aggregating into a strain 
distinct from SOD1
G93A
, similar to previous work that suggested SOD1
G37R
 mice spinal cord 
homogenates could not transmit disease to a SOD1
G85R
 mouse, but that SOD1
G93A
 mice 
homogenates could transmit disease (Ayers et al., 2014a). Given the MS data showed that 
SOD1
G37R
 had the highest abundance of unfolded monomer, it might be predicted to have 
substantially altered aggregation dynamics in the presence of preformed aggregate seed 
(decreased lag phase, increased elongation rate), however this was not the case. This 
SOD1
G37R
 strain may be, for the most part, benign, explaining the comparatively long disease 
duration of this SOD1 variant, although further characterisation of in vitro and in vivo 
SOD1
G37R
 aggregates would need to be performed to substantiate this. 
In conclusion, the work presented here underscores the necessity of combining mass analysis 
techniques with traditional size determination techniques, as the relationship between size 
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and mass may be drastically altered by conformational changes to molecules. Native mass 
spectrometry is an excellent technique as it provides a means to not only separate different 
conformers, but identify modification states, as we have shown above. The conformers we 
identified in this work related to different misfolded monomeric states common to several 
ALS-associated SOD1 variants, showing that disulfide reduction and metal chelation resulted 
in differential conformational states, which correlates with both isolated protein aggregation 
and cellular aggregation. However, SOD1
G37R
 did not follow this relationship; it was 
observed to have a high abundance of unfolded protein, yet a comparatively low aggregation 
propensity. Seeding SOD1
G37R
 aggregation with preformed SOD1
G93A
 aggregates had no 
effect on its aggregation kinetics, suggesting that SOD1
G37R
 may aggregate as a different 
strain. Understanding the interplay between unfolding and subsequent aggregation, as well as 
the potential for the formation of variable aggregate strains of more SOD1 variants may shed 
light on the phenomenon of SOD1 variant related differential patient survival times, and may 
also provide information on the disease causing protein species in SOD1-associated ALS. 
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6. Tryptophan-32 of SOD1 is an 
Aggregation Modulating Residue 
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6.1 Introduction 
 
Neuron death in SOD1-associated ALS is suggested to proceed from a gain of cytotoxic 
function, rather than loss of SOD1 enzymatic function. Evidence has shown that SOD1 
mediated cytotoxicity can proceed through many mechanisms, including dysregulation of the 
ubiquitin proteasome system, mitochondrial dysfunction, disruption of cytoskeletal elements, 
and potential generation of reactive nitrogen species (Cleveland and Rothstein, 2001, Ilieva et 
al., 2009). The exact SOD1 species affecting these pathways is yet to be elucidated but recent 
work using novel antibodies detected misfolded SOD1 in both fALS and sALS patient tissue 
(Bosco et al., 2010, Forsberg et al., 2010, Pokrishevsky et al., 2012b). Other work has shown 
that these misfolded SOD1 species can act in a prion-like fashion and transmit molecular 
pathology which invariably causes cellular pathology (Ayers et al., 2014a, Grad et al., 2011). 
A propagation of misfolding suggests that there may be conserved structural features 
contributing to the molecular transmission. 
SOD1 structure has been studied extensively since its association with fALS was first 
discovered. In its native state, SOD1 is a 32 kDa homodimer where each monomer contains a 
catalytically active copper ion, a zinc ion, and an intramolecular disulfide bond (McCord and 
Fridovich, 1969). These post-translational modifications impart remarkable stability to 
SOD1, allowing it to resist heat denaturation up to 90 °C and retain relatively high enzymatic 
activity under denaturing conditions (Rodriguez et al., 2002, Senoo et al., 1988). Indeed, the 
high stability of SOD1 is at odds with its accumulation into inclusions, and proteopathic 
nature in ALS. This conundrum can be partly explained in 20% of fALS cases that are 
associated with mutations in SOD1. These mostly single nucleotide missense mutations that 
are known to occur throughout the SOD1 primary sequence (http://alsod.iop.kcl.ac.uk - (Abel 
et al., 2013a) can have differential effects upon SOD1 structure by disrupting metal ion 
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coordination, disulfide formation/reduction susceptibility, and dimerization, each of which 
can result in the downstream consequences of misfolding and/or aggregation (Valentine et al., 
2005).  
The combination of ALS associated mutations causing destabilisation of SOD1 structure, and 
the apparent role of wild-type SOD1 in sALS, strongly suggests that there are common 
features within SOD1 structure that are contributing to disease. An interesting observation 
from studies of SOD1 transgenic mouse models and cell culture models of ALS 
overexpressing human SOD1 (hSOD1) is that murine SOD1 (mSOD1) very rarely co-
aggregates with the hSOD1 even though the sequence identity between isoforms is 83% 
(Bergh et al., 2015, Grad et al., 2011). Grad and colleagues (2011) have previously shown 
that oxidative damage can expose a disease specific epitope in hSOD1, and that this damaged 
SOD1 can transmit misfolding to other SOD1 molecules intercellularly (Grad et al., 2014). 
Misfolding transmission was shown to occur to hSOD1 but not mSOD1 when incubated with 
misfolded hSOD1, suggesting that mSOD1 may be resistant to this prion-like mechanism. 
They were able to significantly reduce transmission of hSOD1 misfolding by substituting a 
serine at position-32, where the exposed antibody epitope was localised. Tryptophan-32 
(Trp32) has been previously implicated as a site of oxidative modification in hSOD1 purified 
from human blood and transgenic mouse blood, and also shown to potentiate aggregation in a 
cell system (Taylor et al., 2007). Trp32 is located on β-strand III in a region which is non-
conserved between mice and humans (Fig. 1 A and B), but is highly conserved across fALS 
patients with a SOD1 mutation (Fig. 1 A and C). Here we investigated the effect of a serine 
substitution at position-32 (W32S) on the aggressive fALS-associated SOD1 variants 
SOD1
G93A
 and SOD1
V148G
, to further our understanding of the effect this substitution was 
having in regards to structural stability, isolated protein aggregation kinetics, and aggregation 
in cell systems. We found that whilst W32S substitution leads to the generation of a greater 
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abundance of unfolded SOD1 prior to isolated protein aggregation, W32S variants have a 
significantly reduced aggregation potential even when presented with preformed aggregate 
seeds from which to template. A set of experiments carried out in a cell system showed 
similar results, W32S variants formed fewer inclusions in cells as well as contributing less to 
the formation of dual coloured W32-W32S SOD1 inclusions compared to their disease only 
mutation counterparts.  
 
 
Figure 6.1: Loop II and β-strand III of SOD1 have low mutation frequency in humans and are 
non-conserved when compared to murine SOD1. (A) An alignment of murine and human SOD1 
showing the mutation frequency (only point mutations) within humans, and the conservation of 
residues between humans and mice. Highlighted red is loop-III and β-III, which has low ALS 
mutation frequency in humans and low species conservation between humans and mice. (B) 
Expansion of the highlighted region showing mutation sites (orange) and position-32 (blue box), with 
stars representing conservation score (none = non-conserved, 1 = semi-conserved, 2 = conserved). (C) 
Crystal structure of a SOD1 monomer showing locations of all point mutations associated with ALS 
(orange spheres) and Trp32 (blue sticks) (PDB accession: 1HL5 - (Strange et al., 2003))  
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6.2 Results 
 
6.2.1 W32S variants have decreased aggregation propensities 
 
To compare the aggregation of our disease causing variants to that of their W32S 
counterparts we used our previously established aggregation assay based on published work 
(Furukawa et al., 2008). This assay utilises DTT and EDTA to destabilise the native SOD1 
structure, by reducing the intramolecular disulfide and chelating the copper and zinc ions, as 
well as shaking to induce the formation of fibrillar structures that are thioflavin T reactive. 
SOD1
WT
 was previously shown to be resistant to our typical assay conditions (20 mM DTT 
and 5 mM EDTA) so we increased the concentration of DTT to 30 mM to induce aggregation 
of both SOD1
WT
 and SOD1
WT-W32S
. We observed that under these conditions that the W32S 
form of each SOD1 variant had significantly decreased aggregation propensities (Fig 6.2 A, 
B and C). Interestingly, SOD1
G93A-W32S
 was the only W32S variant to show typical sigmoidal 
fibrillar aggregation kinetics (Fig. 6.2 B), therefore allowing for the determination of both 
fibril elongation rate and the lag-phase time (Fig. 6.2 D). We found that SOD1
G93A-W32S
 had a 
significantly decreased fibril elongation rate, and a significantly increased lag-phase, 
indicating that the W32S substitution was affecting both the formation of aggregate nuclei 
and templating of the aggregating subunits onto fibrils. The lack of sigmoidal aggregation 
profiles for the other W32S variants suggested that they were either resistant to the effects of 
DTT and EDTA, not aggregating, or were aggregating down a non-fibrillar pathway not 
detected by thioflavin T.  
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Figure 6.2: Isolated protein aggregation of W32S variants. SOD1-W32S aggregation was 
compared to that of disease specific SOD1 variants using 20 mM DTT, 5mM EDTA, and shaking to 
promote aggregation. (A) SOD1
WT
 vs SOD1
WT-W32S
 were aggregated with 30 mM DTT due to 
previous assays showing a decreased aggregation potential of SOD1
WT
 to aggregate at lower DTT 
concentrations. (B) SOD1
G93A
 vs SOD1
G93A-W32S
, where SOD1
G93A-W32S
 showed sigmoidal aggregation 
kinetics. (C) SOD1
V148G
 vs SOD1
V148G-W32S
. For all assays dotted lines represent SEM of the mean 
from 3 technical replicates. (D) Δ ThT fluorescence and the lag phase were calculated from an 
analysis of SOD1
G93A
 and SOD1
G93A-W32S
 aggregation kinetics and show that SOD1
G93A-W32S
 had a 
significantly decreased fibril elongation rate and a significantly increased lag-phase. Error bars 
represent standard error and statistical significance was determined from n=3 technical replicates 
using student’s t-test (*** = P < 0.005). 
 
6.2.2 Native mass spectrometry analysis of W32S variants 
 
In order to determine the effect that the W32S substitution was having on SOD1 in the 
context of dimer dissociation, disulfide reduction, and metal chelation, native mass 
spectrometry was utilised. Native mass spectrometry is a useful technique that can reliably 
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separate ions based on mass and charge allowing for assignment of conformational and 
oligomeric status, as well as the modification states of these conformations and oligomers 
(Mehmood et al., 2015).  
Firstly, the dimer dissociation constants of the W32S variants were determined using mass 
spectrometry as previously described (McAlary et al., 2013b, Rose et al., 2011). When 
comparing the dimer dissociation of disease causing variants against their W32S counterparts 
(Fig. 6.3), it was found that for all variants that the W32S forms had an increased propensity 
to dissociate. This increased dissociation propensity was minor in variants SOD1
WT-W32S
 
(Fig. 6.3 A) and SOD1
G93A-W32S
 (Fig. 6.3 C) (1.22 and 1.5 fold increases in W32S variants 
respectively), but relatively larger in SOD1
V148G-W32S
, which had an approximately 4.2 fold 
increase in dimer dissociation constant over SOD1
V148G
. This increase in the dimer 
dissociation constant of SOD1
V148G-W32S
 suggests that there is cross-talk between the two 
areas the Trp32 and Val148 residues occupy within the SOD1 structure. In addition, given the 
distance of W32 from the dimer interface, these data suggest that W32S substitution induces 
destabilisation of the tertiary structure, which results in quaternary destabilisation. 
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Figure 6.3: Dimer dissociation of W32S variants. W32S variant dimer dissociation was assessed 
using native mass spectrometry, by analysing the monomer and dimer ion abundances at different 
solution concentrations of SOD1. (A) SOD1
WT
 and SOD1
WT-W32S
 dissociation curves. (B) SOD1
G93A
 
and SOD1
G93A-W32S
 dissociation curves. (C) SOD1
V148G
 and SOD1
V148G-W32S
 dissociation curves. (D) 
Comparison of dimer KD’s between variants. For all panels, error bars represent SEM of 3 separate 
nano-electrosprays of 3 separate dilutions. Dimer KD’s were determined from binding plots in 
Appendix C. Significance was determined via one-way ANOVA with a Tukey’s post-test (*** = P < 
0.001). 
 
Next we performed analytical size-exclusion chromatography (SEC) to simultaneously 
analyse the oligomeric distribution, and prepare the W32S variants for native mass 
spectrometry, after DTT and EDTA treatment. SOD1 variants were incubated for 2 hours in 
DTT and EDTA in 1 × PBS at 37 °C, before being concentrated to approximately 450 µM at 
4 °C and loaded onto an S-75 column, equilibrated in 200 mM NH4OAc for elution at room 
temperature. The elution profiles of the W32S variants were, for the most part, similar to 
those of their disease only counterparts (Fig. 6.4). SOD1
WT-W32S
 showed peaks eluting at  
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12.3 mL and 14.2 mL, where the abundance of the monomeric peak was decreased in 
comparison to that of SOD1
WT
 (Fig. 6.4 A). Both SOD1
G93A-W32S
 and SOD1
V148G-W32S
 (Fig 
6.4 B and C respectively) showed no monomeric peak, similar to their disease only 
counterparts. Interestingly, SOD1
G93A
 and SOD1
V148G
 showed evidence of higher order 
oligomers with a shoulder eluting (~8.5 - 11 mL) on the dimer peak, whereas their W32S 
counterparts showed no such shoulders, therefore indicating no formation of oligomers. The 
lack of oligomer formation fits with the decreased aggregation propensity observed in our 
previous aggregation assay, and further suggests that the W32S substitution is affecting the 
formation of aggregate nuclei. 
 
Figure 6.4: Analytical size-exclusion chromatography of W32S variants. SOD1 variants were 
incubated at 37 °C, in 1 × PBS, with 20 mM DTT and 5 mM EDTA, for 2 hours. After incubation, 
samples were concentrated at 4 °C to a volume of 100 µl and loaded onto an analytical S-75 column 
equilibrated in 200 mM NH4OAc, and eluted at 0.5 ml/min. Blue is disease variant and red is W32S 
variant (i.e. blue = SOD1
G93A
, red = SOD1
G93A-W32S
). (A) SOD1
WT
 and SOD1
WT-W32S
 elution profiles. 
(B) SOD1
G85R
 and SOD1
G85R-W32S
 elution profiles. (C) SOD1
G93A
 and SOD1
G93A-W32S
 elution profiles. 
(D) SOD1
V148G
 and SOD1
V148G-W32S
 elution profiles. 
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After analytical SEC analysis we pooled the fractions off the column and diluted them to a 
concentration of 10 µM for native mass spectrometry (MS) analysis. By pooling the samples 
we were able to assess the conformational and oligomeric changes induced by DTT/EDTA 
treatment as a whole. For each W32S variant we observed that the oligomeric distribution 
was primarily monomeric (SOD1
WT-W32S 
monomer = 91.8%, SOD1
G93A-W32S
 
monomer = 96.2%, and SOD1
V148G-W32S
 monomer = 97.6% total signal) (Fig. 6.5), similar to 
what we previously observed in section 5.2.5. The charge state distribution of the monomer 
for all variants ranged from 7 – 21+, also similar to what we previously saw for the disease 
only variants. We also found a similar Gaussian distribution of the monomeric charge states 
indicating the existence of conformations similar to what was previously observed. 
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Figure 6.5: Mass spectra of pooled column fractions of DTT/EDTA-treated W32S variants. 
Fractions, across the elution profile, containing SOD1 were pooled, diluted to a concentration of 
10 µM, and subject to mass spectrometry. (A) SOD1
WT-W32S
 showing a high abundance of monomer 
(grey labels) compared to dimer (black labels). Inset is an expansion of the highly charged 10 – 20 + 
monomer ions, normalised to the 10+ ion intensity. (B) SOD1
G93A-W32S
 showing that highly charged 
monomer is the major species present. (C) SOD1
V148G-W32S
 showing that the highly charged monomer 
is the major species present. 
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To this end we determined the relative abundance of each conformation, by fitting Gaussian 
distributions to the charge states, for the W32S variants and compared them to their disease 
mutation specific counterparts discovering that in each case the W32S variants showed a 
greater abundance of unfolded and intermediate conformations (Fig 6.6). While there was no 
statistical significant difference, there seemed to be a trend towards SOD1
WT-W32S
 populating 
a greater abundance of intermediate and unfolded conformations (Fig 6.6 A). Similarly, 
SOD1
G93A-W32S
 was found to have statistically significant differences between conformations, 
specifically a lower abundance of compact, but a higher abundance of intermediate and 
unfolded conformations when compared to SOD1
G93A
. This indicates that the W32S 
substitution is highly destabilising to reduced apo-SOD1
G93A
. Likewise, SOD1
V148G-W32S
 had 
a greater abundance of intermediate conformation, compared to SOD1
V148G
, but no difference 
was apparent when examining the unfolded conformation, indicating that the W32S 
substitution was affecting the transition from compact to intermediate conformation but not 
from intermediate to unfolded conformation in this variant.    
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Figure 6.6: Comparing the relative abundance of conformations for SOD1 disease variants and 
W32S variants. By applying Gaussian fits to the monomer charge states from the pooled fraction 
mass spectrometry we could determine the existence of 3 conformations, defined by charge state 
distribution, termed as compact, intermediate, and unfolded. (A) Comparison between SOD1
WT
 
(black) and SOD1
WT-W32S
 (grey) with no significant difference between variants. Inset is an expansion 
of the intermediate and unfolded conformation relative abundances. (B) Comparison between 
SOD1
G93A 
(dark green) and SOD1
G93A-W32S
 (light green) showing significant differences for all 
conformations. (C) Comparison between SOD1
V148G
 (dark orange) and SOD1
V148G-W32S
 (light orange) 
showing significant differences in abundance for the compact and intermediate conformations, but not 
the unfolded conformation. Error bars represent SD of the mean of 3 separate DTT/EDTA treatments 
and 3 nano-electrosprays. Significance was determined using a one-way ANOVA with a Tukey’s 
post-test (*** = P < 0.001, ** = P < 0.01, * = P < 0.05). 
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Following determination of the abundances of conformations, we then assessed the 
modification states of monomer ions representative of each conformation observed in the MS 
experiments (listed in table 6.1). For SOD1
WT-W32S
, the major protein species of the compact 
conformation (M
8+
 ion) was reduced apo-SOD1 (E,E,SH) (Fig. 6.7 A). A relatively small 
abundance of -18 and -36 Da species was observed, which are potentially S-gamma-glutamyl 
from cysteine and dehydroalanine from cysteine respectively (Wang et al., 2010). The other 
protein species within the ion were identified as sequential +22 Da adducts which is typical 
of sodium, indicating that there was a level of structure in this ion that allowed the binding of 
sodium or that the lower charge was unable to prevent sodium binding. The intermediate 
conformation of SOD1
WT-W32S
 (M
10+
) major species was reduced apo-SOD1 -36 Da, 
indicating a conversion of cysteine to dehydroalanine or two dehydrations on the polypeptide 
(Wang et al., 2010). We also observed +16, +32, and +48 Da modifications here that are 
potentially the additions of 1, 2, and 3 oxygens respectively (oxidation), (Fig. 6.7 B). The 
unfolded conformation ion (M
17+
) major protein species was reduced apo-SOD1 with a +48 
Da modification that we identify as 3 × oxidation, owing to the existence of the +16 and +32 
Da modifications (1 and 2 × oxidation respectively) (Fig. 6.7 C). In comparison to the high 
level of sodium modification seen on the compact SOD1
WT-W32S
 conformation, the compact 
SOD1
G93A-W32S
 conformation showed no evidence of sodium binding, although the ion peak 
itself had a tail that was poorly resolved (Fig. 6.7 G). The major species was identified as 
reduced apo-SOD1 with minor species being identified as dehydration modifications (-18 and 
-36 Da). Oxidative modification was also present here in the form of +16, +32, and +48 Da 
modifications, similar to what was observed previously. Both the intermediate (M
11+
) and 
unfolded (M
16+
) conformations of SOD1
G93A-W32S
 (Fig. 6.7 H and I) showed similar protein 
species profiles, where the major species was reduced apo-SOD1. 
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The protein species observed between conformations for SOD1
V148G-W32S
 were similar, with 
the major species always being reduced apo-SOD1 (Fig. 6.7 J, K and L). The modification 
states change in relative abundance between the different conformations, with the 
dehydration modifications being most abundant in the compact conformation (M
8+
) 
(Fig. 6.7 J). The other modifications identified were +16, +32 and +58 Da. The +16 and + 32 
Da modifications are oxidation. The +58 Da modification is potentially a carboxymethyl 
from cysteine. Taken together, these results show that the major base protein species is 
reduced apo-SOD1 for all of the W32S variants, similar to what was previously reported in 
section 5.2.5 (Fig. 5.10), and that although modification states have different abundances 
across the monomer charge state distribution, they remain similar for the most part.  
Table 6.1: Modifications detected on different charge states of SOD1 variants. Post-translational 
modifications detected on DTT/EDTA-treated W32S variants by mass spectrometry. 
Mass Difference Identification 
-36 Dehydroalanine from cysteine 
-18 S-gamma-glutamyl from cysteine 
0 Full length protein 
+16 S-OH on cysteine 
+32 S-O2H on cysteine 
+48 S-O3H on cysteine 
+58 Carboxymethyl on cysteine 
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Figure 6.7: Identification of protein species across the monomeric charge state distribution of 
DTT/EDTA-treated W32S variants. Monomer ion species from each conformation had specific 
protein species identified by mass (Monomer ion charge state of 8+ = M
8+
). (A) SOD1
WT-W32S
 M
8+
 
showing that the major protein species was reduced apo-SOD1 (E,E,SH) with sequential +22 Da 
adducts indicative of sodium. The -18 and -36 Da adducts are indicative of 1 and 2 × dehydration 
modifications respectively. (B) SOD1
WT-W32S
 M
10+
 showing that the major protein species was reduced 
apo-SOD1 -36 Da (2 × dehydration or dehydroalanine). Other species corresponding to +16, +32 and 
+48 Da which correspond to 1, 2 and 3 oxygens respectively. (C) SOD1
WT-W32S
 M
17+
 showing that the 
major species is reduced apo-SOD1 +48 Da (potential 3 × oxidation), with a low abundance of -18 
and -36 Da, as well as +16 and +32 Da which indicate oxidation (1 and 2 × respectively). (D) 
SOD1
G93A-W32S
 M
8+
 showing the major species is reduced apo-SOD1 with both dehydration and 
oxidation modifications present (-36 and -18 Da for dehydration, +32 Da for 2 × oxidation). (E) 
SOD1
G93A-W32S
 M
11+
 where the major species is reduced apo-SOD1 and oxidation (+32 and +48 Da) 
and dehydration (-18 and -36 Da) are present. (F) SOD1
G93A-W32S
 M
16+
 showing protein species that 
are similar to the M
11+
 ion. (G) SOD1
V148G-W32S
 M
8+
 showing the major species was reduced apo-
SOD1, with the -18 and -36 Da modifications present as well. The + 16 and + 32 modifications 
identified as oxidative modifications are present, as well as a modification of +58 Da which is 
potentially carboxymethyl on cysteine. (H) SOD1
V148G-W32S
 M
11+
 with the major species being reduced 
apo-SOD1 and other species present similar to M
8+
. (I) SOD1
V148G-W32S
 M
16+
 where the major species 
is reduced apo-SOD1 and modifications similar to M
8+
 are present. 
   
6.2.3 Seeded aggregation of W32S variants 
 
The observation that DTT/EDTA treatment resulted in a greater abundance of destabilised 
protein for our W32S variants, relative to their W32 counterparts, prompted us to test the 
effect of adding preformed aggregate seed to these variants. Seeded aggregation does not 
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require nuclei to form and as such eliminates this step from the aggregation process. This 
allows us to test whether the W32S variants are poor nucleators or poor aggregators more 
generally. To this end we performed aggregation assays similar to those above, with the 
exceptions that lower concentrations of DTT and EDTA (10 mM and 1 mM respectively) 
were used, as well as the addition of preformed aggregate to a final amount of 0.3 % total 
protein. 
Given that the SOD1
G93A
 variant more consistently showed reproducible aggregation kinetics 
between assays, and the fact that SOD1
G93A-W32S
 had kinetics upon which lag phase and 
elongation rate could be analysed, we elected to focus our analysis of seeded aggregation on 
this disease variant. Given the reported stochastic nature of SOD1 aggregation and potential 
differences between assays, here we show the results of 3 independent experiments. All 
assays were performed using aggregated SOD1
G93A
 as seed, and in each independent 
experiment showed similar trends for the aggregation of SOD1
G93A
 and SOD1
G93A-W32S
. Both 
SOD1
G93A
 and SOD1
G93A-W32S
 were susceptible to seeding but SOD1
G93A
 showed a much 
higher aggregation propensity in comparison (Fig. 6.8 A). Analysis of the lag-phase of 
aggregation revealed a trend across assays for seeded variants to have decreased lag-phases 
compared to assays conducted without seed, indicative of the addition of seed effectively 
eliminating the requirement of primary nucleation (Fig. 6.8 B). The lag-phase of 
SOD1
G93A-W32S
 did not decrease to the same extent as that of SOD1
G93A
 with the addition of 
seed. We also observed that the rate of fibril elongation (as measured by change in ThT 
fluorescence) was, at least in assays 2 and 3, significantly reduced when comparing seeded 
SOD1
G93A
 to seeded SOD1
G93A-W32S
, suggesting that the W32S substitution was affecting 
elongation by lowering its rate (Fig. 6.8 C). These results taken together indicate that W32 
plays a role at multiple points throughout fibrillar aggregation dynamics.  
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Further analysis was also performed after normalisation of all treatments to their respective 
minimum and maximum ThT fluorescence values (Fig. 6.9 A, B, and C). Interestingly, after 
inputting this data into the derived Boltzmann sigmoidal formulae to determine the values of 
specific events (lag-phase and elongation rate) (Fig. 6.9 D, E respectively), it was apparent 
that the results were different to those shown in figure 6.8, where the data were normalised to 
the maximum ThT value in each assay.  It is also interesting to note the presence of an 
irregularity in the elongation phase of the seeded SOD1
G93A
, presenting itself as a ‘jiggle’ in 
the ThT curve. Owing to the difficulty of precisely determining the molecular events within 
an assay such as this we cannot be sure as to what is causing this. It appears ot only occur in 
the seeded samples, indicating that the presence of seed is modifying the aggregation by 
means greater than just providing nuclei on which to template. 
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Figure 6.8: Seeded aggregation of SOD1
G93A-W32S
. SOD1
G93A 
and SOD1
G93A-W32S
 were aggregated 
with (or without) preformed SOD1
G93A
 aggregate seed in the presence of ThT. (A) 3 separate 
aggregation assays of SOD1
G93A
 and SOD1
G93A-W32S
 showing similar trends between assays, where 
SOD1
G93A-W32S
 was resistant to seeding. (B) Analysis of the lag-phase for each assay showing a trend 
where seeded SOD1
G93A-W32S
 had a decreased lag-phase time but not as much as seeded SOD1
G93A
. 
(C) Analysis of the rate of elongation (measured as Δ ThT signal) showing a trend of seeded 
SOD1
G93A-W32S
 having a slower rate of elongation compared to seeded SOD1
G93A
. Error bars represent 
SEM of the mean from 4 technical replicates (data points not analysedif the sigmoidal fit r
2
 < 0.8) and 
significance was determined using a one-way ANOVA with a Tukey’s post-test (*** = P < 0.005, 
** = P < 0.01, * = P < 0.05, ns = not significant). 
 
 
176 
 
 
Figure 6.9: Analysis of normalised seeded assays including fits. The data from figure 6.8 was 
analysed by normalising the mean values per-treatment of each aggregation assay. (A, B and C) Each 
separate aggregation assay with data and fits coloured to match the treatments (G93A = orange, G93A 
+seed = green, G93A-W32S = purple, G93A-W32S +seed = blue). R values of Boltzmann sigmoidal 
fits are inset in each panel. (D) Analysis of the mean lag-phase of aggregation of each treatment. (E) 
Analysis of the mean elongation rate of aggregation of each treatment. Error bars represent SEM of 
the mean from 3 assays (data points not analysed if the sigmoidal fit r
2
 < 0.8) and significance was 
determined using a one-way ANOVA with a Tukey’s post-test (*** = P < 0.005, ** = P < 0.01, * = P 
< 0.05, ns = not significant). 
 
177 
 
Following these seeded aggregation assays we selected one well of each seed treatment at 
random for which to perform transmission electron microscopy (TEM) to confirm 
aggregation (or the lack thereof) and assess aggregate morphology. We placed samples onto 
carbon coated nickel-mesh grids and negatively stained them using uranyl acetate. TEM 
images showed that seeded SOD1
G93A
 produced aggregates with a fibrillar morphology 
(Fig. 6.10 A and B), in line with the relatively high ThT fluorescence value observed from 
the previous plate assay. In contrast, the seeded SOD1
G93A-W32S
 (assay 1) produced small 
negatively stained puncta (Fig. 6.10 C and D). This indicates that even with the addition of 
seed there was minimal formation of aggregate by SOD1
G93A-W32S
 and the aggregates 
produced were small and amorphous, further suggesting that W32 plays a role in fibril 
elongation, although the ThT signal of aggregation suggests these small puncta may contain 
β-sheet structure. 
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Figure 6.10: Transmission electron microscopy of SOD1
G93A
 and SOD1
G93A-W32S
 aggregates. 
Samples from isolated protein aggregation assays were placed onto TEM grids and negatively stained 
with uranyl acetate prior to imaging. (A) Seeded aggregation of SOD1
G93A
 showing clear fibril 
structures. (B)  Increased magnification of seeded SOD1
G93A
 aggregates, clearly showing fibril 
structures. (C) Seeded aggregation of SOD1
G93A-W32S
 showing an abundance of small distinct 
negatively stained structures. (D) Increased magnification of one of the SOD1
G93A-W32S
 structures 
showing a lack of ordered structure. 
 
6.2.4 Cellular aggregation and seeding of W32S variants 
 
The isolated protein aggregation assays showed that W32S substitution was decreasing the 
aggregation propensity of SOD1, affecting both aggregate nucleation and fibril elongation. 
Studies in cells and in animal models suggest that SOD1 aggregates formed in cells may 
differ when compared to those formed isolated protein assays (Bergh et al., 2015, Farrawell 
et al., 2015). Considering this, the cellular aggregation of the W32S variants was tested by 
transiently transfecting NSC-34 cells with SOD1-EGFP fusion proteins, comparing the 
formation of intracellular inclusions between the disease variants and their corresponding 
W32S forms using confocal microscopy. It was observed that every W32S variant had a 
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significantly decreased number of cells containing inclusions compared to their disease 
mutation only counterparts, agreeing with similar work performed previously where 
SOD1
G93A-W32F
 was expressed in cultured cells (Taylor et al., 2007). SOD1
V148G-W32S
 had a 
considerably substantial decrease in the number of cells containing inclusions, in line with 
previous isolated protein aggregation assays, suggesting a particularly strong interaction of 
Trp32 in the V148G SOD1 mutation.  
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Figure 6.11: W32S variants have a lower aggregation propensity than their disease specific 
counterparts when expressed in cells. NSC-34 cells were imaged 48 hrs post-transfection and the 
number of transfected cell containing inclusions was counted. (A) Representative images of NSC-34’s 
transfected with SOD1
G85R
, SOD1
G85R-W32S
, SOD1
V148G
, and SOD1
V148G-W32S
 showing cells containing 
bright puncta that were determined to be inclusions (arrows). White bars are 50 µm. (B) Manual 
counting of cells with inclusions 48 hours post-transfection showed that SOD1 variants had 
differential aggregation propensities when expressed in NSC-34’s. Significance is determined against 
SOD1
WT
-EGFP, and where marked significance is between disease specific variant and W32S variant 
for the same mutant (ie SOD1
A4V
-EGFP vs SOD1
A4V-W32S
-EGFP). Error bars represent SD of the mean 
from 3separate transfections on different days. Statistical significance was determined via a one-way 
ANOVA with a Tukey’s multiple comparison test where ^ symbols are comparisons to 
SOD1
WT
-EGFP and * symbols are comparisons between W32 and W32S variants (*** = P < 0.001, 
** = P < 0.01, * = P < 0.05, ns = not significant). 
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Following determination of the aggregation of our W32S variants, we next tested their ability 
to template onto preformed aggregates in cultured cells. To achieve this we performed 
co-transfections, of SOD1-EGFP and SOD1-tdTomato, in NSC-34 cells (an advantageous 
cell line due to the preclusion of interaction with any endogenous human SOD1). Cells were 
transfected with EGFP (empty vector, SOD1
mutant
, or SOD1
mutant-W32S
) and tdTomato fusions 
(SOD1
mutant
), and 48 hours post-transfection individual cells were imaged using confocal 
microscopy. From these images, the fluorescence intensity was determined of both EGFP and 
tdTomato in inclusions and compared to their corresponding diffuse fluorescence intensities 
in the remainder of the cell, to determine a ratio of EGFP signal to tdTomato signal specific 
to the inclusions. In every case the ratio of vector-EGFP signal in the inclusion was minimal, 
indicating that the EGFP tag was not co-aggregating with the SOD1-tdTomato fusions, 
suggesting that the co-aggregation observed for our SOD1-EGFP fusions was likely 
proceeding through SOD1 contact only. In all cases, in the absence of the W32S substitution, 
co-aggregation of the EGFP and tdTomato tagged variant occurred at a ratio that was close to 
1:1, suggesting almost equal contribution of both tags. However, there was a clear bias 
favouring the SOD1
mutant
-EGFP fusion, indicating that the EGFP fusions were more likely to 
contribute to inclusion formation, in agreement with our previous analysis showing that 
SOD1-tdTomato fusions had decreased aggregation propensities compared to SOD1-EGFP 
fusions (Section 5.2.1, Fig 5.1 B). Again, the most likely cause for this is the size of the 
tdTomato tag. The W32S-EGFP fusions had significantly reduced ratios of EGFP signal in 
inclusions in all cases, indicating that the W32S substitution was also affecting the ability of 
SOD1 to template onto already formed aggregates in the cellular context.    
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Figure 6.12: Dual colour transfection seeding analysis of W32S variants. NSC-34 cells were co-
transfected with either EGFP, SOD1
(disease variant)
-EGFP, or SOD1
(disease variant-W32S)
-EGFP, and 
SOD1
(disease variant)
-tdTomato, and imaged 48 hours post-transfection. (A) Representative images of co-
transfected cells in the EGFP and tdTomato channels showing inclusions (white outline). (B) Analysis 
of co-transfections, showing the ratio of EGFP to tdTomato fluorescence signal in the inclusion, 
where each data point is a separate cell. Error bars represent SD of the mean from 3 separate 
transfections on different days with at least 10 cells imaged per transfection (3 for vector-EGFP 
measurements). Statistical significance was determined via a one-way ANOVA with a Tukey’s 
multiple comparison post-test (*** = P < 0.001, ** = P < 0.01, * = P < 0.05, ns = non-significant). 
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6.3 Discussion 
 
Here we have shown that a substitution of a serine in place of the tryptophan at position-32 
can drastically alter the aggregation of SOD1 both in isolated protein assays and in a cellular 
context, affecting the ability of SOD1 to template onto preformed aggregate species. An 
interesting observation made here, was that in each case, treatment of the W32S variants with 
DTT and EDTA resulted in the formation of higher abundances of destabilised SOD1 
conformations when compared to their disease mutation only counterparts. Previous work has 
emphasised that the amount of destabilised/unfolded SOD1 in a system is a determinant of its 
aggregation (Lang et al., 2012). That we observed higher abundances of destabilised W32S 
variants after DTT/EDTA-treatment, and lower aggregation propensities of the W32S 
variants, signifies the importance of Trp32 in SOD1 aggregation. Furthermore, there are 
multiple sequence segments predicted to have favourable energies to facilitate fibrillar 
aggregation, with these segments being 
14
VQGIINFE
21
, 
30
KVWGSIKGL
38
, 
101
DSVISLS
107
, 
and 
147
GVIGIAQ
153
 (Ivanova et al., 2014). Ivanova and colleagues (2014) determined that the 
C-terminal segments, 
101
DSVISLS
107
 and 
147
GVIGIAQ
153
, dominated the formation of fibrils 
in their aggregation assays, which were performed under conditions similar to that performed 
here. They also determined that a proline substitution at residue 35 (isoleucine) did not block 
fibrillar aggregation of SOD1 leading them to conclude that segment 
30
KVWGSIKGL
38
 does 
not form the β-sheet spine of the SOD1 fibrils they observed with electron microscopy. This 
is interesting in the context of the work presented here as, from our analysis of the abundance 
of unfolded protein, we would expect that the W32S variants would proceed to form fibrillar 
structures due to the presence of unmodified sequence segments 
14
VQGIINFE
21
,
 
101
DSVISLS
107
, and 
147
GVIGIAQ
153
, however this was not the case. Indeed, the initial 
aggregation of SOD1
G93A-W32S
 was the only non-seeded W32S variant to show fibrillar 
aggregation kinetics (Fig. 6.2 C and E), however the decrease in elongation rate, increase in 
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lag-phase, and significantly lower maximum fluorescence were suggestive of a significant 
decrease in aggregation propensity. However, we cannot rule out the interaction of segments 
14
VQGIINFE
21
, 
101
DSVISLS
107
, and 
147
GVIGIAQ
153
 in the fibrillar structures observed here. 
It is interesting to speculate that perhaps the stochasticity routinely observed in SOD1 
aggregation (Abdolvahabi et al., 2016) is a result of these competing aggregation prone 
segments, which may also play roles in the formation and propagation of different aggregate 
strains observed in animal models (Ayers et al., 2014a, Bergh et al., 2015, Bidhendi et al., 
2016, Lang et al., 2015). Importantly, the work presented here demonstrates that regardless of 
how the aggregates are formed (isolated or in-cell) the loss of the tryptophan (or gain of 
serine) reduces the amount of aggregation observed. 
The idea that protein aggregation in neurodegenerative disease follows a prion-like pathway 
is gaining increasing traction. Indeed, the pathophysiology of ALS, where motor neurone loss 
is ordered and progresses in correlation with an increase in protein aggregate load, seems to 
suggest a prion-like feature is affecting disease progression and spread. SOD1 is one such 
protein that is implicated to have prion-like properties, as evidenced by previous work 
showing the cell to cell transmission of misfolding using novel antibodies. Grad and 
colleagues (2011) identified Trp32 as a potential factor in the prion-like properties of SOD1, 
suggesting this residue as a target for therapeutics. The seeded aggregation assays and dual-
colour transfection work presented here agree with their hypothesis that Trp32 is a dominant 
contributor in SOD1 aggregation and transmission, and provides greater understanding of the 
events at a molecular level. Our cell based assays determined that, across a panel of SOD1 
variants, W32S substitution resulted in a significantly decreased participation in inclusion 
formation. Although it is not yet fully understood, it is possible that SOD1, and its 
aggregates, can exit cells through various pathways (cell death, transport vesicle mediated 
exocytosis) (Grad et al., 2014, Munch et al., 2011, Sabado et al., 2014). This released SOD1 
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can be taken up into cells via macropinocytosis (Munch et al., 2011, Zeineddine et al., 2015), 
potentially facilitating the aggregation or misfolding of the endogenous SOD1 within the new 
cell. Although the cell based assays presented here do not investigate cell-to-cell aggregation 
transmission, the data are consistent with the idea that the blocking of the intracellular 
aggregation induced by the W32S substitution would affect further propagation. Our analysis 
clearly indicates that Trp32 is a significant component of the molecular dynamics that govern 
the intracellular aggregation of SOD1, but that it is not the only determinant of aggregation as 
we still observed inclusion formation and co-aggregation of W32S variants albeit at a 
significantly lower level. A possible explanation for this may be the other sequence segments 
that have been suggested to contribute to aggregation as discussed above (Ivanova et al., 
2014). 
An advantage of our mass spectrometry based analysis is that we are able to identify the 
existence of specific protein species that are generated prior to aggregation. This is important 
in the context of SOD1 aggregation, where protein modification states (metal binding and 
disulfide status) have significant effects upon stability (Hayward et al., 2002, Lynch et al., 
2004, Svensson et al., 2010, Tiwari and Hayward, 2003) and therefore aggregation propensity 
(Arnesano et al., 2004, Ding and Dokholyan, 2008). Previous work investigating Trp32 has 
shown that this residue is susceptible to oxidative modification, promoted by interaction with 
bicarbonate ion, and that this modification can lead to the formation of Trp32 cross-linked 
non-native SOD1 dimers (Medinas et al., 2010). Our previous mass spectrometry based 
analysis of the DTT/EDTA treated SOD1 species (section 5.2.5) showed no evidence of any 
oxidative modification to Trp32 of any of our SOD1 variants (Fig. 5.10) suggesting that 
oxidation of Trp32 was not playing a role in our experiments, which was expected due to the 
lack of bicarbonate in any of the steps leading to our analyses, and the highly reducing 
environment in our aggregation assays. This, and the striking decrease in aggregation 
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propensity of our W32S variants, suggests that Trp32 does not require oxidative modification 
to modulate aggregation.  
Perhaps the defining feature of Trp32 is that it is an aromatic amino acid and that aromatic 
amino acids are implicated in protein aggregation (Gazit, 2002, Pawar et al., 2005). Previous 
work has shown that removal of aromatic side chains (Phe19 and Phe20) in Amyloid β-
protein (Aβ) modulates its aggregation kinetics by increasing the length of the lag-phase, 
indicating that they are affecting nucleation of small oligomers. Furthermore, the compound 
1,4-naphthoquinon-2-yl-L-tryptophan (NQTrp) significantly inhibited the formation of Aβ 
oligomers, significantly reduced the cytotoxic effect of Aβ oligomers in cultured neurons, 
and completely restored movement in an Alzheimer’s disease drosophila model (Scherzer-
Attali et al., 2010). The molecular rationale provided for this, by Scherzer-Attali and 
colleagues (2010), was that NQTrp was binding to the phenylalanine residues at positions 19 
and 20 and blocking self-association of Aβ through this interaction. Similar interactions have 
been shown with SOD1, where 5-fluorouridine was found to bind to Trp32 by X-ray 
crystallography (Wright et al., 2013), and that 5-fluorouridine can inhibit in vitro aggregation 
of SOD1
A4V
 (Nowak et al., 2010). These small molecules, or similar analogues, could 
potentially be used to prevent SOD1 aggregation or misfolding transmission in a cellular 
context, however, more work would be required to determine this. 
In conclusion, the data presented here provides further evidence signifying the importance of 
W32 in the aggregation and propagation of aggregation in SOD1 associated fALS. Using a 
combination of mass spectrometry based conformational analysis and aggregation assays, we 
have shown that the W32S substitution dramatically alters the aggregation propensity of 
several fALS associated SOD1 mutants, whilst decreasing their stability. We further show 
that the aggregation propensity of W32S variants is decreased in cells, even when fALS 
associated disease variant aggregates are available for templating. This underpins the 
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conclusion that Trp32 is a promising target for therapeutic strategies involving small 
molecule or antibody based treatments.  
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7. Conclusions and Future Research 
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7.1 Overview 
 
The main focus of this thesis was to investigate a range of ALS associated SOD1 variants, in 
regards to particular disease linked characteristics such as dimer dissociation, aggregation, 
and unfolding, as well as the interplay between these characteristics. Given that mutations in 
SOD1 are associated with fALS, and that there is growing evidence implicating SOD1 in 
sALS cases, it is important to understand how different SOD1 mutations alter protein 
dynamics to result in common structural modifications that differ from the wild-type.  
Advancing our understanding of this process could potentially lead to a determination of a 
structural basis for disease and the subsequent development of targeted therapeutics. In order 
to address this, several ALS associated SOD1 variants were used to examine dimer 
dissociation, aggregation propensity, response to denaturation, and the effect of a serine 
substitution at the disease implicated tryptophan  at position-32.  
In agreement with previous studies, the work presented here indicates that SOD1 variants 
display significantly modified structural dynamics across the range of characteristics that 
were investigated. The most interesting observations surrounded the SOD1
G37R
 variant, which 
is associated with a relatively slow progression of ALS pathology in patients.  It was 
observed that SOD1
G37R
 showed vastly different gas-phase dynamics to that of SOD1
WT
, a 
propensity to unfold similarly to the aggressive SOD1
G93A
 and SOD1
V148G
 variants, as well as 
an interesting inability to template onto preformed SOD1
G93A
 aggregates. This work also 
draws attention to the significant effect of Trp32 in SOD1 aggregation, where a W32S 
substitution was found to increase the abundance of unfolded protein under aggregation 
conditions yet decrease aggregation, similar to the SOD1
G37R
 mutation. As a result of this 
combined work, it is proposed that a sequence segment that includes residues 32 and 37 are 
involved in SOD1 associated aggregation and aggregation transmission. 
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7.2 SOD1 is a Potential Model Protein for the Investigation of in 
vacuo Protein Dimer Characteristics 
 
The utility of native mass spectrometry, when investigating the characteristics of protein 
structure, is remarkable. The first body of work presented here attempted to assess the ability 
of routinely used native mass spectrometry techniques to determine differences in the 
dissociation and unfolding pathways of several fALS associated SOD1 mutants. It was 
discovered that the in vacuo dissociation and unfolding characteristics of SOD1 were not 
representative of the previously reported variant dependant solution-phase characteristics, 
indicating that analyses performed on data acquired from the gas-phase must be interpreted 
carefully to ensure relevance to solution. However, when viewing these gas-phase data from 
a pure biophysical perspective it is highly intriguing that SOD1
G37R
 presented remarkably 
different dissociation and unfolding dynamics, comparative to the other mutants, disagreeing 
with current dimer charge partitioning models. Current models stipulate that in an 
asymmetric dimer system, the monomer carrying more charge unfolds at a lower energy 
before the complex dissociates, and that monomers from more symmetrically charged dimers 
are subject to comparatively much smaller structural perturbations prior to complex 
dissociation (Wanasundara and Thachuk, 2009). Our results disagreed with this model, with 
the unexpected observation that the evolution of more asymmetrically charged monomers 
from the comparatively less unfolded SOD1
G37R
 dimer, showed no apparent change in 
dissociation rate to the other SOD1 variants. However, it becomes clear from study of a 
heterodimer (composed of both SOD1
WT
 and SOD1
G37R
) that these curious observations 
appear to be a result of allosteric effects imparted by the arginine substitution at position-37. 
Furthermore, this indicates that SOD1 would be an exceptional model protein for which to 
study gas-phase protein dimer characterisitcs, owing to the number of naturally occurring 
mutants and the differential metallation states; combining to make a highly modular system 
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from which gas-phase characteristics can be tested against models derived from the extensive 
structural characterisation data currently in the literature. Therefore, from the context of gas 
phase analysis, this work may influence future studies that assess protein dissociation and 
unfolding via in vacuo based techniques.  
7.3 SOD1 Post-translational Modification and ALS 
 
The ability to resolve proteins based on mass, charge, and cross-sectional size, provided by 
mass spectrometry is unparalleled. This is highlighted by the work presented in this thesis by 
the interrogation of recombinant SOD1 post-translational modification (PTM) states and the 
ability to examine corresponding conformational and aggregation states. The initial 
assessment of SOD1 PTM directed our downstream analysis and was useful in the 
determination of dimer KD values of differentially glutathionylated SOD1 in a mixed sample, 
highlighting the necessity of determining protein PTM state prior to structural or functional 
assessment. It is readily apparent that protein biological structure, and therefore function, is 
modulated by PTMs and that this is likely to be an important factor in diseases such as ALS. 
The human genome currently has ~21 000 protein coding genes identified, and the proteome 
is even larger still, estimated at anywhere between ~10 000  to several billion (Ponomarenko 
et al., 2016) different protein species when PTMs are considered. Protein species are defined 
as synthesised polypeptide sequences that have undergone transcriptional, translational, or 
post-translational processing that may modify the protein in some way, including nucleotide 
polymorphisms, gene splicing events, proteolysis, PTM, and binding of cofactors (Schluter et 
al., 2009). One could also include different folding states, such as natively folded, misfolded, 
or aggregated, under the umbrella of different protein species. Indeed, the PTM state of 
SOD1 has been implicated in disease including the bicarbonate dependent oxidative 
modification of W32 to a formylkynurenine that can cross-link to form non-native dimers 
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(Coelho et al., 2014, Medinas et al., 2010), and the exposure of a disease associated epitope 
in glutathionylated SOD1 (Redler et al., 2014). 
Furthermore, the effect of glutathionylation on SOD1 structure extends beyond the 
augmentation of dimer dissociation. In vitro glutathionylation of Cys111 of SOD1 was shown 
to induce non-native oligomerization, as well as reactivity to the C4F6 antibody in several 
recombinantly expressed fALS associated SOD1 variants (Redler et al., 2014). The C4F6 
antibody is generated against apo-SOD1
G93A
 (Urushitani et al., 2007) and recognises an 
epitope within amino acid sequence positions 80-119 (Bosco et al., 2010), with residues 90-
93 being critical for antibody binding (Ayers et al., 2014b). It reacts strongly with both sALS 
and fALS post-mortem tissue (Ayers et al., 2014b, Bosco et al., 2010). It could be argued, 
that glutathionylation may contribute to disease both by increasing the dissociation 
propensity of SOD1 dimers, and by facilitating misfolding. It is interesting to note however, 
that hSOD1 extracted from human and murine neural tissue was not glutathionylated, but 
rather cysteinylated at Cys111  (Auclair et al., 2014), a modification which can also alter 
dimer interfacing (Auclair et al., 2013a), however, it is unknown whether cysteinylation can 
induce misfolding. Current knowledge also suggests that Cys111 plays a role in SOD1 
associated pathogenesis via cross-linking as substitution of this residue showed a marked 
decrease in oligomers and inclusions in cultured cells (Cozzolino et al., 2008, Niwa et al., 
2007), as well as delaying phenotype onset in SOD1
H46R/C111S
 mice (Nagano et al., 2015). As 
stated earlier, oxidative modification of W32 is implicated as a cause for the formation of 
non-native SOD1 oligomers, mediated by oxidative damage (Coelho et al., 2014). Cultured 
cells expressing ALS-associated SOD1 mutants with a W32F substitution showed decreased 
cell death and aggregate load (Taylor et al., 2007), similar to what was observed in variants 
where Cys111 was replaced. This suggests that oxidatively induced cross-linking of either 
Trp32 or Cys111 may contribute to pathogenic aggregation, however  our analysis using 
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mass spectrometry showed no modification to Trp32, suggesting that oxidative modification 
of Trp32 may not be necessary for aggregation to proceed. This being said, we cannot rule 
out that some form of oxidative modification is occurring at a later time point in our isolated 
protein assay or in our cell based assays.  
There are likely dozens of possible SOD1 protein species that can be derived from various 
modifications and identification of the toxic species or structural feature is paramount to 
development of targeted therapeutics. While high-resolution analyses such as X-ray 
crystallography and Nuclear Magnetic Resonance (NMR) provide angstrom level structural 
information these techniques may not be effective at elucidating a target structure, as it is 
likely that any such toxic species exists in low abundance and is not amenable to the 
increased concentrations or chemical environments that are required of these techniques. 
Mass spectrometry based techniques, however, while relatively low resolution compared to 
X-ray and NMR data, offer mass resolving capabilities that are invaluable for delineating 
protein species within a mixture. This capability was demonstrated here in regards to SOD1 
glutathionylation and dimer dissociation.  
7.4 SOD1 Mutation and its Relation to Aggregation 
 
Extensive study has been conducted on fALS associated SOD1 variants and primarily due to 
the presence of SOD1 positive aggregates in patient tissue. One of the main focal points of 
this study has been around the structural stability of the protein. When considering natively 
folded mutant SOD1, it is apparent that whilst mutation can have an effect on stability, the 
destabilisation effect of mutation is effectively muted if disulfide formation and binding of 
metal cofactors is successful. An example of this is the similar melting temperatures of native 
SOD1
WT
 (~90 °C) and mutant forms of SOD1 (Furukawa and O'Halloran, 2005, Rodriguez et 
al., 2002). The stabilising effects of the intramolecular disulfide and copper binding are a 
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product of folding facilitated by the copper-chaperone for SOD1 (hCCS) (Furukawa et al., 
2004, Rae et al., 2000). The reduced apo-form of SOD1
WT
 has a significantly decreased 
thermal stability with a melting temperature of ~43 °C (Lindberg et al., 2002). From these 
stability based observations, it would stand to reason that the formation of SOD1 aggregates 
potentially proceeds through an immature form of SOD1 that is destabilised by mutation (Fig. 
7.2). This idea is consistent with the work presented in this thesis that showed differential 
levels of destabilisation of our SOD1 variants, primarily in the reduced apo-state, with higher 
levels of unfolding correlating with increased thioflavin T positive aggregate formation in 
isolated protein assays. SOD1
G37R
 was an outlier here showing relatively low thioflavin T 
fluorescence, comparative to the level of destabilised SOD1 observed using mass 
spectrometry. Even more interesting was that SOD1
G37R
 showed levels of intracellular 
aggregation similar to that of SOD1
A4V
, suggesting the formation of non-fibrillar aggregates 
in vitro may be a characteristic of SOD1
G37R
. It could be speculated that rather than mutation 
affecting only conformational stability, it also directs the process of SOD1 aggregation and 
the specific structures generated through precise intermolecular contacts. This potentially 
contributes to differential patient survival times of SOD1 associated fALS cases. SOD1 
associated fALS patients with a SOD1
G93A
 or SOD1
V148G
 mutations die rapidly after 
diagnosis (means of 2.1 and 1.2 years respectively), whereas patients carrying SOD1
G37R
 
have a mean survival time of 17.6 years (Wang et al., 2008), suggesting a different or milder 
molecular basis of pathology. 
Another curious observation was the inability of SOD1
G93A
 aggregate seeds to induce 
increased aggregation in a solution containing abundant unfolded SOD1
G37R
. This inability of 
SOD1
G37R
 to template onto preformed aggregates is similar to the observations described here 
that show a serine substitution at amino acid Trp32 of SOD1 significantly decreased seeded 
and non-seeded aggregation across multiple variants. Gly37 is relatively close to Trp32, and 
195 
 
it is possible that a steric effect or charge repulsion effect is occurring to block the self-
association of this segment of the SOD1 polypeptide, as the arginine side chain is bulkier 
than that of glycine, and in addition, it can be charged. Relative to the whole SOD1 primary 
structure, the sequence segment around position-32 and 37 is remarkably conserved amongst 
SOD1 associated fALS patients (http://alsod.iop.kcl.ac.uk (Abel et al., 2013a), but compared 
to mice the segment is highly non-conserved (Grad et al., 2011). These collective 
observations suggest that this sequence segment of SOD1 is a potential mediator and initiator 
of aggregation and misfolding propagation..   
Previous work has emphasized the importance of particular sequence segments 
(
14
VQGIINFE
21
, 
30
KVWGSIKGL
38
, 
101
DSVISLS
107
, and 
147
GVIGIAQ
153
) of SOD1 for the 
initial self-assembly into aggregates (Ivanova et al., 2014). Analysis of the SOD1 amino acid 
sequence using the aggregation hot-spot finder tool ‘Aggrescan’ (Conchillo-Sole et al., 2007) 
identifies 6 aggregation hot-spots, including a sequence segment encompassing Trp32 (Fig. 
7.1), similar to the above mentioned segments. This may indicate that blocking aggregation 
of any one segment, including the Trp32 encompassing segment, could lead to SOD1 
aggregation being facilitated by other sequence segments, although we did not directly 
observe this. The results presented here suggest that altering Trp32 significantly supressed 
(for SOD1
G93A
 we observed a ~50% reduction of inclusions in cultured cells (Fig. 6.10 B) but 
does not totally block aggregation, this is consistent with the region encompassing W32 being 
important but not necessary for aggregation. An explanation for this can be drawn from the 
stochastic nature of protein aggregation (Abdolvahabi et al., 2016), resulting in several types 
of aggregates such as amorphous or variously structured fibrillar aggregates (Fig. 7.2). It is 
possible then that the segment most likely responsible for ordered aggregation is the segment 
containing Trp32.  Therefore, any unfolded SOD1 is likely to proceed down a disordered 
aggregation pathway due to the probability of the initiation of ordered aggregation at a 
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particular segment being low. To test this, one could perform a high number of ThT based 
assays on recombinant SOD1-W32S protein to examine stochastic differences in fibrillar 
kinetics; aggregates that appear at low frequency with significantly different kinetics that (are 
propagatable) are likely generating different strains of aggregate that are dependent on other 
sequence segments. 
  
Figure 7.1: SOD1 fALS-associated mutations and aggregation hot spots. Six aggregation hot-
spots (blue line) are identified by Aggrescan (Conchillo-Sole et al., 2007) with one hot spot (*) 
corresponding to a sequence segment encompassing Trp32 and Gly37,  with high conservation of 
residues across SOD1 associated fALS cases. 
 
7.5 Aggregate Strains and Prion-like Characteristics are 
Dependent on Specific Residues 
 
An increasing amount of evidence suggests that SOD1 may have prion-like characteristics 
(Ayers et al., 2014a, Ayers et al., 2016, Bidhendi et al., 2016, Grad et al., 2011, Grad et al., 
2014, Munch et al., 2011, Pokrishevsky et al., 2012a). Briefly, Prion protein (PrP) is a protein 
that can assume an energetically favourable and protease resistant non-native conformation, 
associated with neurodegenerative disease, that can transform native PrP into this same form 
and transmit misfolding to nearby cells and also separate organisms (Málaga-Trillo and 
Sempou, 2009, Riesner, 2003). In the case of neurodegenerative diseases such as Alzheimer’s 
(amyloid-β), Parkinson’s (α-synuclein) and ALS (SOD1, TDP-43, FUS etc.), the pathological 
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propagation is typically the recruitment of soluble proteins onto aggregates. The fact that 
these aggregates may display different kinetics and structural arrangements has resulted in 
them being categorized as different ‘strains’. Another significant distinction is that evidence 
for the infectious transmission of the above mentioned diseases is limited (Irwin et al., 2013). 
Owing to these distinctions, the term ‘prion-like’ is commonly used to define the mechanism 
of propagation in these diseases.  
Organism-to-organism transmissibility of ALS was effectively shown to occur in a study that 
injected spinal cord homogenate from terminal transgenic mice expressing either SOD1
G93A
 
or SOD1
G37R
 into the spinal cords of mice expressing low levels of SOD1
G85R
-YFP (yellow 
fluorescent protein). It was observed that the injection of SOD1
G93A
 homogenate was able to 
induce ALS-like symptoms and pathology in the SOD1
G85R
-YFP mice, and that this could be 
further passaged to newborn SOD1
G85R
-YFP mice. Interestingly, the homogenate from the 
SOD1
G37R
 mice did not induce ALS symptoms or pathology, even though the SOD1
G37R
 mice 
developed an ALS-like pathology (Ayers et al., 2014a). As stated previously, Gly37 is 
proximal to Trp32, and it is highly possible that the lack of transmission observed in these 
mice is a consequence of the structure or strain of aggregate that SOD1
G37R
 develops, and 
perhaps the propagation competent epitope is not (or less) exposed in this structure, resulting 
in the low expressed endogenous SOD1
G85R
-YFP being unable to effectively template onto 
the exogenous material. This agrees with our previous statement that mutation directs 
aggregation not only through reduced conformational stability, but perhaps by exposure of 
precise intermolecular contacts (Fig. 7.1).   
Recent work has identified the presence of two separate aggregate strains from transgenic 
mice overexpressing SOD1
D90A
 (Bergh et al., 2015). These strains were found to have 
different kinetics, structures, and stabilities and were therefore termed A and B strains. The 
coarse-grain structure of these aggregates was identified using binary epitope mapping, and 
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interestingly the common core of the structures was found to roughly encompass the SOD1 
amino acid sequence from 1 – 39 (more precisely Strain A: 1-39 and 100-127, Strain B: 1-
72). Furthermore, injection of these strains into mice overexpressing human SOD1
WT
 showed 
propagation and maintenance of the physical characteristics of each strain, where epitope 
mapping again showed similar results in strain extracted from inoculated mice to that of the 
donor mice (Bidhendi et al., 2016). Perhaps the most interesting component of this work is 
that both strains maintained a common aggregate core composed of residues 1-39, which 
strongly suggests that this sequence segment is contributing to both aggregation and 
propagation by providing the main structure of the aggregate species. Other work has 
highlighted part of this segment, and in particular Trp32, as a key component of the prion-
like characteristics of SOD1 in ALS (Grad et al., 2011). The work here, where the decreased 
ability of W32S variants to template onto preformed aggregates both in isolated protein 
assays and in cells was observed supports the idea that SOD1 aggregation is primarily 
dependent upon Trp32 or at least the sequence segment containing Trp32. Although we 
observed a significant decrease in co-aggregation between disease only and W32S variants, 
there was still evidence that co-aggregation was occurring, meaning that further work would 
need to be performed in order to examine the contribution of different aggregation prone 
sequence segments to the formation and propagation of SOD1 aggregates. If Trp32 and its 
sequence segment are the main contributors to the spread of SOD1 aggregates in SOD1 
associated fALS cases, then it would provide an ideal target for therapeutic intervention 
owing to it being unique as the only tryptophan residue in the SOD1 sequence. 
We propose a model of SOD1 folding, misfolding and aggregation below based the current 
literature and the knowledge gained from this study. Following synthesis, SOD1 is thought to 
assume a partially folded conformation which can be stabilised by the binding of zinc 
(Furukawa and O'Halloran, 2006). Once zinc is non-covalently bound to the polypeptide, the 
199 
 
copper chaperone for SOD1 (hCCS) forms a heterodimer with the copper deficient folding 
intermediate and directs the correct coordination of copper into SOD1. The CCS is also 
thought to facilitate the formation of the intramolecular disulfide between Cys57 and Cys146, 
thus creating a mature SOD1 monomer that can form a homodimer with other mature SOD1 
monomers (Furukawa et al., 2004, Rae et al., 2000). At virtually any point on this pathway 
the process can be disrupted or proceed in an aberrant way due to mutation or other erroneous 
interactions such as oxidative modification, reduction, incorrect input of metal cofactors, and 
post-translational modifications. Disruption of proper folding pushes the equilibrium 
increasingly to off-folding pathways through which SOD1 can misfold and form aggregate 
structures of varying morphology (Sekhar et al., 2015). Firstly, small oligomers are necessary 
step on the path to larger aggregates and have been detected in vitro (Banci et al., 2007), 
although the intracellular concentration of these species is potentially too low to detect 
(Polling et al., 2014). Following from small oligomers is the formation of larger aggregates 
which grow from the successive addition of destabilised SOD1 monomers to the main body 
of aggregate. It is not fully clear if SOD1 aggregate structure is ordered or amorphous as 
staining with common amyloid dyes (congo red and thioflavin S) has been reported to be 
negative and weak (Kerman et al., 2010), but use of sequence specific antibodies has shown 
some order within the seemingly amorphous structures (Bergh et al., 2015, Lang et al., 2015). 
Taking the evidence for SOD1 prion-like propagation into account suggests that a misfolded 
monomer or structured aggregate is able to propagate itself inter and extracellularly (Bergh et 
al., 2015, Bidhendi et al., 2016, Grad et al., 2011). Propagation of aggregate structures 
between mice has shown that they can cause differential rates of disease progression 
(Bidhendi et al., 2016) or no progression at all (Ayers et al., 2014a). Of all these proposed 
misfolded and aggregated forms it is unclear which one is the primary neurotoxic species 
responsible for ALS, but it is clear that SOD1 mediated toxicity can proceed through many 
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mechanisms, including dysregulation of the ubiquitin proteasome system, mitochondrial 
dysfunction, disruption of cytoskeletal elements, and potential generation of reactive nitrogen 
or oxygen species, as well as other mechanisms (Cleveland and Rothstein, 2001, Ilieva et al., 
2009). This complexity makes choosing a specific target for therapeutic development 
difficult. 
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Figure 7.2: Schematic of SOD1 folding, proposed misfolding, and the associated cytotoxic 
consequences. Following synthesis, SOD1 proceeds to fold into a mature monomer first by binding 
of zinc to the nascent chain which is followed by noncovalent association with the copper chaperone 
for SOD1 (CCS) which facilitates binding of copper and formation the intramolecular disulfide, 
following which two mature monomers form the native homodimer (although metal occupancy can 
vary, leading to dimers composed of mixed metallated monomers). At any step in this pathway 
mutation or covalent modification can prevent correct folding. The more unstable intermediate steps, 
and to some extent a mature SOD1 monomer destabilised by modification or mutation, can misfold or 
form small oligomeric species. Misfolded monomer and small oligomers are thought to be neurotoxic 
as well as contribute to the formation of larger aggregates that can be amorphous or ordered. Different 
molecular contact points between the monomers that constitute ordered aggregates are thought to 
contribute to the formation of different aggregate strains that are associated with variable disease 
progression. A specific toxic effect caused by the unknown disease causing SOD1 species is yet to be 
identified, however mitochondrial dysfunction, ER stress, dysregulation of the UPS, oxidative and 
nitrosative stress, as well as disruption of the cytoskeleton are all correlated with SOD1 associated 
fALS. 
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7.6 Therapeutic Strategies for Targeting SOD1 in ALS 
 
The development of therapeutics for the treatment of ALS has been hindered in no small part 
due to the difficulty of discovering a common cause of pathology. Mutations in SOD1 are 
associated with ~2% of all ALS cases, and although SOD1 is implicated in sALS and non-
SOD1 associated fALS cases (Bosco et al., 2010, Forsberg et al., 2010, Pokrishevsky et al., 
2012b), it is still not fully clear how much SOD1 contributes to these cases (Kerman et al., 
2010). Regardless, alleviation of disease for sufferers of SOD1 associated ALS is a path that 
should be pursued. Genetic sequencing technology can identify people at risk of developing 
SOD1 associated ALS, allowing for the application of more effective treatment prior to 
symptom onset as once the phenotype is noticeable the damage to neural pathways may 
already be extensive. Classical therapeutic development strategy has relied upon 
understanding structure and targeting specific motifs with small molecules to block an active 
site or induce an allosteric effect that inhibits or excites activity (Mandal et al., 2009). It has 
been proposed that targeting SOD1 with small molecules designed to maintain the native 
state would be an effective strategy as it could potentially lower the abundance of misfolded 
SOD1 in a cell system. A portion of the research into small molecules aimed at attenuating 
SOD1 toxicity has focused on cross-linking SOD1 monomers to maintain the dimer (Auclair 
et al., 2010, Hallewell et al., 1989, Ray et al., 2004). The main problem associated with this 
approach is that any covalent cross-linking agent will potentially have high cross-reactivity in 
an in vivo environment. Another weakness is that SOD1 is present at high concentrations 
throughout all tissue and to assert effective binding in neurons would require large 
stoichiometric quantities of drug.  Furthermore, this would not address the issue of the 
multiple states of folding SOD1 can assume dependent upon mutation, binding of metal 
cofactors and disulfide status. Even though there may very well be an unidentified highly 
defined structural basis for the initiation and propagation of SOD1 toxicity in ALS cases, 
203 
 
elucidating this will be exceedingly difficult given these protein species are uncooperative 
with current high resolution techniques due to low abundance and structural flexibility. 
Although a small molecule with a high specificity to the toxic SOD1 conformation would be 
ideal, it is currently unfeasible. 
The answer may lie in the usage of antibodies raised against specific epitopes of misfolded 
SOD1 that are associated with ALS. Indeed, research has shown that vaccination, prior to 
symptom onset of transgenic mice expressing SOD1
G37R
, with recombinant human apo-
SOD1
G93A
 extended survival approximately 4 weeks. Antibody titres in these mice were also 
found to have a positive correlation with life span (Urushitani et al., 2007). A similar 
approach was shown to be effective in cultured cells where induced misfolding of hSOD1
WT
 
was propagated from culture-to-culture through incubation in condition media, which was 
blocked by addition of misfolded SOD1 specific antibodies to the condition media prior to 
incubation (Grad et al., 2011). An advantage of this approach is that antibodies that are highly 
selective for the identified subpopulations of misfolded SOD1 could be used, meaning that 
there would be no interference with natively folded SOD1. A disadvantage to this strategy 
would be that antibodies would be unable to enter the intracellular space of disease affected 
cells, and would therefore rely upon the hypothesis that SOD1 misfolding is transmitted cell-
to-cell in a prion-like manner, and not through other mechanisms. 
Rather than stabilising misfolded SOD1 or targeting its misfolded forms with binding 
partners, an effective strategy could be to ensure proper folding in the first place or clearance 
of the offending species by controlling cellular protein quality control machinery. Targeting 
the protein quality control mechanisms within neurons has previously shown some promise. 
Such mechanisms include the proteasome, heat-shock response, and autophagy. Upregulation 
of the proteasome would enhance clearance of misfolded protein, and in theory reduce the 
toxic effects associated with these species. Indeed, enhanced survival of Huntingtin disease 
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patient derived skin fibroblasts was observed when over-expression of the proteasome 
activator28γ subunit was induced (Seo et al., 2007).  Research has also shown similar effects 
with overexpression of heat-shock factor protein-1, which induces the expression of the 
chaperone heat-shock proteins and upregulates the heat-shock response, has shown to be 
effective at reducing the phenotype and toxicity in models of neurodegenerative disease (Lin 
et al., 2013, Pierce et al., 2013). In the context of SOD1-associated ALS, autophagy is a 
questionable target due to evidence suggesting both detrimental and beneficial effects of 
upregulation. For example, targeting autophagy using lithium has shown a delay in symptoms 
onset and disease duration in transgenic SOD1
G93A
 mice (Fornai et al., 2008), but similar 
work has shown that lithium has no effect in these mice (Pizzasegola et al., 2009) or even in 
humans (UKMND-LiCALS, 2013). The heat-shock response, the proteasome, and to a lesser 
extent, autophagy, all show some promise as viable therapeutic targets, but in the case of 
SOD1, ensuring proper structural integrity is potentially simpler than targeting these broad 
systems. 
Proper folding and maturation of SOD1 is dependent upon correct metal coordination and its 
association with the aptly named ‘copper chaperone for SOD1’ (hCCS), as well as the proper 
functioning of cellular copper homeostasis. Therefore, theoretically, upregulation of hCCS 
would result in an increase in SOD1 – hCCS interactions, inducing proper folding of the 
nascent protein and preventing its aggregation, however, practically, overexpression of 
human CCS in transgenic SOD1
G93A
 mice (hCCS:SOD1
G93A
) significantly decreased survival 
time and increased the neurological deficits of the model (Son et al., 2007). This suggests that 
an aberrant interaction between hCCS and SOD1 is involved in SOD1-associated ALS, 
making this target questionable. However, understanding of the models implies that 
increasing both SOD1 and CCS load in an organism would further perturb copper 
homeostasis and therefore lead to an increased abundance of apo-SOD1, which is more likely 
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to misfold and aggregate, therefore it was postulated that delivery of copper into mice would 
alleviate disease by increasing the levels of copper bound SOD1. Delivery of copper into 
SOD1
G93A
 mice using the drug Cu
II
(atsm) was found to significantly increase lifespan even in 
symptomatic mice (Soon et al., 2011). A study that orally treated SOD1
G37R
 mice with 
Cu
II
(atsm) found that the levels of SOD1 in neural tissue were increased and that there was a 
greater relative abundance of holo-SOD1 compared to untreated mice, as well as this increase 
in holo-SOD1 concentration having a positive correlation with increased survival (Roberts et 
al., 2014). Furthermore, recent research has shown a further amelioration of neurotoxicity and 
significantly increased survival of the previously mentioned transgenic hCCs:SOD1
G93A
 
mice, when treated with Cu
II
(atsm). Remarkably, the lifespan of these mice increased from 
~30 days to 20 months, as well as this again correlating with an increased concentration of 
holo-SOD1 in the neural tissue. Interestingly, discontinuing treatment led to a development of 
ALS-like symptoms and death, however restoring treatment rescued these symptomatic mice 
(Williams et al., 2016). Although the effects of Cu
II
(atsm) are exceptional, it is not yet known 
if the same outcomes would be observed in metal binding region mutants of SOD1, such as 
SOD1
H46R
 which disrupts copper coordination, or highly destabilising mutants which have a 
lower affinity for zinc (Crow et al., 1997, Luchinat et al., 2014), which are suggested to have 
a deficient interaction with hCCS that may lead to the formation of toxic hetero-oligomers 
composed of both proteins (Wright et al., 2016). Analysis of the interactions between hCCS 
and different SOD1 mutants would need to be performed in order to elucidate the efficacy of 
mediating correct folding through CCS. We have performed a preliminary experiment where 
SOD1
G37R
 folding was monitored by mass spectrometry in real time as it was incubated with 
the yCCS (Appendix C – Fig. C4). It would be possible to quickly assess the difference in the 
folding of SOD1 mutants at variable concentrations and in the presence of different metals 
using this technique in future. 
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7.7 Concluding Statements 
 
Neurodegenerative diseases associated with protein deposition have been the focus of intense 
study for decades. Although most neurodegenerative diseases have characteristic symptoms 
and pathologies that are different from each other, a common theme is the misfolding and 
aggregation of specific proteins into potentially neurotoxic species. The process of misfolding 
and aggregation produces many different species including misfolded monomers, small non-
native oligomers, and large intracellular inclusions, making it difficult to identify a particular 
species that may be the causative agent of disease. In light of this, research into protein 
folding, misfolding, and aggregation has been extensive, with the hypothesis that 
understanding these processes will yield a viable therapeutic target that will limit or stop 
these events from occurring. In the case of SOD1, there is now growing evidence that 
misfolding and a prion-like propagation is contributing to the ordered spatiotemporal 
progression of pathology observed in SOD1-associated ALS cases. The work presented in 
this thesis has provided further evidence for the rationale that unfolded or nascent SOD1 can 
accumulate into aggregate structures, and that the kinetics and dynamics of formation, as well 
as the type of structure, can be influenced by both ALS associated mutation and non-ALS 
associated mutation. We draw particular emphasis to amino acid Trp32 in SOD1 which 
significantly augments the aggregation of the protein. It is hoped that the implication that 
Trp32 of SOD1 as a key determinant of the formation of aggregates will aid in the 
development of therapeutics to treat ALS. 
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Appendix A: Media and general buffer compositions 
 
All media and buffer were made up using distilled H2O, unless stated otherwise. 
MEDIA 
Luria-Bertani (LB) broth 
Tryptone 10 g/L 
Yeast Extract 5 g/L 
NaCl 10 g/L 
 
LB agar 
Tryptone 10 g/L 
Yeast Extract 5 g/L 
NaCl 10 g/L 
Agar 15 g/L 
 
BUFFERS 
1 × Phosphate buffered saline 
NaCL 8 g/L 
KCl 0.2 g/L 
Na2HPO4 1.44 g/L 
KH2PO4 0.24 g/L 
Make up to 800 mL volume with dH2O, adjust to pH 7.4 and fill to 1 L with dH2O 
 
5 × SDS-PAGE sample buffer 
Tris-HCl (pH 6.8) 200 mM 
Glycerol 50 % (v/v) 
SDS 1 g/L 
2-Mercaptoethanol 300 mM 
Bromophenol blue 0.4 % (w/v) 
 
Native-PAGE sample buffer 
Tris-HCl (pH 6.8) 200 mM 
Glycerol 50 % (v/v) 
Bromophenol blue 0.4 % (w/v) 
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Coomassie blue stain 
Coomassie blue  2 g/L 
Methanol 40 % (v/v) 
Glacial acetic acid 10 % (v/v) 
 
Rapid destain 
Methanol 40 % (v/v) 
Glacial acetic acid 10 % (v/v) 
 
Ammonium acetate (200 mM) 
7.5 M NH4OAc 2.66 % (v/v) 
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Appendix B: Plasmid sequences and maps 
pACA-forward-yCCS-hSOD1 plasmid sequence 
SOD1 
yCCS 
TCGACCTCTAGACCAAGCTTGGCTGCAGGTCGACGGATCTCGATCCCGCGAAATTAATACGA
CTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACCATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCGACGGCCCAGTGCAGGGCAT
CATCAATTTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTGTGGGGAAGCATTAAAGGAC
TGACTGAAGGCCTGCATGGATTCCATGTTCATGAGTTTGGAGATAATACAGCAGGCTGTACC
AGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTGGGCCAAAGGATGAAGAGAG
GCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGTGTGGCCGATGTGTCTATTG
AAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTGGCCGCACACTGGTGGTCCAT
GAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTACAAAGACAGGAAACGCTGG
AAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCAATAACAGATTGATTCAGTTTCACTTT
CACTGGGGTTCACTTGATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGC
AGAACTTCACTTGGTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAAC
CTGATGGACTGGCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAG
AAAGTTGTTGATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTT
CGATCCTCGTGGCCTCCTTCCTGAATCCCTGGATTACTGGACCTACCCAGGCTCACTGACCA
CCCCTCCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGC
GAGCAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGAT
GGTGGACAACTGGCGCCCAGCTCAGCTAAGAAGGAGATATACCATGACCACGAACGATACAT
ACGAGGCTACTTATGCCATTCCCATGCACTGTGAAAATTGCGTGAATGATATAAAGGCATGC
CTAAAAAATGTCCCAGGAATCAATTCATTGAATTTCGATATAGAGCAACAAATAATGAGCGT
GGAAAGCTCAGTAGCCCCTTCAACCATCATCAACACCTTGCGAAACTGTGGTAAAGACGCCA
TCATAAGAGGCGCCGGGAAGCCGAATTCTTCCGCGGTCGCTATCTTAGAGACCTTTCAAAAA
TATACTATAGACCAGAAAAAGGACACCGCCGTGAGGGGCCTAGCAAGAATCGTTCAGGTTGG
AGAGAATAAGACTCTTTTTGACATCACTGTAAATGGCGTCCCAGAGGCGGGAAATTACCACG
CCAGCATTCACGAGAAAGGCGACGTCTCCAAGGGCGTGGAATCTACTGGTAAAGTTTGGCAC
AAGTTCGACGAACCCATTGAATGCTTCAACGAGAGTGATTTGGGCAAGAACTTGTACAGTGG
GAAGACCTTTCTGAGCGCTCCCTTGCCAACATGGCAACTTATCGGCCGCAGCTTTGTCATTT
CCAAGTCTCTGAACCACCCAGAAAACGAGCCTTCCTCCGTTAAGGACTACTCATTTCTGGGA
GTCATTGCGAGAAGCGCTGGTGTGTGGGAAAATAATAAACAAGTGTGTGCGTGTACCGGAAA
GACTGTTTGGGAAGAGAGAAAAGATGCCTTGGCCAACAACATCAAATAGGCTCAGCCACTGA
AGAACAGGCAAATCAAAGCTTCCTTCAAATAAGATGGTCCCATAGTCTGTATCCAAATAATG
AATCTTCGGGTGTTTCCCTTTAGCTAAGCACAGATCCGGCTGCAACAAAGCCCGAAAGGAAG
CTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGG
GTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATGGGAATTCCCCGCGCGCGA
TGCCCTTTCGTCTTCGAATAAATACCTGTGACGGAAGATCACTTCGCAGAATAAATAAATCC
TGGTGTCCCTGTTGATACCGGGAAGCCCTGGGCCAACTTTTGGCGAAAATGAGACGTTGATC
GGCACGTAAGAGGTTCCAACTTTCACCATAATGAAATAAGATCACTACCGGGCGTATTTTTT
GAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATCACTGGATATAC
CACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTC
AATGTACCTATAACCAGACCGTTTAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAA
AATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCC
GGAATTTCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTT
ACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGAT
TTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTA
TTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCA
CCAGTTTTGATTTAAACGTGGCGAATATGGACAACTTCTTCGCCCCCGTTTTCACTATGGGC
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AAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGT
CTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGC
AGGGCGGGGCGTAATTTTTTTAAGGCAGTTATTGGTGCCCTTAAACGCCTGGTTGCTACGCC
TGAATAAGTGATAATAAGCGGATGAATGGCAGAAATTCGAGCCCGCCTAATGAGCGGGCTTT
TTTTTAGCCCGCCTAATGAGCGGGCTTTTTTTTCGAAAGCAAATTCGACCCATCGCGCGCGG
GGAGTCAACTCAGCAAAAGTTCGATTTATTCAACAAAGCCACGTTGTGTCTCAAAATCTCTG
ATGTTACATTGCACAAGATAAAAATATATCATCATGAACAATAAAACTGTCTGCTTACATAA
TATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGC
GGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAG
ATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAG
AGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGC
GGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGA
ATGACTTGGTTGAGTAGTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGA
GAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAAC
GATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCC
TTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATG
CCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTC
CCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGG
CCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTGGCGGT
ATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGG
GAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTA
AGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCAT
TTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTA
ACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAG
ATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTG
GTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGC
GCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTG
TAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGAT
AAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGG
CTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGAT
ACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTAT
CCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTG
GTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCT
CGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCC
TTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCG
TATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGATCAA
ATTGTAAACGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTT
TAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGT
TGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAA
GGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTT
TTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAG
CTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGC
GCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAA
TGCGCCGCTACAGGGCGCGTGATCTGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGA
GCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGAGCTTGGAATTG
CGAATAATAATTTTTTCACGTTGAAAATCTCCAAAAAAAAAGGCTCCAAAAGGAGCCTTTAA
TTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATTAGCTTGGAATTGCGAATAATAATTTT
TTCACGTTGAAAATCTCCAAAAAAAAAGGCTCCAAAAGGAGCCTTTAATTGTATCGGTTTAT
CAGCTTGCTTTCGAGGTGAATT 
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Figure B1. Restriction map of pEGFP-N1 plasmid. 
 
SOD
WT
-EGFP 
SOD1 
EGFP 
SalI site used for original cloning (Turner et al) 
 
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCG
TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACG
TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGC
CCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA
TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCG
GTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCC
ACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGT
CGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATAT
AAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCT
CAAGCTTCGAATTCTGCAGTCGACAAGCATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCG
ACGGCCCAGTGCAGGGCATCATCAATTTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTG
TGGGGAAGCATTAAAGGACTGACTGAAGGCCTGCATGGATTCCATGTTCATGAGTTTGGAGA
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TAATACAGCAGGCTGTACCAGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTG
GGCCAAAGGATGAAGAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGT
GTGGCCGATGTGTCTATTGAAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTGG
CCGCACACTGGTGGTCCATGAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTA
CAAAGACAGGAAACGCTGGAAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCAAGCGTCG
ACGGTACCGCGGGCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTT
CACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCG
TGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTG
CTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAG
GCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGA
GGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCA
TGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGAC
GGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
GCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGC
GCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAG
CTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTT
TTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAAT
TGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAA
ATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAAT
GTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAA
TAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGT
GGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCAT
CACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGG
AGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAA
AGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCA
CACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTG
CGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACA
ATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCA
GCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTA
TGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCC
GCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTT
TTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGA
GGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTC
GCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTC
GGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGC
GCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAG
ACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGAC
GTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCT
GTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGC
ATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCA
CGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCT
CGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCG
TGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTC
ATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGA
TATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCG
CTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTC
TGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACC
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GCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCT
CCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGGAGGCTAACTGAAACAC
GGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACG
CACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGTCCCAGGGCTGGCACTCTGTCGA
TACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCCCACCCCACC
CCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGGCCCTGCCATA
GCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGAT
CTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCC
ACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGC
GTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCA
AGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTG
TCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATAC
CTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGG
GTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGT
GCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTA
TGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGT
CGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTG
TCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC
CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGC
TCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT 
 
SOD1-tdTomato 
SOD 
tdTomato 
SalI site used for original cloning (Turner et al) 
 
 
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCG
TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACG
TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGC
CCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA
TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCG
GTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCC
ACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGT
CGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATAT
AAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCT
CAAGCTTCGAATTCTGCAGTCGACAAGCATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCG
ACGGCCCAGTGCAGGGCATCATCAATTTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTG
TGGGGAAGCATTAAAGGACTGACTGAAGGCCTGCATGGATTCCATGTTCATGAGTTTGGAGA
TAATACAGCAGGCTGTACCAGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTG
GGCCAAAGGATGAAGAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGT
GTGGCCGATGTGTCTATTGAAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTGG
CCGCACACTGGTGGTCCATGAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTA
CAAAGACAGGAAACGCTGGAAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCAAGCGTCG
ACGGTACCGCGGGCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGGTCAT
CAAAGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCATGAACGGCCACGAGTTCGAGA
TCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACC
AAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCATGTACGGCTCCAA
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GGCGTACGTGAAGCACCCCGCCGACATCCCCGATTACAAGAAGCTGTCCTTCCCCGAGGGCT
TCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGTCTGGTGACCGTGACCCAGGACTCC
TCCCTGCAGGACGGCACGCTGATCTACAAGGTGAAGATGCGCGGCACCAACTTCCCCCCCGA
CGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCC
GCGACGGCGTGCTGAAGGGCGAGATCCACCAGGCCCTGAAGCTGAAGGACGGCGGCCACTAC
CTGGTGGAGTTCAAGACCATCTACATGGCCAAGAAGCCCGTGCAACTGCCCGGCTACTACTA
CGTGGACACCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACG
AGCGCTCCGAGGGCCGCCACCACCTGTTCCTGGGGCATGGCACCGGCAGCACCGGCAGCGGC
AGCTCCGGCACCGCCTCCTCCGAGGACAACAACATGGCCGTCATCAAAGAGTTCATGCGCTT
CAAGGTGCGCATGGAGGGCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGG
GCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCC
TTCGCCTGGGACATCCTGTCCCCCCAGTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCC
CGCCGACATCCCCGATTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGA
TGAACTTCGAGGACGGCGGTCTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCACG
CTGATCTACAAGGTGAAGATGCGCGGCACCAACTTCCCCCCCGACGGCCCCGTAATGCAGAA
GAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGGCGTGCTGAAGG
GCGAGATCCACCAGGCCCTGAAGCTGAAGGACGGCGGCCGCTACCTGGTGGAGTTCAAGACC
ATCTACATGGCCAAGAAGCCCGTGCAACTGCCCGGCTACTACTACGTGGACACCAAGCTGGA
CATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAGCGCTCCGAGGGCCGCC
ACCACCTGTTCCTGTACGGCATGGACGAGCTGTACAAGAGCGGCCGCGACTCTAGATCATAA
TCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTG
AACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTA
GTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTT
GTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCG
GCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGG
AACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTA
AAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCG 
AACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGT
AGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGT
CAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT
TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAG
GAAGAGTCCTGAGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTC
CCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGT
GTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCA
GCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCA
TTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCT
CTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGA
TCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTC
CGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCT
GATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCT
GTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGG
GCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTG
GGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCAT
CATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACC
AAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGAT
GATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAG
CATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGG
TGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTAT
CAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCG
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CTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTC
TTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACC
TGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTT
TTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCA
CCCTAGGGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGA
CGGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTT
CGGTCCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCG
CGTTTCTTCCTTTTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCA 
ACGTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTA
AAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAA
AATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTA
CCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTT
CAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCA
AGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCC
AGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCA
GCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCG
GACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGG
AAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTT
TGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGG
TTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGT
GGATAACCGTATTACCGCCATGCAT 
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Appendix C: Mass spectrometry supplementary 
information 
 
 
Figure C1: Calibration of Synapt-G1 HDMS using myoglobin and cytochrome c. Myglobin and 
cytochrome c were prepared in 2% acetic acid 49% MeOH 49% Milli-Q and nano-electrosprayed 
under gentle conditions under IM-MS mode. Mass and drift time data was acquired at wave heights of 
8, 9, and 10 V. 
 
Figure C2:  Plots of [D]eq against [M]eq 2 revealing Kd values for uSOD1 and gsSOD1 variants. 
Least squares regression (R2) is shown. Dimer KD values are derived from the line of best fit gradient. 
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Figure C3:  Plots of [D]eq against [M]eq 2 revealing Kd values for uSOD1 and gsSOD1 variants. 
Least squares regression (R2) is shown. Dimer KD values are derived from the line of best fit gradient. 
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Figure C4: Refolding of SOD1
G37R
 monitored by mass spectrometry. Purified recombinant 
SOD1
G37R
 was unfolded by incubation in 20 mM DTT 5 mM EDTA 1 × PBS. Following unfolding, 
the protein was concentrated using a centrifugal concentrator to a concentration of ~450 µM and 
loaded onto a Superdex-75 10/300 GL column equilibrated in 200 mM NH4OAc. The eluted fraction 
containing SOD1 were pooled and diluted to a concentration of 15 µM. Purified recombinant yCCS 
was equilibrated into 200 mM NH4OAc similarly. SOD1
G37R
 and yCCS were mixed at a ratio of 10:1 
respectively, incubated at 22 °C, and the mixture was nano-electrosprayed under gentle conditions. 
(A) The relative abundance of monomeric SOD1 decreased with longer incubation times. (B) Plotting 
the relative abundance of dimer against incubation time showed the refolding of SOD1
G37R
 (black) to 
be at final dimer abundance similar to native SOD1
G37R
 (red), well above SOD1
G37R
 that was not 
mixed with yCCS (blue). (C) By denaturing the final product of the assay, we determined at time 0 
the mass of SOD1
G37R
 was consistent with disulfide reduced protein (~15904 Da), and that at 60 mins 
the mass was consistent with disulfide oxidised protein (15902 Da). 
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Figure C5: Lag-phase of aggregation vs mean disease duration. This figure is associated with 
figure 5.2 and shows the relationship between the observed lag-phase of the first in vitro aggregation 
assay to cells with inclusions at 48 hours. The r
2
 value is inset (0.83), however there are only 4 data 
points. Error bars represent SEM. 
 
 
